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For over 25 years, the Canadian Centre on Substance Abuse 
(CCSA) has provided national leadership to advance solutions 
that will reduce the harms of alcohol and drugs on individuals 
and their families. Part of our unique role involves bringing 
people and knowledge together to effect changes in policy, 
practice and programs, and make a difference in the lives 
of Canadians. This role includes advancing knowledge and 
promoting research on the disease of addiction and issues 
around substance abuse in Canada and globally. 
To this end, CCSA regularly produces reports in the Substance 
Abuse in Canada (SAIC) series; the latest, released in June 
2014, was on childhood and adolescent pathways to 
substance use disorders. That report examined how biological, 
behavioural and social factors, and experiences during the early 
developmental years can lead to or protect against later-life 
substance use disorders and concurrent mental and physical 
health problems. 
The 2014 SAIC report highlighted important questions about 
the connection of mental health issues, environmental factors 
and substance abuse in younger children and adolescents. 
As we are all aware, adolescence is a time of significant 
development and change. It is also the period when substance 
use most commonly begins. In Canada, the drug of choice for 
young people is cannabis, with almost one-quarter of 15- to 
24-year-olds reporting past-year cannabis use. In fact, 
Canadian youth are the highest users of cannabis compared 
to youth in other developed countries. Of particular concern is 
recent research suggesting that Canada’s youth do not have 
the knowledge they need about the risks associated with this 
drug to make informed decisions. 
Because young people are disproportionately more likely than 
those in other age groups to use substances, engage in risky 
patterns of use and experience harms from that use, CCSA 
considered it vital to take a closer and more comprehensive 
look at exactly what effects can arise from adolescent use of 
this illicit drug. This examination is of particular importance given 
public dialogue in Canada about cannabis policy, the move 
towards regulation and legalization in some American states, 
and the use of cannabis for medical and therapeutic purposes. 
Foreword
The issue of cannabis use is given a great deal more attention 
today than even a few years ago, and mixed messages in 
our own country and abroad are being internalized by young 
people. Public debates about cannabis need to be informed by 
evidence. To make the evidence available is precisely the role 
of CCSA, an organization dedicated to finding the signal amidst 
the noise on complex issues like cannabis. This SAIC report 
provides an overview of current knowledge to help ensure that 
converging evidence of the effects of cannabis on the brain and 
behaviour is brought to bear on discussions of the issue, and to 
bring about changes where needed.
CCSA chose to focus on youth because young people 
represent the future of our country. Brain development during 
adolescence lays the foundation for success later in life or, 
conversely, for challenges in adulthood. And so, while there are 
many other issues involved in the larger debate about where 
cannabis fits in political, health and law enforcement spheres, 
the focus of this report is squarely on the health effects youth 
could experience if they use cannabis: in essence, what we 
know about those effects, what we don’t know and what we 
need to focus attention on in the future, so that we can work 
together towards better policies, practices and programs aimed 
at this cohort.
So what does this report tell us about the health effects of 
adolescent cannabis use? First and foremost, cannabis is not 
a harmless drug. It can be addictive and the risk increases the 
earlier it is used. Early and frequent use also increases the risk of 
short-term cognitive impairment and under performing in school, 
as well as psychotic symptoms and disorders. Cannabis use 
significantly impairs coordination and reaction time, so it is not 
surprising that it is the most common illicit drug found to be 
involved in car accidents, including fatal ones. And although we 
do not know the full extent of the impact of early cannabis use 
on long-term cognitive ability and associated educational and 
occupational successes, evidence is mounting that cannabis 
affects the young brain in a harmful way that cannot be ignored. 
All Canadians need to be made more aware of the health risks 
and harms outlined in this report. This knowledge must be used 
to communicate with youth through comprehensive, factual 
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and multi-faceted prevention messaging and programs that 
involve family members, schools and the community. Evidence-
informed approaches to drug prevention — like those found 
in CCSA’s Canadian Standards for Youth Substance Abuse 
Prevention — can have a significant impact on youth substance 
use and abuse and can contribute to the overall health and 
well-being of young people.
As importantly, when we harness opportunities for prevention 
and intervention at the earliest stages, these investments in our 
young people can yield long-term improvement in health and 
socioeconomic outcomes for both individuals and families. The 
evidence in this report is important for healthcare professionals, 
who are often the first line of defence in early screening and 
intervention for problematic substance use. This focus follows 
recommendations made by the House of Commons Standing 
Committee on Health earlier this year to increase the capacity 
of healthcare professionals in this regard.
Another key recommendation arising from the report is the need 
for a national research agenda in Canada aimed at improving 
understanding of the short- and long-term harms related to 
cannabis, including its relationship to the development of 
addiction in vulnerable population groups, such as youth. 
Regardless of the future of cannabis from a legal or medical 
perspective, we all need to ensure that we have a common 
and scientifically rooted understanding of how this substance 
interacts with the developing brain of adolescents and under 
what conditions — not only for their health and safety in the 
short term, but also considering long-term implications for them 
and society as a whole. 
This report presents an immediate opportunity to enhance 
youth drug use prevention and intervention programs, as well 
as emerging policy frameworks, with factual information and in 
a fashion that has been shown to work. We know that cannabis 
is not a benign substance. It has clear harms and poses risks 
to those who use it on a regular and frequent basis, including 
negative health, economic and social ramifications. It is now up 
to readers to take the information in this report and use it to help 
reduce the incidence of harms associated with cannabis use 
among adolescents, to help young people make smarter and 
more informed choices about their todays and their tomorrows.
Acknowledgements
It gives me great pleasure to take this opportunity to thank 
the authors of the report — Dr. Joanna Henderson, Dr. Andra 
Smith, Dr. Tony George, Michelle Goodman, Dr. Bernard Le Foll, 
Dr. Kevin Gray, Dr. Aimee McCrae-Clark and Dr. Harold Kalant — 
for their expertise and superb work in gathering and synthesizing 
the vast amount of cutting-edge research discussed in 
this report. Special thanks to the editorial team, Drs. Tony 
George and Franco Vaccarino, for their exceptional editing of 
and contributions to the entire report, and for integrating the 
evidence and key messages of the individual authors. CCSA 
is also indebted to Dr. Amy Porath-Waller, interim director of 
research, who played an essential leadership role in developing 
this report and pulling together all the experts to bring this 
evidence forward. I am also happy to have the occasion once 
again to thank members of CCSA’s Scientific Advisory Council 
for their expert advice and assistance with this report and the 
SAIC series in general. Last but not least, I would like to draw 
attention to the continued hard work and dedication of CCSA 
staff who support our research program and make possible 
such publications as this.
Rita Notarandrea
Chief Executive Officer (interim)
Canadian Centre on Substance Abuse
3Canadian Centre on Substance Abuse
SUBSTANCE ABUSE IN CANADA—The Effects of Cannabis Use during Adolescence
Cannabis remains the most commonly used illegal substance in 
Canada. Many people have used cannabis, or know someone 
who has, and infer from their first-hand knowledge that 
cannabis is a harmless or relatively benign substance that can 
be used safely. “I have tried marijuana several times and nothing 
bad has happened to me; it is less harmful than alcohol” is an 
oft-heard assertion. Although the insights gained from personal 
knowledge can be compelling, all good scientists know that 
solid research evidence is not established with the casual study 
of a single person.
Current debates about cannabis use are rife with mere opinion 
and misinformation. And, to complicate the matter further, the 
evidence related to the possible health risks of cannabis use 
appears to be contradictory. How do we weigh the evidence? Is 
it a drug with a variety of adverse or hazardous effects or does it 
pose low risk to people’s health? What is one to believe?
There are many websites and authorities that claim to offer 
accurate information about cannabis. Indeed, a simple Google 
search of the word cannabis yields over 60 million results. How 
can the average person make sense of this confusing picture?
Several researchers have engaged young people to better 
understand their attitudes and beliefs about cannabis — why 
they use it or don’t use it and, more specifically, what they want 
to know about it (Bottorff, Johnson, Moffat, & Mulvogue, 2009; 
Haines, Johnson, Carter, & Arora, 2009; Haines-Saah, Moffat, 
Jenkins, & Johnson, 2014; Moffat, Jenkins, & Johnson, 2013). 
Young people are clearly interested in receiving scientifically 
sound information about cannabis. And we have learned 
that scare tactics and the provision of misinformation, even if 
well intended, are not helpful; they only serve to discredit the 
source. When information is not freely available, youth tend to 
rely on Internet sources to piece together information as best 
they can, or they rely on their often equally ill-informed peers for 
the information they seek. 
Foreword
The research evidence suggests that, more than information, 
young people are seeking opportunities to discuss what is 
known about substances such as cannabis, and the decisions 
they must make about various forms of substance use. To be 
effective, we must engage in informed and rational discussions 
with young people about decision making and cannabis use, 
and support them in their quest for understanding.
Parents, teachers, public health practitioners and many others 
with important relationships with youth often struggle with how 
to have meaningful conversations about cannabis. They too are 
searching for credible sources of information. 
This report, Substance Abuse in Canada: The Effects of 
Cannabis Use during Adolescence, fills an important void; it 
summarizes the current scientific evidence related to cannabis 
use. The reader will receive a thorough assessment of the state 
of the science. What emerges is a picture of the heightened 
risks experienced by particular young people — including those 
who are very young, who smoke cannabis frequently, or who 
have a family history of serious mental illness. In many ways, our 
understanding of the effects of cannabis use is not as complete 
as we would like. Despite decades of research and thousands 
of years of use, there are many unanswered questions related 
to the consequences of cannabis use. We must answer these 
questions and we must determine the best ways to prevent or 
minimize the associated risks for people who choose to use the 
substance and for society as a whole. 
Regardless of the gaps in our knowledge, it is important to 
clearly communicate what we do know about the risks to 
which young people are exposed when they use cannabis. In 
the concluding chapter, Dr. Harold Kalant summarizes several 
important ideas emphasized in this report and they are worth 
repeating here:
• Cannabis is not a harmless drug.
• It can be addictive, especially if use starts in 
adolescence.
• Early and frequent cannabis use is linked with 
reduced IQ, lower school performance and 
increased risk of dropping out.
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• Cannabis use affects cognitive and motor 
functions, and is a safety hazard for drivers.
• Early and frequent use can alter the structure of 
the developing brain, including areas responsible 
for memory, decision making and executive 
functioning.
• There is a link between cannabis and mental illness.
• Some adverse effects might be irreversible, with 
the potential to seriously limit a young person’s 
educational, occupational and social development.
Joy Johnson
Vice-President, Research, 
Simon Fraser University
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TERMINOLOGY NOTES
Several of the terms used in this document have specific and distinct clinical significance, but to avoid repetition have 
been used as equivalents. Unless otherwise noted, the definitions below are based on those provided in the fourth 
and fifth editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR and DSM-5, respectively) 
(American Psychiatric Association, 2000, 2013).
Addiction: Generally applied to patterns of heavy, compulsive use of psychoactive drugs and an inability to stop 
substance use, even though it is leading to severe, clinically relevant problems in multiple domains of a person’s life 
(e.g., when such use becomes physically hazardous; causes failure to fulfill obligations at work, school or home; or 
creates legal, social or interpersonal problems).
Substance dependence: Also referred to as “drug or alcohol dependence,” substance dependence constitutes 
a cluster of cognitive, behavioural and physiological symptoms indicating continued substance use despite the 
occurrence of severe substance-related problems. In DSM-5, the diagnosis of substance dependence has been 
combined with that of substance abuse (see below) and both have been replaced by the single term “substance 
use disorder,” underscoring the fact that a substance use disorder is not synonymous with physical dependence. In 
DSM-5, the severity that was previously captured by the diagnostic label “substance dependence” is now captured 
by specifying current severity (e.g., “substance use disorder, severe”).
Substance abuse: Also known as “drug or alcohol abuse,” this term refers to a maladaptive pattern of substance 
use resulting in recurrent and significant adverse consequences. It is a pattern of use under hazardous circumstances 
and involves neglecting one’s external obligations, legal problems and interpersonal problems. It has also been 
replaced by the term “substance use disorder,” but is indicative of a disorder of mild severity.
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Introduction
By Joanna Henderson, PhD, Assistant Professor,  
Department of Psychiatry, University of Toronto, and  
Head of Research, Child, Youth and Family Program,  
Centre for Addiction and Mental Health
About Substance Abuse in Canada
Since 2005, Substance Abuse in Canada has shone a 
spotlight on key contemporary issues related to substance 
abuse, and identified specific areas for action in both policy 
and practice. Each report in the series is intended for a broad 
audience that includes policy makers, program development 
personnel, researchers, educators and health professionals. 
Health journalists are also an important audience as they can 
help raise the public profile of the issues discussed and help 
create the impetus for change.
THE SERIES TO NOW
The first Substance Abuse in Canada report, Current Challenges and Choices, examined a variety of topics, 
including the prevention of alcohol problems, alternative sanctions for cannabis use and possession, drug-impaired 
driving, and the abuse and diversion of prescription medication. 
The second report, Focus on Youth, looked at the prevalence of substance use and its associated harms among 
young people, exploring the underlying neurobiology of substance use in adolescence and identifying existing gaps in 
youth-centric services. 
The third edition, Concurrent Disorders, focused on the co-occurrence of mental health and substance abuse 
problems, examining the interconnections between addiction and mental illness, the costs concurrent disorders place 
on the healthcare system, and why treating these complex cases requires new and innovative approaches.
The fourth in the series, Licit and Illicit Drug Use during Pregnancy, addressed the medical and obstetrical 
consequences of drug abuse and dependency in pregnant women, as well as the short- and long-term effects that 
prenatal exposure to drugs can have on a child’s development.
The fifth edition, Childhood and Adolescent Pathways to Substance Use Disorders, explored influences during 
childhood and adolescence that can affect substance abuse later in life, as well as the implications an understanding 
of those influences has for prevention and treatment.
The Effects of Cannabis Use during Adolescence, the current report, reviews the effects of cannabis use 
during adolescence, looking specifically at the drug’s impact on youth health and brain development, as well as the 
interventions currently available for treating cannabis use disorders.
This sixth Substance Abuse in Canada report focuses on 
the effects of cannabis use during adolescence. After a brief 
introduction emphasizing the scope of the issue and why it 
matters to Canadians, the report presents the cognitive and 
behavioural effects of cannabis use in youth, looking at its 
impact on adolescent brain development and exploring the 
links between cannabis use and mental illness. The report also 
examines the question of whether cannabis is addictive and 
summarizes the interventions currently available for cannabis 
use disorders. Finally, the report concludes with a call to action 
that outlines the practical implications of the latest research on 
cannabis use during adolescence
This report is not meant to be a systematic review; instead, 
it is intended to provide a high-level, broad overview of this 
important health issue by integrating neuroscience with the 
behavioural and social context of cannabis use by youth.
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Why it’s time to take a closer look at youth 
cannabis use
Cannabis has always been a significant political, health and 
law-enforcement issue. With its recent legalization in Alaska, 
Colorado, Oregon, Washington and the District of Columbia, 
however, the debate around this illicit substance has gained 
considerable profile.
Across North America, the public discourse on cannabis 
tends to focus on sociopolitical and legal issues: assessing 
the economic impact of legalization or decriminalization, for 
instance, or determining how cannabis for medical purposes 
figures into the equation. 
Yet as policy makers and media outlets explore the issue in 
greater detail, the answers to many questions are still unclear. 
What is the distinction between adult and adolescent use? 
Why is there seemingly a double standard about medical 
and recreational use? With new evidence, opinions and 
perspectives being released and discussed every day — 
covering a broad spectrum of considerations — the public 
has become increasingly confused about cannabis’ status, 
prevalence and effects.
For teenagers, making decisions about cannabis without having 
the facts can have profound consequences. Adolescence is 
marked by significant social, psychological and physiological 
changes. It is a time when young people begin to develop 
increasingly close bonds with their peers and explore their own 
distinct social identities. It is also when mental health problems 
can start to emerge and substance use begins.
Because of the rapid changes in brain structure and function 
that occur during adolescence, use of cannabis during this 
developmental period can have negative cognitive, mental 
health and physical effects.
How prevalent is youth cannabis use in 
Canada?
Canadian youth use cannabis more than any other illicit drug 
and many start using it as early as late elementary school. In 
fact, Canadian adolescents have among the highest rates 
of cannabis use compared to their peers in other developed 
countries (UNICEF Office of Research, 2013). 
According to the 2013 Canadian Tobacco, Alcohol and Drugs 
Survey, 22.4% of youth aged 15–19 reported past-year use of 
cannabis; among young adults aged 20–24, 26.2% reported 
past-year use. In total, youth use cannabis at a rate 2.5 times 
higher than adults aged 25 and older, of whom only 8.0% 
reported past-year cannabis use (Statistics Canada, 2015).
Other national studies have shown similar results. In the 
2012–2013 Youth Smoking Survey (YSS), 19% of grade 7–12 
students reported past-year cannabis use. For students in 
grades 7–9, past-year cannabis use rates were 3%, 7% and 
15%, respectively (Health Canada, 2014). These are lower than 
the rates reported for alcohol (41%) and binge drinking (29%), 
but higher than cigarettes (14%) and other illegal drugs (6%). 
At the provincial level, a series of school surveys conducted 
in Ontario, Quebec, New Brunswick, Nova Scotia, and 
Newfoundland and Labrador in 2012–2013 (see Table 1; 
Asbridge & Langille, 2013; Boak, Hamilton, Adlaf, & Mann, 
2013; Gupta, Wang, Collette, & Pilgrim, 2013; Newfoundland 
and Labrador Student Drug Use Survey Working Group, 2013; 
Traoré et al., 2014) found that the rates of past-year cannabis 
use by all students in grades 7–12 ranged from 22.9% (in 
Quebec) to 34.7% (in Nova Scotia), with rates peaking in grade 
12 (as high as 54.7% in Nova Scotia). As a point of comparison, 
the reported rates of past-year cigarette smoking were 
substantially lower than those for cannabis use (Ontario, 8.5%; 
New Brunswick, 14.1%; Nova Scotia, 13.2%; Newfoundland 
and Labrador, 16.4%).
Rates of past-year cannabis use across grades have declined 
significantly over the past decade in both Ontario and New 
Brunswick; in Nova Scotia and Newfoundland and Labrador, 
past-year cannabis use rates have remained relatively stable. 
In contrast, all four jurisdictions have seen large declines in 
cigarette smoking during that same time.
While the current levels of past-year cannabis use are 
concerning, more problematic is the high-frequency use of 
cannabis reported by some students. Daily or near-daily use 
by adolescents is associated with increased harms (Hall, 
2015) and, as shown in Table 1, the rates for this type of heavy 
cannabis use range from 1% to 6% in the five provinces that 
conducted student surveys in 2012–2013. 
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These surveys include only youth attending school who were 
able to participate. Given these limitations, the actual rates of 
both past-year and heavy cannabis use among Canadian youth 
are likely to be higher than reported.
What motivates youth to use cannabis?
Like adult cannabis users, youth report feelings of increased 
sociability and euphoria when using cannabis (Menghrajani, 
Klaue, Dubois-Arber, & Michaud, 2005). Yet youth also describe 
a number of other factors that motivate their cannabis use, 
which can be divided into five distinct categories: enhancement 
(“it’s exciting”); social (“it helps me enjoy a party”); coping (“it 
helps me forget about my problems”); expansion (“it helps me 
understand things differently”); and conformity (“so I won’t feel 
left out”) (Green, Kavanagh, & Young, 2003; Simons, Correia, 
Carey, & Borsari, 1998). Recently, this list has been extended to 
include an additional category: routine (“I use it out of boredom”) 
(Benschop et al., 2015). 
Substantial individual variations in motives for cannabis use have 
been noted, as well as different motives for different episodes 
of use (Bonn-Miller & Zvolensky, 2009; Shrier & Scherer, 2014). 
In addition, different motives have been found to be related to 
different affective states and traits. For example, social anxiety 
and child maltreatment are both associated with cannabis-
related problems through higher rates of use associated with 
coping motives (Buckner, Bonn-Miller, Zvolensky, & Schmidt, 
2007; Vilhena-Churchill & Goldstein, 2014).
While motives reflect the valuing or prioritizing of particular 
experiences, cannabis use can also be looked at in terms of 
expectancies, which reflect an individual’s beliefs about the 
experiences that will result from cannabis use (Cooper, 1994; 
Kuntsche, Wiers, Janssen, & Gmel, 2010). A number of 
expectancy domains have been identified, including cognitive 
and behavioural impairment, relaxation and tension reduction, 
social and sexual facilitation, perceptual and cognitive 
enhancement, physical effects and cravings, and overall negative 
effects (Schafer & Brown, 1991; Torrealday et al., 2008). 
As a whole, these domains can be grouped into two broader 
categories: negative expectancies and positive expectancies. 
Adolescents who delay initiating cannabis use tend to have 
high negative expectancies; those who start using cannabis 
with greater frequency typically have high positive expectancies 
(Aarons, Brown, Stice, & Coe, 2001; Fulton, Krank, & Stewart, 
2012; Schafer & Brown, 1991; Skenderian, Siegel, Crano, 
Alvaro, & Lac, 2008). 
How do youth perceive cannabis use?
Canadian youth perceive cannabis use to be widespread, not 
just among their peers but also among adults as well. It is often 
described as a substance “everyone” is using “all the time.” 
They also believe cannabis to be relatively harmless, viewing 
it as a more “natural” substance that is not really a drug at all 
(Porath-Waller, Brown, Frigon, & Clark, 2013). Evidence from 
the Monitoring the Future Study in the United States shows 
7Canadian Centre on Substance Abuse
SUBSTANCE ABUSE IN CANADA—Cannabis Effects on Youth in Canada
These surveys include only youth attending school who were 
able to participate. Given these limitations, the actual rates of 
both past-year and heavy cannabis use among Canadian youth 
are likely to be higher than reported.
What motivates youth to use cannabis?
Like adult cannabis users, youth report feelings of increased 
sociability and euphoria when using cannabis (Menghrajani, 
Klaue, Dubois-Arber, & Michaud, 2005). Yet youth also describe 
a number of other factors that motivate their cannabis use, 
(“it’s exciting”); social (“it helps me enjoy a party”); coping (“it 
helps me forget about my problems”); expansion (“it helps me 
understand things differently”); and conformity (“so I won’t feel 
left out”) (Green, Kavanagh, & Young, 2003; Simons, Correia, 
Carey, & Borsari, 1998). Recently, this list has been extended to 
include an additional category: routine (“I use it out of boredom”) 
(Benschop et al., 2015). 
Substantial individual variations in motives for cannabis use have 
been noted, as well as different motives for different episodes 
of use (Bonn-Miller & Zvolensky, 2009; Shrier & Scherer, 2014). 
In addition, different motives have been found to be related to 
different affective states and traits. For example, social anxiety 
and child maltreatment are both associated with cannabis-
related problems through higher rates of use associated with 
coping motives (Buckner, Bonn-Miller, Zvolensky, & Schmidt, 
2007; Vilhena-Churchill & Goldstein, 2014).
experiences, cannabis use can also be looked at in terms of 
expectancies
experiences that will result from cannabis use (Cooper, 1994; 
Kuntsche, Wiers, Janssen, & Gmel, 2010). A number of 
behavioural impairment, relaxation and tension reduction, social 
and sexual facilitation, perceptual and cognitive enhancement, 
physical effects and cravings, and overall negative effects 
(Schafer & Brown, 1991; Torrealday et al., 2008). 
As a whole, these domains can be grouped into two broader 
categories: negative expectancies and positive expectancies. 
Adolescents who delay initiating cannabis use tend to have 
high negative expectancies; those who start using cannabis 
with greater frequency typically have high positive expectancies 
(Aarons, Brown, Stice, & Coe, 2001; Fulton, Krank, & Stewart, 
2012; Schafer & Brown, 1991; Skenderian, Siegel, Crano, 
Alvaro, & Lac, 2008). 
Table 1. Rates of cannabis use among Canadian students by province, 2012–2013
1 Estimates for Ontario are based on grades 7 through 12.
2 Estimates for Quebec are based on grades 7 through 11. 
Quebec asks only about daily use and not almost daily use.
^ Suppressed due to small number.
— Not asked.
12 at p < .01.
Past-year cannabis use (%) Daily or almost daily cannabis use (%)
Grade Grade
Province 7 9 10 12 Total 7 9 10 12 Total
ON1 (2013) 1.7 14.6 24.5 39.2* 23.0 ^ ^ 2.0 5.1* 2.7
QC2 (2013) 4.3 24.9 32.2 — 22.9 ^ 1.2 1.2 — 1.4
NB (2012) 6.0 27.0 32.0 45.0* 28.3 — — — — —
NS (2012) 7.0 32.7 39.9 54.7* 34.7 ^ 5.8 7.0 11.1* 6.4
NL (2012) 4.2 27.4 40.2 46.5* 30.0 0.4 3.8 8.3 8.9* 5.4
 sti ates for ntario are based on grades 7 through 12.
 sti ates for uebec are based on grades 7 through 11. Quebec asks only about daily use and not almost daily use.
^ Suppres ed due to small numb r.
— Not asked. * D n tes sig ificant difference between Grade 7 and Grade 12 at p < .01.
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an inverse association between the perception of the risk 
associated with cannabis use and past-year use among high 
school seniors over the past 40 years (see Figure 1). 
In general, young people have a wide range of opinions 
about cannabis, some of which reflect inaccurate information 
and others reflecting conflicting messages received through 
the media, peers and adults. For example, some youth have 
expressed the belief that cannabis can prevent — or even 
cure — cancer. Youth have also expressed mixed beliefs about 
cannabis’ impact on one’s ability to drive, with some stating 
that using cannabis improves driving performance and is not as 
dangerous as drinking and driving (Porath-Waller et al., 2013).
What are the effects of cannabis use on 
youth?
Dose, potency and cumulative exposure all contribute to the 
potential effects of cannabis use in youth. Of these factors, dose 
has been less studied due to the fact that the amount of active 
ingredient to which youth are exposed during each episode 
of use varies according to the overall substance content (i.e., 
proportions of cannabis and non-cannabis ingredients), the 
amount of active ingredient (e.g., THC, cannabidiol), the mode 
of administration (e.g., joints, vaporizers) and individual versus 
shared use. 
Acute safety risks associated with cannabis use
While some people, especially inexperienced users, will 
experience unpleasant events such as intense anxiety, panic 
and psychotic symptoms when using cannabis, the risk of 
overdose is extremely low, even among individuals with the 
highest levels of use (Calabria, Degenhardt, Hall, & Lynskey, 
2010; Gable, 2004). That said, cannabis use can lead to 
hospitalization: in 2011, approximately 1,600 hospital stays in 
Canada were recorded as being primarily due to a cannabinoid-
related disorder (Young & Jesseman, 2014). In comparison, 
there were nearly 20,000 hospital stays due to alcohol-related 
disorders during that same time period. The duration of the 
hospital stay varies by age group, with youth between the ages 
of 15 and 24 likely to be in hospital longer than other age groups 
when receiving treatment for cannabinoid-related disorders. 
Perhaps the most significant acute safety concern for youth is 
driving under the influence of cannabis. In the student surveys 
discussed earlier, approximately 10–20% of senior or licensed 
students reported driving within one hour of using cannabis 
— nearly identical to the rates reported for driving under the 
influence of alcohol (Asbridge & Langille, 2013; Boak et al., 
2013; Newfoundland and Labrador Student Drug Use Survey 
Working Group, 2013; Gupta et al., 2013; Traoré et al, 2014; 
Young et al., 2011). Although evidence suggests it is not 
Figure 1. Perception of risk and actual cannabis use in U.S. students, 1975–2013
Source: Volkow, Baler, Compton, & Weiss, 2014; reproduced with permission, Massachusetts Medical Society
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quite as dangerous as driving under the influence of alcohol, 
driving under the influence of cannabis is still associated with a 
significantly increased risk of collision and injury; that risk climbs 
even higher when driving under the influence of both alcohol 
and cannabis (Asbridge, Hayden, & Cartwright, 2012; Hartman 
& Huestis, 2013; Li et al., 2012; Ramaekers, Berghaus, van 
Laar, & Drummer, 2004).
Short- and long-term effects of cannabis use
Also of great concern for youth are the numerous studies 
indicating that cannabis use can result in a number of short- 
and long-term physical, mental and psychosocial effects. 
Specifically, evidence suggests that high-frequency use — in 
particular, daily or near-daily use beginning in adolescence 
— is associated with a wide range of poor outcomes. Some 
studies have also suggested that these associations may have 
dose-response characteristics, potentially indicating a causal 
connection (Silins et al., 2014). 
Many studies of cannabis-related outcomes, however, have 
lacked methodological rigor and do not provide adequate 
evidence regarding the direction of influence (Hall, 2014). Did 
the psychosocial or health problem exist before the cannabis 
use and increase the risk of cannabis use? Did cannabis use 
lead to the psychosocial or health problem? Or was there  a 
common factor that led to both the psychosocial or health 
problem and the cannabis use? Moreover, examination of the 
biological indicators of the actual cannabinoid doses consumed 
has been lacking (Freeman, Mokrysz, & Curran, 2014), limiting 
the extent to which conclusions about causality can be drawn.
The following bullets overview health, mental health and 
psychosocial outcomes from studies where there is strong 
evidence of a connection between cannabis use and the 
variable of interest, after controlling for other potential factors, 
and where the causal association is plausible. (Subsequent 
chapters provide a more comprehensive summary and 
discussion of this evidence.) Unless otherwise specified, these 
findings  are based on “regular” or “heavy” use, which is typically 
defined as daily or near-daily cannabis use (Hall, 2014).
• When compared to alcohol and tobacco, cannabis 
use has the fastest rate of transition to substance 
use disorder among adolescents (Ridenour, Lanza, 
Donny, & Clark, 2006). Youth who are regular 
cannabis users are more likely to use other illicit 
substances (Fergusson & Boden, 2008; Hurd, 
Michaelides, Miller, & Jutras-Aswad, 2014; Lynskey, 
Coffey, Degenhardt, Carlin, & Patton, 2003; Silins 
et al., 2014). 
• The risk of dependence (i.e., lack of control over 
use of cannabis despite the associated harms) 
is approximately 9% among individuals with any 
lifetime cannabis use (Lopez-Quintero et al., 2011) 
and approximately 16% among those who initiated 
cannabis use during adolescence (Anthony, 2006). 
While most individuals who use cannabis do 
not become dependent, heavy cannabis use in 
adolescence is associated with an increased risk 
for dependence (Silins et al., 2014). Symptoms 
of tolerance and withdrawal, such as depression, 
insomnia, anxiety and disturbances in appetite, are 
reported by some cannabis users, experienced 
typically in the context of high-frequency, long-term 
use (Allsop et al., 2012; Budney, Hughes, Moore, & 
Vandrey, 2004).
• Regular cannabis use in adolescence is associated 
with experiencing psychotic symptoms, especially 
when there is a family or personal history of 
psychotic disorders (Fergusson, Horwood, & 
Swain-Campbell, 2003; Large, Sharma, Compton, 
Slade, & Nielssen, 2011; Moore et al., 2007; 
Zammit, Allebeck, Andreasson, Lundberg, & Lewis, 
2002). Indeed, the risk of reporting psychotic 
symptoms or being diagnosed with schizophrenia 
in adulthood is doubled in individuals with regular 
cannabis use in adolescence (Hall, 2015; Moore 
et al., 2007). While the evidence is not as strong 
regarding other mental health issues, there are 
possible links between regular cannabis use in 
youth and increased risk for depression and suicide 
(Lev-Ran et al., 2013; Silins et al., 2014). 
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• Acute cannabis intoxication has been linked to 
deficits in attentional focus, information processing, 
motor coordination and reaction time (Hall, 
2015), while long-term regular use that starts in 
adolescence has been found to be associated 
with impairments in attention, memory and verbal 
learning (Crane, Schuster, Fusar-Poli, & Gonzalez, 
2013; Porath-Waller, 2009; Solowij & Battisti, 
2008). There is also evidence that, among long-
term daily cannabis users, these deficits coalesce 
into declines in IQ (Meier et al., 2012), although 
some have challenged this finding (Rogeberg, 
2013). In some contexts, the long-term cognitive 
impairments that result from regular cannabis use 
have been reversed, but this appears less likely for 
heavy use that begins in adolescence (Meier et al., 
2012; Porath-Waller, 2009). 
• As the acute effects of cannabis can impact 
learning and schoolwork completion, youth who 
use cannabis regularly are more likely to drop out 
of high school and, in turn, less likely to pursue 
post-secondary education (Fergusson & Boden, 
2008; Horwood et al., 2010; Lynskey et al., 2003; 
Silins et al., 2014). In addition, youth who are 
already vulnerable to poor educational outcomes 
due to other factors might be more likely to use 
cannabis regularly and affiliate with peers who also 
use cannabis.
Youth might be particularly vulnerable to these negative 
outcomes due to the extensive structural and neurochemical 
changes that are taking place in the brain during adolescence, 
especially the ongoing development and maturation of the 
prefrontal cortex, which is critical to higher-order cognitive 
processes such as impulse control, working memory, planning, 
problem solving and emotional regulation (Luna, Garver, Urban, 
Lazar, & Sweeney, 2004; Spear, 2013).
Adolescent brain development is also affected by the 
endocannabinoid system. Endocannabinoids (cannabinoids 
naturally occurring in the body) regulate the activity of 
neurotransmitters like dopamine and serotonin, which in turn 
affect memory, coordination, appetite, pain, mood, pleasure 
and motivation. Cannabis use can disrupt the functioning and 
development of these systems (Bossong & Niesink, 2010). 
Given the high rates of cannabis use by youth during this 
critical period of their development — as well as the multitude 
of cannabis-related information being released and discussed 
every day — it is more important than ever to review what is 
known, what is not known and what evidence is emerging about 
the effects of cannabis use during adolescence. The evidence 
reviewed in this report will help support efforts to reduce harm to 
youth by decreasing the number who use cannabis and delaying 
the initiation of use. By situating the relevant neuroscience in the 
broader behavioural and social contexts of youth cannabis use, 
this report aims to provide a much-needed resource for any 
person or institution responsible for youth policies, programs 
and practices pertaining to cannabis. 
Chapter-by-chapter summary
Chapter 1: What are the brain and 
behavioural effects of cannabis use in youth?
A number of key neurodevelopment phases must occur during 
adolescence before the brain is fully ready for adulthood. The 
brain’s process of pruning inefficient neurons and insulating 
axons optimizes it for future success, but also makes youth 
more vulnerable to the effects of cannabis use. The regions 
of the brain that undergo the most fine-tuning during the 
teenage years are those responsible for decision making, 
judgment, planning and problem solving, and these regions are 
potentially most susceptible to cannabis when they are not yet 
fully developed.
This chapter explores the role of the endocannabinoid 
system and how it can be hijacked by the psychoactive 
component of cannabis, delta-9-tetrahydrocannabinol (THC). 
THC induces neurotoxic changes that affect the natural 
process of neurodevelopment in adolescence and in 
turn promote physical changes in the brain’s structure — 
effectively altering the functions responsible for emotional and 
cognitive performance. 
The chapter then reviews recent assessments of the impact 
of cannabis on behaviours like cognitive functioning, academic 
performance, motivation, risk taking and psychomotor skills, 
presenting findings from both traditional neuropsychological 
assessments and neuroimaging technologies, such as 
magnetic resonance imaging. The latter allow researchers 
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to observe the actual changes happening to the brain’s 
architecture (e.g., volume and health of grey and white matter) 
and functioning (e.g., blood flow) when exposed to THC.
Chapter 2: Is there a link between cannabis 
and mental health?
Several neuropsychiatric disorders and unsafe behaviours, 
including mental illness and substance abuse, typically 
begin to emerge during adolescence. Cannabis use has 
been found to have potentially adverse effects among those 
who are vulnerable to mental illness. Presenting the latest 
epidemiological, neurobiological and clinical evidence, this 
chapter looks at how cannabis use affects the development 
and prognosis of schizophrenia, mood and anxiety disorders, 
eating disorders and childhood behavioural disorders (such as 
attention deficit hyperactivity disorder).
Current evidence suggests cannabis use is associated with 
the development of psychotic symptoms and disorders, with 
an enhanced vulnerability to psychosis linked to disturbances 
in the endocannabinoid system and genetic variations in the 
enzymes responsible for dopamine metabolism. In contrast, the 
development of childhood behavioural disorders likely precedes 
and might lead to later cannabis use.
So does drug use induce mental illness? Or does mental 
illness increase risk for drug use? While there is clearly a 
strong relationship between mental illness and cannabis use, 
the direction and causal nature of that relationship is not well 
understood and is likely different for each type of disorder. As 
such, further research into the underlying mechanisms that put 
individuals at risk for both substance use and mental illness, 
including interventional and neurophysiological studies, will be 
essential moving forward. 
Chapter 3: Is cannabis addictive?
Cannabis is the world’s most widely used illicit drug, with 
approximately 23% of Canadian youth using it on a daily or 
near-daily basis during the past three months, but does it 
prossess the same addictive properties as other drugs of 
abuse? Despite the perception that it is not an addictive drug, 
evidence indicates cannabis use can lead to addiction: one in 
six of those who initiate cannabis use during adolescence will 
become dependent.
This chapter begins with a primer on addiction, describing how 
addictive substances are classified by the medical field and 
defining key terms like “abuse,” “dependence” and “substance 
use disorder.” It then presents the neurobiological, preclinical 
and clinical evidence on cannabis’ addictive potential, 
including animal-based studies showing that THC induces 
self-administration behaviour in primates, as well as clinical 
studies exploring the symptoms of cannabis dependence and 
withdrawal. It also presents epidemiological evidence on the 
frequency of addictive states associated with cannabis, with 
a particular focus on how individuals transition from use to 
dependence and whether cannabis can actually be considered 
a “gateway” drug to other illicit substances. The chapter 
concludes by looking at the biological and environmental factors 
that might affect a person’s vulnerability to addiction, including 
genetics, gender, socioeconomic status and age of initiation of 
use — making efforts to prevent or delay the onset of cannabis 
use particularly important.
Chapter 4: What interventions are available 
for cannabis use disorders?
The detrimental effects of cannabis use discussed in the 
previous chapters underscore the importance of prevention, 
early detection and treatment interventions targeting youth. This 
chapter looks at the efficacy of prevention initiatives and many 
emerging treatments for adolescents, including:
• Comprehensive prevention programs, which have 
been shown to be most effective when delivered in 
school-based settings;
• Screening and brief intervention tools administered 
by clinicians, which can help healthcare providers 
assess and address clinically relevant risk 
categories of substance use;
• Behavioural and psychotherapeutic interventions 
such as cognitive behavioural therapy (i.e., helping 
correct inaccurate or negative thinking), motivational 
enhancement therapy (i.e., increasing commitment 
to change), multidimensional family therapy (i.e., 
targeting inter- and intrapersonal functioning) and 
contingency management (i.e., providing rewards 
upon demonstration of desired behaviour) — all 
of which show promising but modest effects in 
reducing cannabis use; and
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• Pharmacological interventions and medications 
targeting withdrawal symptoms, abstinence initiation 
and relapse prevention, as well as the treatment of 
co-morbid cannabis use and mental illness.
Although the development of treatments specifically for cannabis 
use has lagged behind advancements for other substances of 
abuse, an evidence base has emerged to guide the treatment 
of adolescents with cannabis use disorders with the strongest 
evidence being in support of psychosocial interventions.
Chapter 5: Cannabis and Youth — A 
Summary of Key Findings and Major 
Questions, and a Call  to Action
Summarizing the key findings presented in the previous chapters, 
this final section of the report outlines recommendations for 
research topics that will help improve prevention and treatment 
outcomes, as well as immediate actions that can be taken 
to inform cannabis-related policy and help reduce the harms 
associated with cannabis use during adolescence.
While progress continues to be made in recognizing and 
understanding the causes, mechanisms and long-term 
effects of cannabis use in youth, many questions still need 
to be addressed. Future research should focus on improving 
our understanding of why youth use cannabis, in particular 
identifying the specific attitudes and values that have contributed 
to the high level of use by Canadian youth. Research should 
also focus on their patterns of use, the links between cannabis 
use and mental disorders such as depression and anxiety, and 
the efficacy of various therapeutic interventions and preventive 
education programs.
In addition to these longer-term projects, a number of practical 
measures should be implemented today to mitigate the risk posed 
to youth by cannabis. These include, for example, working with 
the healthcare sector to encourage the use of brief screening 
procedures for cannabis use among young patients; bringing 
together health and education experts to develop standardized 
school-based education programs; and being more systematic 
about the collection of cannabis-related data in all venues, from 
police incident reports to hospital admissions to the roadside 
collection of oral fluid from suspected impaired drivers. 
Above all, it is urgent that the evidence reviewed in this report 
be seriously taken into account by governments and research 
agencies when important policy issues are being contemplated.
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What are the Brain and 
Behavioural Effects of 
Cannabis Use in Youth?
1
Chapter at a Glance
• Several key neurodevelopmental phases must occur during adolescence before the brain is 
fully prepared to deal with the challenges associated with adulthood.
• The prefrontal cortex, which is responsible for higher-order cognitive functions like decision 
making and problem solving, is particularly susceptible to the effects of cannabis during 
these developmental phases. 
• The psychoactive component of cannabis (THC) hijacks the brain’s internal cannabinoid 
system, resulting in disrupted neural regulation and neurotoxic changes in the brain.
• Structural brain imaging suggests that cannabis users, especially early onset users, have 
altered grey and white matter. 
• Functional brain imaging shows that cannabis has a negative impact on processes such as 
executive functioning, motivation and risk-taking behaviour. 
• Despite the accumulating evidence, a wide range of variables such as study methodology, 
dosage, age of onset and other substance use limit the conclusions that can be made from 
the current literature. 
• Teens, adults and the community at large, including policy makers, need to be further 
educated about the significant impact cannabis has on the developing brain.
By Andra Smith, PhD
Associate Professor, School of Psychology, University of Ottawa
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1.1 Cannabis and the  
developing brain
While the brain is continually reshaping itself well into adulthood, 
its development shifts into high gear during the teenage years. 
A number of key neurodevelopmental phases must occur 
before the brain is fully ready to deal with the challenges of 
the adult world. For example, the adolescent brain undergoes 
a pruning phase to remove neurons that are not being used 
or are inefficient (Giedd, 2008). A process of myelination also 
takes place in which a fatty substance called myelin forms 
an insulating shield around the axons of neurons, increasing 
the speed of electrical transmission to make communication 
between neurons more efficient (Anderson, 2002). 
Processes like pruning and myelination are essential to 
optimizing the brain for success during early adulthood, and 
their streamlining of neural development is the very thing 
that makes youth more vulnerable to the effects of cannabis 
use. The regions of the brain that undergo the most pruning, 
myelination and other fine-tuning are those required for higher-
order cognitive processes such as decision making, judgment, 
emotional regulation, planning and problem solving. Key among 
these regions is the prefrontal cortex (Anderson, Anderson, 
Northam, Jacobs, & Catroppa, 2001; Rubia et al., 2000; 
Sowell et al., 2003), which is most susceptible to the neurotoxic 
effects of cannabis when it is not yet fully developed. 
Without a well-developed prefrontal cortex, a teen has to rely 
on other brain regions for cognition, namely the less-evolved 
limbic system, which is responsible for emotions. This reliance 
allows the “emotional” brain to control behaviour, rather than 
enlisting the help of the prefrontal cortex or the “thinking” brain. 
This control of behaviour by the emotional brain can lead to 
increased risk-taking behaviour, poor decision making and 
inferior reasoning ability.
1.1.1 The endocannabinoid system
The human brain makes its own chemicals that 
resemble the psychoactive component of cannabis, 
delta-9-tetrahydrocannabinol (THC). Two of these naturally 
occurring cannabinoids, anandamide and 2-arachidonoyl-
glycerol (2-AG), are considered neurotransmitters because they 
bind to cannabinoid receptors (CB
1
 and CB
2
) located in the 
prefrontal cortex, anterior cingulate, basal ganglia, amygdala, 
hippocampus and cerebellum (Herkenham, Lynn, Melvin, de 
Costa, & Rice, 1991; Batalla et al., 2013). 
This endocannabinoid system plays an important role in the 
maturation of the cortical neuronal networks that reach maximal 
levels during late adolescence. It is also involved in modulating 
other neurotransmitter systems such as dopamine, enhancing 
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brain cell growth and, ultimately, controlling brain functions such 
as appetite, motor activity, motivation, mood, immune system 
activity, reward, learning and memory (Breivogel & Sim-Selley, 
2009; Gray, 2013; Pope, Mechoulam, & Parson, 2010). 
The presence of endogenous cannabinoids (i.e., those 
occurring in the brain) has led some to suggest that cannabis 
use is “natural” and benign. However, when THC is taken into 
the brain, it targets the CB
1
 receptors in much higher quantities 
than endogenous cannabinoids, effectively flooding the system 
to the point that it no longer works efficiently. This “hijacking” of 
the endocannabinoid system wreaks havoc on many complex 
neurophysiological processes, disrupting the regulatory role the 
system plays and inducing neurotoxic changes in brain regions 
rich with CB
1
 receptors (Breivogel & Sim-Selley, 2009). These 
neurotoxic changes have been shown to dramatically affect 
the natural process of neurodevelopment in adolescence and, 
in turn, promote physical changes in the brain’s structure — 
effectively altering the functions responsible for emotional and 
cognitive performance (Batalla et al., 2013).
Given that CB
1
 receptors are widely dispersed throughout the 
brain, many different types of behaviour are affected by cannabis 
use, ranging from academic performance to motivation to 
psychomotor skills like driving. While there are many individual-
level variables that make it difficult to make unequivocal 
assertions, through the use of both neuropsychological testing 
and neuroimaging technologies, the evidence is mounting that 
early onset cannabis use has a tremendous impact on the 
structure and functioning of the teenage brain and can weaken 
the foundation for future life success.
1.2 Behavioural Impact of 
Cannabis Use
Much of the research on the impact of cannabis on the 
developing brain has come from traditional neuropsychological 
testing batteries and the field of brain imaging, particularly 
magnetic resonance imaging (MRI) and functional MRI (fMRI). 
However, consistent results have been difficult to ascertain given 
the multifaceted nature of this type of research and the wide 
range of variables that must be taken into account, including the 
age and socioeconomic status of test participants, the number 
of years they have been using cannabis, frequency and quantity 
of use, the potency and dosage of the cannabis used, and 
any potential interactions between cannabis and other licit or 
illicit drugs. In addition, few longitudinal studies have measured 
behaviour before and after cannabis use in a young population, 
making it difficult to compare short- and long-term effects. 
That said, the existing neuropsychological evidence from the 
few longitudinal studies indicates behavioural deficits resulting 
from early cannabis use, particularly in the areas of cognitive 
ability and academic performance (Bava, Jacobus, Thayer, 
& Tapert, 2013; Hatchard, Fried, Hogan, Cameron, & Smith, 
2014; Meier et al., 2012; Smith, Longo, Fried, Hogan, & 
Cameron, 2010; Smith et al., 2011).
1.2.1 Impact on cognitive ability, IQ and 
executive functioning
Cognitive ability is often associated with intelligence quotient 
(IQ), but as IQ studies typically have several confounding 
variables, there have been mixed and controversial results with 
respect to cannabis’ impact on a person’s IQ. 
The findings of a long-running longitudinal study in New Zealand 
by Meier and colleagues (2012) associated adolescence-
onset heavy cannabis use with an eight-point decrease in IQ 
by age 38. Those losing the most IQ points were those who 
had started cannabis use during their teenage years. Some 
critics, however, suggested these results were an artifact of 
socioeconomic status (Rogeberg, 2013). 
Another longitudinal study from the United Kingdom reported that 
teens who had used cannabis at least 50 times by age 15 did 
not show a decrease in IQ compared to prior testing conducted 
at age eight (Mokrysz et al., 2014). In a counter argument, 
Moffitt, Meier, Caspi, & Poulton (2013) refuted the challenges 
to their study (Meier et al., 2012) to show that their results could 
not be accounted for by socioeconomic status and that their 
results were in fact accurate. Meier has also commented on the 
Mokrysz study suggesting that this study was not comparable 
to the New Zealand study because the children were only 15 at 
the time of testing, meaning they would not show results similar 
to those of adults who had been using cannabis four or more 
times per week for 20 years after adolescence. 
The two studies highlight the difficulties of using IQ as a measure 
of cognitive ability when studying the effects of cannabis on 
youth. Furthermore, IQ studies have historically been criticized 
for having limited predictive validity for life outcomes (Duckworth, 
Quinn, Lynam, Loeber, & Stouthamer-Loeber, 2011). 
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Executive functioning is a more credible predictor of future 
success, and refers to the group of cognitive processes 
involved in goal-directed behaviour such as planning, organizing, 
decision making, impulse control and working memory. The 
longitudinal study by Meier and colleagues (2012), for example, 
linked cannabis to a broad decline across several cognitive 
domains related to executive functioning, including verbal 
comprehension, processing speed, perceptual reasoning and 
memory. Continual use was associated with greater decline. 
Among those who started using cannabis during adolescence 
but eventually quit, the cognitive deficits caused by persistent 
use were not fully restored by cessation. 
1.2.2 Impact on academic performance 
Given the adverse effects of cannabis on executive functioning, 
it is no surprise that academic performance — and as a 
result, long-term success into adulthood — can be affected 
negatively by cannabis use. Results from the longitudinal 
study by Mokrysz and colleagues (2014) showed that teens 
who used cannabis at least 50 times by age 15 scored an 
average of three percent lower on compulsory school exams at 
age 16 than those who did not smoke cannabis. Furthermore, 
after integrating data from three large, long-running studies in 
Australia and New Zealand, Silins and colleagues (2014) found 
that young adults who used cannabis daily before the age of 17 
were significantly less likely to complete high school or obtain a 
university degree. There was also a dose-response relationship 
between frequency of adolescent cannabis use and all adverse 
young adult outcomes, strongly supporting the hypothesis that 
early use can indeed impact long-term success into adulthood. 
1.3 Using neuroimaging to take 
a closer look at how cannabis 
affects the brain
With neuropsychological testing providing variable results 
that have not been unequivocally or consistently published 
in the literature, the field of neuroimaging — specifically, 
magnetic resonance imaging (MRI) — plays an increasingly 
important role in understanding the impact of cannabis on the 
developing brain.
Two main types of MRI will be discussed here: structural MRI 
and functional MRI. Structural MRI, which is used to view the 
anatomy of the brain, including the neuronal connections 
between brain regions, is a powerful tool for identifying the 
extent to which cannabis use alters the brain’s grey matter and 
white matter. Functional MRI (fMRI) is a technique that measures 
changes in the brain’s blood flow during cognitive tasks, 
providing a non-invasive window into the brain as it works. 
fMRI’s ability to observe and measure brain activity is more 
sensitive than neuropsychological testing alone. Specifically, it 
can identify subtle differences in brain activity even when the 
individuals participating in the cognitive test show similar task 
scores and performance, making it invaluable for demonstrating 
the damage early onset cannabis use can have on 
brain functioning.
1.3.1 What structural MRI reveals about 
cannabis’ impact on the brain
In general, structural MRI results have demonstrated that 
cannabis exposure during the adolescent years has a significant 
negative effect on brain volume, the folding patterns of the 
cortex, neural connectivity and white matter integrity (Lisdahl, 
Wright, Medina-Kirchner, Maple, & Shollenbarger, 2014; Wrege 
et al., 2014). 
More specifically, a number of studies have revealed differences 
in the volume of the hippocampus, amygdala, cerebellum, 
striatum, insula, temporal pole and prefrontal cortex between 
groups of adolescent cannabis users and non-users (Ashtari 
et al., 2011; Battistella et al., 2014; Churchwell, Carey, Ferrett, 
Stein, & Yurgelun-Todd, 2012; Cousijn et al., 2012a; Filbey 
et al., 2014; Gilman et al., 2014; Gruber, Dahlgren, Sagar, 
Gonenc, & Killgore, 2012; Medina, Schweinsburg, Cohen-Zion, 
Nagel, & Tapert, 2007; Medina et al., 2009; Medina, Nagel, & 
Tapert, 2010; McQueeny et al., 2011; Schacht, Hutchison, & 
Filbey, 2012). 
Interestingly, some of these studies showed increased brain 
volumes in cannabis users while others showed decreased 
volumes. This bidirectional relationship between cannabis 
and brain volume might seem counterintuitive; however, when 
looked at in conjunction with reports of changes to executive 
functioning, mood and risk-taking behaviour, changes in brain 
volume are indicative of negative effects. Rather, they represent 
altered grey and white matter architecture suggestive of 
disrupted neuronal pruning and less efficient connectivity, both 
of which are important for healthy neurodevelopment.
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Brain volume, folding and thickness
A recent study that used voxel-based morphometry 
(a neuroimaging analysis technique) found that the age of onset 
of cannabis use significantly influenced the magnitude of brain 
volume reductions in the medial temporal cortex, temporal pole, 
parahippocampal gyrus, insula and orbitofrontal cortex, and 
volume increases in the cerebellum between regular cannabis 
users and occasional users (Battistella et al., 2014). Reductions 
were observed in regions dense with CB
1
 receptors that 
contribute to emotional, motivational and executive functioning 
abilities, which suggests that the increased volume of the 
cerebellum experienced by regular cannabis users was related 
to the developmental processes that occur in the brain during 
adolescence, in particular, the pruning of excess neurons. 
Because the cerebellum is also rich in CB
1
 receptors, exposure 
to cannabis during early adolescence might have affected its 
ability to prune unnecessary synaptic connections. 
A similar explanation might be applied to Gilman and colleagues’ 
(2014) findings of a difference in three structural measurements 
(shape, size and density) of the nucleus accumbens when 
comparing cannabis users (mean of 11 joints per week with 
a large standard deviation of 9.61) compared to non-users. 
While these results have been met with criticism, they highlight 
the importance of using multiple structural MRI measures to 
identify the early effects of cannabis exposure on the brain’s 
architecture. For example, while several regions of the brain 
were shown to be significantly different between the using 
and non-using groups, others showed a difference in only one 
of the three structural measures. If the other two measures 
were the only ones quantified, the results would have been 
misinterpreted — emphasizing the need for future research to 
focus on multimodal imaging. 
Structural MRI measurements have also suggested that 
cannabis use has an adverse effect on the folding and 
thickness of the cortex (Lopez-Larson et al., 2011; Mata et al., 
2010). In addition, a number of studies have used magnetic 
resonance spectroscopy (a technique for quantifying certain 
neurotransmitters and chemicals found in the brain, including 
glutamate, n-acetyl aspartate, creatinine, GABA and myo-
inositol) to compare adolescent chronic cannabis users to 
non-users. Two studies conducted by Prescot and colleagues 
(2011; 2013), for example, have shown reduced amounts of 
certain chemicals in the anterior cingulate of cannabis users. 
Building from the previous work of Silveri and colleagues (2011), 
Mashhoon and colleagues (2013) found that white matter 
reductions in cannabis users were localized to the thalamus. 
Their assertion that this effect among cannabis-dependent 
young men (with an average of only 5.5 years of use) might 
reflect an early neurochemical response to the toxicity of 
cannabis is suggestive of the suppression of glial cell function, 
which support neurons, and increased compensation efforts 
to maintain cellular volumes. However, further investigation is 
required to determine if these neuronal and glial cell variations 
underlie the other structural and functional anomalies observed 
in young cannabis users and if these neurochemical alterations 
could have a long-lasting impact on brain health into adulthood.
Predictive brain signatures
As most of the MRI studies cited so far have been cross-
sectional in design, the antecedents of the structural differences 
between cannabis users and non-users are questionable. In 
particular, it remains unclear whether the results of these studies 
reflect pre-existing brain differences that lead to increased 
cannabis use and subsequent variations in brain development 
and behavioural outcomes. 
The importance of this question was highlighted by Cheetham 
and colleagues (2012), who examined whether existing 
structural abnormalities in the brain were predictive of future 
cannabis use in adolescence. After obtaining brain images of 
participants at age 12 (before the onset of cannabis use) and 
then again at 16 (after they had commenced use), they found 
that the orbitofrontal cortex volume was smaller in the 12- year- 
olds who went on to use cannabis. Because no other brain 
regions were significantly predictive of this behaviour, these 
results suggest that the structural size of the orbitofrontal cortex, 
which is responsible for many aspects of behaviour, including 
decision making, impulse control, self-regulation and reward 
sensitivity, might contribute to a risk of cannabis use. 
Interestingly, both left and right orbitofrontal size predicted later 
cannabis use. However, when controlling for other substance 
use, only the size of the right side remained significant. This 
difference highlights a methodological issue that plagues any 
kind of drug-related research: the use or abuse of multiple 
substances. As it can be difficult to find a sample of young 
participants who use only cannabis, the specificity of any 
results is limited.
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Clinical Vignette
Steve
Steve is 16 years old and lives with his mother, who works three 
part-time jobs to make ends meet. While Steve did well in elementary 
school and was active in team sports, he found high school much 
harder and struggled to keep up. He also started to feel insecure: he 
didn’t reach puberty when his friends did, he didn’t make any of the 
school teams and he was intensely afraid of speaking up in class.         
At home, his mother wasn’t often around — and when she was,       
she seemed stressed. 
Some friends shared weed with Steve at his first high school dance. 
His connection to it was immediate. He felt relaxed and socially 
confident. Over the next few months he started to smoke up more 
frequently and hung out with friends who liked to do the same. Over 
the summer between grades 9 and 10, he smoked weed almost 
every day; when the new school year started he would sometimes 
get high at lunch. Steve noticed right away that he worried less about 
doing class presentations and talking in front of his peers when he 
was high. By the second semester of Grade 10, however, he was 
skipping classes to get high with friends and started to fail some 
courses. When one of his teachers talked to him about whether he 
“has what it takes” to go to university, Steve was embarrassed and 
agreed to switch out of courses geared toward university preparation. 
In the summer before Grade 11, Steve found out his father likes 
to smoke weed occasionally and they got high together on a          
camping trip. 
Now, near the end of Grade 11, Steve’s attendance at school is 
very poor and he hasn’t completed many assignments. Instead, he 
smokes weed a few times each day and stays up late at night playing 
video games with friends online. His mother is constantly on his case 
about his use of cannabis — but Steve finds if he isn’t high, he can’t 
stop worrying about his future. 
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Health of white matter
Evidence of altered neuronal health following adolescent 
cannabis use has emerged from studies using diffusion tensor 
imaging (DTI), which is an MRI technique that allows for an 
investigation into the quality or health of the white matter tracts 
in the brain (Le Bihan et al., 2001). For example, DTI is able to 
localize changes in the axonal health of the corpus callosum 
(the large bundle of white matter that connects the brain’s two 
hemispheres) that might impair communication between the left 
and right sides of the brain, and potentially affect a person’s 
cognitive abilities. Several DTI studies have reported reduced 
white matter quality in the corpus callosum of cannabis users 
(Arnone et al., 2008; Ashtari, Cervellione, Cottone, Ardekani, 
& Kumra, 2009; Bava et al., 2009; Bava, Jacobus, Thayer, & 
Tapert, 2013; Gruber, Silveri, Dahlgren, & Yurgelun-Todd, 2011; 
Gruber, Dahlgren, Sagar, Gonenc, & Lukas, 2014; Jacobus, 
Squeglia, Infante, Bava, & Tapert, 2013; Zalewsky et al., 2012). 
Once again, the difficulty of quantifying the impact of cannabis 
exclusively, without other contributing factors, comes into play. 
Bava and colleagues (2013) performed a longitudinal DTI study 
in which they imaged cannabis and alcohol users twice: once 
at the start of the study period and then again 18 months later. 
While adolescent cannabis users had attenuated white matter 
integrity in seven tracts throughout the brain, it was actually 
the use of alcohol between imaging sessions that predicted a 
change in structural measurements.
Other cross-sectional studies have controlled for alcohol use 
and observed similar disorganization of white matter structure 
in young cannabis users. Zalewsky and colleagues (2012) 
showed, using DTI, that the earlier heavy users started using 
cannabis, the more impaired the axonal connectivity, particularly 
in the hippocampus. Given that developing white matter has 
higher concentrations of cannabinoid receptors than the mature 
brain and is therefore more susceptible to the potential damage 
caused by cannabis, these findings suggest that delaying the 
age of onset might help protect the white matter microstructure. 
The alteration of neuronal structure — specifically, reducing the 
health of the axons that are the foundation for the communication 
between brain regions — is paramount to cognitive challenges. 
This connection was highlighted most recently by Gruber and 
colleagues (2014) who showed that earlier cannabis use onset 
was related to reduced white matter health and increased 
impulsivity. Cannabis users were divided into early and late 
onset groups, with the former showing a correlation between 
low white matter integrity and high impulsivity, while the latter did 
not show this relationship. 
1.3.2 What functional MRI reveals about 
cannabis’ impact on the brain
Given the widespread impact cannabis has on grey and white 
matter, including connectivity, cortical thickness, density, 
volume and neurochemical health, and the complex relationship 
between these alterations and a wide range of individual-level 
variables, concisely synthesizing the results of structural MRI 
studies would be a difficult task. Using fMRI, which measures 
changes in the brain’s blood flow, to support the findings derived 
from structural MRI techniques can help us better understand 
the impact of cannabis on brain development. 
More specifically, fMRI measurements of brain activity are 
based on the blood oxygen level dependent effect. Increased 
neuronal activity and communication between brain regions 
requires increased blood flow, which can be observed and 
quantified during the performance of cognitive tasks and while 
at rest (i.e., when no task is being performed).
Resting-state fMRI 
A study by Behan and colleagues (2013) found that chronic 
cannabis users showed heightened neural activity between the 
bilateral inferior parietal lobules and the left cerebellum when 
compared to non-users. These findings suggest a different 
pattern of connectivity or communication between parts of the 
brain of cannabis users. Looking specifically at younger users, 
Houck and colleagues (2013) performed resting-state fMRI on 
a group of high-risk adolescents (aged 14–18) and found that 
high cannabis use was correlated with increased connectivity 
within a fronto-temporal network. Orr and colleagues (2013), 
meanwhile, observed that cannabis users had increased 
intra-hemispheric frontal to cerebellum connectivity as well as 
decreased inter-hemispheric frontal to cerebellum connectivity 
when compared to non-users. 
Similar to those of structural MRI studies, these findings have 
varied results due to the range of methodologies used and 
regions imaged by each study. Nonetheless, this differential 
pattern of communication between brain areas at rest suggests 
a significant alteration of intrinsic connectivity in cannabis users. 
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In another study, Cheng and colleagues (2014) used resting-
state fMRI to differentiate between cannabis users and non-
users on an individual basis. They found patterns of connectivity 
ranging from the prefrontal cortex to the cerebellum to be 
predictive of whether a participant was a cannabis user. In 
fact, based on these connectivity patterns, they were able to 
correctly predict cannabis use in 84–88% of participants, further 
emphasizing the consistency of altered functional connectivity 
in cannabis users.
While this one study showed a high accuracy rate in predicting 
brain signatures of cannabis users, it is difficult to assimilate 
the findings from resting-state fMRI results, as both increases 
and decreases have been reported in functional connectivity 
and blood flow, making the results seem dichotomous. Still, 
the imaging results provide valuable insight into the neural 
mechanisms that are the basis for cannabis’ effect on cognition.
Task-driven fMRI
By measuring activity in the brain as a task is being performed, 
fMRI can be used to quantify changes in neural functioning as 
a result of acute administration of cannabis. Specifically, the 
altered blood flow observed during several types of cognitive 
tasks can further enhance our understanding of the neural 
impact of cannabis, particularly on important types of cognition 
that contribute to the orchestration of goal-directed behaviour. 
The immediate effects of cannabis on cognition have been 
reported in a number of studies that used fMRI after administering 
cannabis or a placebo, then repeating the procedure later with 
the substance not administered during the first session. For 
example, van Hell and colleagues (2011) showed that cannabis 
increased blood perfusion in the anterior cingulate cortex, 
superior frontal cortex, insula, cerebellum and substantia nigra, 
while reducing perfusion in the post-central and occipital gyri. 
These brain regions coincide with the behavioural effects that 
occur following cannabis use, including an altered sense of 
time, euphoria, impaired psychomotor activity, and reduced 
attention and working memory. 
Similar results were observed by Bossong and colleagues 
(2012), who found that, following cannabis use, performance 
on the Sternberg item-recognition task decreased while brain 
activity for low working memory loads increased. However, as 
the task became more difficult, a negative linear relationship 
between working memory load and activity was observed. 
Other effects noted following cannabis administration included 
an impact on the dorsolateral prefrontal cortex, inferior temporal 
gyrus, cerebellum and inferior parietal lobule. The behavioural 
effects mentioned above correlate with blood-flow alterations 
in these brain regions and also involve areas where structural 
differences have been observed between cannabis users and 
non-users. 
While the van Hell and Bossong studies were interested in 
the brain’s direct response to cannabis, others have imaged 
abstinent participants (Schweinsburg et al., 2010; Tapert et al., 
2007) and others long-term users to compare the effects of 
early and later onset use. Variability in the methodology makes 
it difficult to consolidate these results; however, the underlying 
consensus from the fMRI literature is that patterns of brain 
activity are less efficient in cannabis users compared to non-
users and the earlier the onset, the more significant the negative 
influence of cannabis on brain functioning (Gruber et al., 2012).
Using fMRI to assess performance on         
specific tasks
fMRI can be used to evaluate the performance of cannabis 
users in a variety of different cognitive tasks. For example, 
Tapert and colleagues (2007) used fMRI during a go/no go 
task in abstinent adolescent cannabis users to demonstrate 
that even after 28 days of cannabis abstinence, brain activity 
was significantly different between users and non-users, with 
users having significantly more activity in several prefrontal, 
parietal and occipital areas. An increase in neural activity was 
also detected during a go/no go task by Smith and colleagues 
(2011) and during a counting Stroop task by Hatchard and 
colleagues (2014). 
Although increased neural activity might seem like a positive 
adaptive response, it is likely that cannabis is forcing the 
brain to work harder to perform the task and engaging more 
resources to respond accurately. This increased demand on 
the brain is a sign of a required or necessary compensation 
to perhaps overcome its altered structural integrity. Over time, 
the brain cannot compensate further and it gets fatigued and 
falters. In real-life situations (i.e., outside the imaging scanner), 
this compensation might be insufficient and problems with 
cognitive efficiency might arise (Smith et al., 2011). This is 
particularly problematic at a time of brain development when the 
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prefrontal cortex is undergoing fine-tuning and optimization for 
executive functioning. 
Go / No Go task (tests inhibitory function)
This test involves the presentation of white letters, 
one at a time, on a black screen. Fifty percent of the 
letters are “X” and the rest are other randomly selected 
letters. There are two test conditions: one where 
participants are instructed to press a button when an 
X is presented and refrain from pressing for all other 
letters, and one where they are instructed to refrain 
from pressing for X and press for all other letters.
Counting Stroop task (tests conflict processing)
This test involves number words (e.g., “one,” “two”) 
and animal words (e.g., “dog,” “cat”) printed in white on 
a black background. Participants are presented with up 
to four identical words, one above another, and asked 
to report the number of words observed using the 
appropriate button on the response pad (e.g., index 
finger for one word, middle finger for two words). The 
test consists of 16 30-second blocks, each containing 
20 groups of words.
In addition to cognitive inhibition, other behaviours that fall under 
the umbrella of executive functioning, including working memory, 
attention and visuospatial processing, have been studied 
with fMRI and shown to be negatively affected by cannabis 
use. Smith and colleagues (2010) imaged a group of young 
adults between 19–21 years of age from the Ottawa Prenatal 
Prospective Study as they performed a visuospatial 2-back 
working memory task. Because this longitudinal study followed 
participants since they were in utero, control for many lifestyle 
variables, including other drug use and prenatal drug exposure, 
was possible, and further socio-demographic information was 
available. Like the other studies mentioned above, researchers 
found that the youth who has smoked one or more joints per 
week for at least three years showed significantly more brain 
activity than non-users in the dorsolateral prefrontal cortex and 
several temporal lobe regions when completing the task. 
Visuospatial 2-back task (tests working 
memory)
This test involves a circle presented in white on a black 
background at one of nine different positions on a 
screen. The circle is displayed in a given position for 75 
milliseconds before being relocated. The task includes 
two conditions: a control condition where participants 
are asked to press a button each time the circle is 
in the middle of the screen, and a working memory 
condition where they are required to press a button 
each time the circle appeared in the same position it 
occupied two appearances before.
Other studies have shown similar results, including increased:
• Activity in prefrontal regions of male teenage 
cannabis users (13–19 years old) as they 
performed a novel working memory task (Jager, 
Block, Luijten, & Ramsey, 2010);
• Activation of the left superior parietal lobe in early-
onset cannabis users compared to later-onset 
users as they performed a verbal working memory 
challenge (Becker, Wagner, Gouzoulis-Mayfrank, 
Spuentrup, & Daumann, 2010), and 
• Prefrontal cortex blood flow in chronic cannabis 
users compared to non-users (Abdullaev, Posner, 
Nunnally, & Dishion, 2010). 
Other fMRI studies have revealed reduced activity in cannabis 
users or abstinent users compared to non-users (De Bellis et 
al., 2013; Schweinsburg et al., 2008). 
Although these studies all reveal altered blood flow in cannabis 
users, methodological differences (such as the ages of the 
participants and the cognitive tasks performed) significantly limit 
the ability to compare and synthesize the evidence. To implicate 
a network of functional and morphological alterations that might 
moderate the effects of cannabis on executive functioning, 
there will need to be a more concerted effort for methodological 
consistency, including multimodal assessment and the use of 
different types of fMRI data analyses.
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1.4  What neuroimaging reveals 
about cannabis’ impact on youth 
behaviour
Using neuroimaging to explore how cannabis affects the 
structure and functioning of the developing brain can also 
lead to important conclusions on how cannabis influences 
youth behaviour.
1.4.1 Impact on motivation 
One way to look at the negative impact of cannabis on 
cognition is to examine the correlation between cannabis use in 
adolescence and apathy or amotivation (Lynskey & Hall, 2000). 
Adolescents who are less motivated typically do not perform as 
well in school, leading to a possible cascade effect on future 
achievement. 
Neuroimaging has begun to uncover the mechanisms through 
which the motivation of cannabis users is reduced. In perhaps 
one of the most comprehensive MRI studies to investigate 
the neurobiological impact of cannabis, Filbey and colleagues 
(2014) incorporated DTI, voxel-based structural morphometry 
and resting-state fMRI to show that the orbitofrontal cortex 
of cannabis users had reduced grey matter volume as well 
as increased structural and functional connectivity. They also 
showed that these effects lead to neural alterations that are 
modulated by the age of onset and duration of use. 
The orbitofrontal cortex, which is rich in CB
1
 receptors, acts 
as a network hub for many behaviours involved in reward 
processing, motivation, self-awareness and decision making. 
It is also one of the last brain regions to complete the pruning 
and myelination processes, making it a significant target for the 
neurotoxic effects of cannabis, especially when early onset and 
chronic use occurs. Alterations in this region might well underlie 
the motivational and affective changes observed in young 
people who use cannabis. 
Neuroimaging studies have provided valuable information on 
the neural underpinnings of reward processing and decision 
making, both of which play an important role when youth are 
choosing whether to use cannabis or to change how much 
they use. Cousijn and colleagues (2012b; 2013; 2014) have 
performed several studies using fMRI during gambling and 
working memory tasks to determine if brain activity can predict 
future drug use. While both heavy cannabis users and non-
users demonstrated normal performance in both tasks, the 
former showed higher activation in core areas associated with 
decision making and working memory. Within the cannabis 
users, these brain activity patterns predicted changes in 
cannabis use, with more activity (i.e., working harder to perform 
the task) correlating with escalated cannabis use six months 
later. The results from the gambling task, meanwhile, suggest 
an alteration in processing of motivational information in heavy 
cannabis users and that users who are biased toward immediate 
rewards have a higher probability of increasing drug use.
But how does abstinence from cannabis affect motivation? 
To address this question, Jager and colleagues (2010) used 
a monetary incentive delay task with fMRI in abstinent, but 
previously frequent, cannabis users and non-using controls. 
Again, despite performance similarities between the two 
groups, the task activated different brain regions of the reward 
circuitry in the cannabis users, who showed augmented activity 
in the striatum during the anticipatory stages of both reward and 
non-rewarding events. This finding suggests that users, even 
after abstinence, might have an overly sensitive motivational 
response to reward. 
The findings also suggest that adolescent cannabis use actually 
reduces the ability of the brain to disengage the motivational 
circuit when no reward can be obtained, strengthening the 
need for reinforcements (i.e., the high from using cannabis), 
even when facing the negative consequences of this risk-
seeking behaviour. This finding might also suggest an increased 
vulnerability for other kinds of risk-taking behaviour that could 
continue into adulthood, including continued and heightened 
drug use. 
Similar findings come from De Bellis and colleagues (2013), 
who used fMRI on individuals performing the decision-reward 
uncertainty task. Compared to the control group, abstinent 
users with cannabis use disorder showed augmented activity 
in posterior decision-making brain regions when making risky 
decisions, as well as attenuated activations to reward in the 
orbitofrontal cortex. These findings further support the role of 
the orbitofrontal cortex in cannabis use and its relationship to 
altered neurophysiology during risky behaviour, decision making 
and motivation. 
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1.4.2 Impact on driving skills 
As cannabis use is associated with a potential increase 
in risk-taking behaviour, the probability that youth will drive 
while under the influence of cannabis, which brings with it a 
significantly increased risk of motor vehicle collisions compared 
to unimpaired driving, is an issue of great concern (Asbridge, 
Hayden, & Cartwright, 2012, Gerberich et al., 2003). 
Based on recent epidemiological and laboratory evidence, the 
acute effects of cannabis increase the risk of motor vehicle 
collision by two to three times, a level of risk that increases 
even further when cannabis is mixed with alcohol (Hall, 2015). 
This increased risk is not surprising given the deleterious effects 
of cannabis on psychomotor functions such as balance, 
psychomotor speed, visual tracking and coordination (Liguori, 
Gatto, & Jarrett, 2002; Messinis, Kyprianidou, Malefaki, & 
Papathanasopoulos, 2006; Weinstein et al., 2008). While 
drivers who use cannabis have been shown to compensate by 
driving slower than normal, they typically have reduced control 
when there is increased task complexity, resulting in more lane 
weaving, slower reaction times, impaired divided attention task 
performance and reduced critical tracking test performance 
(Anderson, Rizzo, Block, Pearlson, & O’Leary, 2010; Downey 
et al., 2013; Hartman & Huestis, 2013; Lenne et al., 2010).
This effect has been supported with fMRI research into the 
impact of cannabis on the motor network, namely the cingulo-
cerebellar circuitry (Lopez-Larson et al., 2012). The cerebellum 
is involved in motor control, while the cingulate gyrus is the 
cognitive–attentional component of the motor network. Activity 
in this circuitry was found to be altered (in fact, reduced) in 
adolescent cannabis users compared to non-users during a 
simple finger-tapping task. This relationship between activity in 
the cingulo-cerebellar circuitry and lifetime quantity of cannabis 
use accentuates the negative effect cannabis has on motor 
functioning, including driving skill. Because of this negative effect 
on driving, jurisdictions that have recently legalized cannabis 
use need to institute strict driving regulations pertaining to 
cannabis-related impairment. 
In Washington, a state that legalized cannabis in 2013, 
Couper and Peterson (2014) looked at whether the legislative 
changes had affected the prevalence of cannabis in the state’s 
suspected impaired-driving cases. They found an increase 
from 19.1% to 24.9% for THC and from 27.9% to 40% for 
carboxy-THC (a metabolite of THC) in the blood of drivers 
suspected of impaired driving. A similar study was performed 
in Colorado using the Fatality Analysis Reporting System, which 
allows for the comparison of the proportion of drivers involved 
in fatal crashes who were cannabis-positive to those who were 
alcohol-impaired (Salomonsen-Sautel, Min, Sakai, Thurstone, & 
Hopfer, 2014). Since 2009, when medical marijuana became 
commercially available in the state, there has been an increase 
in the proportion of drivers who were cannabis-positive, but no 
such increase in alcohol-related crashes. When compared to 
other states that had not commercialized medical cannabis, 
Colorado showed an increased proportion of drivers in fatal 
crashes who were cannabis-positive. 
1.5 Conclusions and implications 
The dynamic neurodevelopment that occurs during 
adolescence is instrumental in creating an optimized brain that 
will help propel teens into a prosperous adulthood. By hijacking 
the neurodevelopment process, cannabis significantly affects 
cognition, academic achievement, motivation, risk-taking 
behaviour and psychomotor skills. 
The most consistent finding from both structural and functional 
MRI studies has been a negative effect of cannabis on the 
structure and functioning of the anterior cingulate, cerebellum 
and prefrontal cortex (specifically, the orbitofrontal cortex). 
These brain regions are critical for executive functioning, 
decision making, response inhibition and the ability to carry out 
goal-directed behaviour, all of which are necessary for long-
term success into adulthood.
While the results emerging from the latest neuroimaging 
studies align well with each other, further research that can 
better control for many different variables (including other drug 
use, age of onset of use and dosage) and can incorporate 
multivariate outcome measures and techniques (including a 
mix of neuroimaging and neuropsychological assessments) 
is required. Until then, the high incidence of cannabis use 
in youth and the mounting evidence of its disruption of brain 
development must be taken seriously by teenagers, their 
parents, healthcare professionals and policy makers across the 
country, as it is a critical societal issue with implications that 
cannot be minimized or ignored.
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Is There a Link Between 
Cannabis and Mental Illness?
2
Chapter at a Glance
• High rates of substance use disorders have been observed among individuals 
living with mental illness. 
• This co-morbidity has a negative impact on the prognosis and course of illness 
of all psychiatric disorders, especially when cannabis use is initiated during 
adolescence.
• Current evidence suggests a strong relationship between cannabis use and 
psychosis; however, the role of adolescent cannabis use in the onset of 
depression, anxiety, eating disorders and childhood behavioural disorders is 
less understood.
• Further research using multidisciplinary approaches will be needed to develop 
a greater understanding of the underlying relationship between cannabis use 
and mental illness.
By Michelle Goodman, BSc 
Institute of Medical Science, University of Toronto, and Schizophrenia Division, Centre for Addiction and Mental Health
and
Tony George, MD, FRCPC
Professor, Co-Director, Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto,   
and Chief, Schizophrenia Division, Centre for Addiction and Mental Health
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2.1 Introduction
Adolescence is a critical period of psychosocial and 
physiological development — and is also the time when several 
neuropsychiatric disorders and unsafe behaviours, including 
mental illness and substance abuse, typically begin to emerge.
In this context, it is important to recognize that cannabis use 
has potentially adverse effects among those who are vulnerable 
to mental illness, including teens. For example, we know that 
cannabis use leads to an earlier onset of psychotic symptoms 
(Veen et al., 2004) and is a major risk factor for developing 
schizophrenia (Semple, McIntosh, & Lawrie, 2005). Cannabis 
use has also been shown to worsen symptoms of mood and 
anxiety disorders (Degenhardt, Hall, & Lynskey, 2003), eating 
disorders (Ross & Ivis, 1999) and childhood behavioural 
disorders (Fergusson & Boden, 2008). 
While there is a strong relationship between mental illness and 
substance use, the underlying reasons why are still largely 
unknown. Does drug use induce mental illness? Or does 
mental illness increase risk for drug use? While researchers 
have traditionally attempted to answer this question through 
epidemiological methods (i.e., by uncovering the pattern of 
substance use in association with the onset of symptoms), 
causality cannot be determined in this way. Because of 
this limitation, researchers have turned to interventional and 
neurophysiological studies to uncover the underlying links 
between adolescent cannabis use and the development of 
mental illness.
2.2 The endocannabinoid 
system and the development of 
psychiatric disorders
As discussed in the previous chapter, the primary psychoactive 
component in cannabis, delta-9-tetrahydrocannabinol (THC), 
hijacks the endocannabinoid system by targeting the 
cannabinoid type 1 (CB
1
) receptor in much higher quantities 
than the cannabinoids produced naturally by the brain. With 
such a vast pattern of expression, CB
1
 receptors are implicated 
in many neurological functions, including emotional regulation, 
motor control, cognition, memory, reward and addiction 
(Herkenham, 1991). The presence of exogenous cannabinoids 
such as THC likely interferes with the regulatory role of the 
endocannabinoid system, potentially leading to long-lasting 
consequences for adult brain functioning.
Aberrant endocannabinoid functioning may be directly 
associated with the development of several psychiatric 
disorders and may account for cannabis’ deleterious effect on 
the course of these disorders. For example, cannabis users with 
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schizophrenia or depression have lower levels of anandamide 
(one of the naturally occurring cannabinoids) compared to non-
users (Hill & Gorzalka, 2005; Leweke et al., 2007). Post-mortem 
studies have also revealed a decrease in CB
1
 receptor density 
in people with depression, with contrasting density increases in 
those with schizophrenia (Ceccarini et al., 2013). 
While these findings suggest that aberrant endocannabinoid 
system functioning might contribute to the development 
of co-morbid cannabis dependence and mental illness, 
inconsistencies in the research highlight the need for continued 
investigation. 
2.3 Cannabis’ link to 
schizophrenia 
Individuals with schizophrenia report severe psychotic 
symptoms and often experience substantial social disability, a 
loss of motivation, disturbed behaviour and cognitive deficits. 
While the notion of a cannabis–psychosis link has been around 
for decades, the potential causal relationship between these 
two disorders is still being debated. However, the current 
epidemiological and neurobiological research suggests that 
individuals with a predisposition to schizophrenia might be more 
vulnerable to the psychosis-inducing effects of THC.
2.3.1 Epidemiological evidence
Some of the most compelling evidence outlining the association 
between cannabis use and the onset of psychosis originates 
from longitudinal studies. One of the first studies on this topic 
followed 50,465 Swedish adolescents over the course of 
15 years, with investigators finding that individuals who used 
cannabis on more than 50 occasions by age 18 were six times 
more likely to develop schizophrenia than those who did not 
use cannabis (Andréasson, Engström, Allebeck, & Rydberg, 
1987). This increased risk for schizophrenia held true even 
when controlling for concomitant mental illnesses and social 
background, and persisted in a follow-up study conducted 27 
years later (Konings, Henquet, Maharajah, Hutchinson, & Van 
Os, 2008), thus demonstrating that cannabis represents an 
independent risk factor for the development of schizophrenia.
These findings have been replicated in longitudinal studies 
around the world, with both Henquet and colleagues (2005) 
and Arseneault and colleagues (2002) associating adolescent 
cannabis use with a greater probability of reporting psychotic 
symptoms later in life. Importantly, a number of studies have 
shown that this risk of developing schizophrenia is increased 
dose-dependently with increasing cannabis consumption 
(Henquet et al., 2005; Zammit, Allebeck, Andréasson, 
Lundberg, & Lewis, 2002). 
More recently, Di Forti and colleagues (2015) suggested that 
regular use of cannabis with high levels of THC and low levels of 
cannabidiol (often referred to as “skunk”) substantially increases 
the risk of developing schizophrenia. Specifically, they compared 
cannabis use in first-episode cases of psychosis to matched 
controls with higher than average rates of psychoses and 
cannabis use. While both groups showed equally high rates of 
lifetime cannabis use, the first-episode cases were three to five 
times more likely to report daily skunk use, and this association 
persisted after statistical adjustment for confounders. 
While these studies clearly provide evidence for the association 
between cannabis use and schizophrenia, they do not provide 
definitive answers regarding the direction of this relationship. 
2.3.2 Neurobiological evidence
Neurobiological studies employing genetic, neurophysiological 
and neuroimaging-based approaches suggest the existence 
of common underlying factors associated with a vulnerability 
to both cannabis use and schizophrenia. In particular, the 
current evidence proposes that the detrimental effects of 
cannabis use on schizophrenia might be linked to disturbances 
in endocannabinoid signalling and genetic variants associated 
with cannabinoid-type genes.
Research focusing on the cannabinoid receptor gene (CNR1) 
suggests that variations in this gene may influence the 
development of concurrent cannabis use and schizophrenia 
(Kohn & Lerer, 2005; Zhang et al., 2004). Furthermore, studies 
have found that individuals with schizophrenia who possess a 
specific type of CNR1 gene and use cannabis heavily show 
greater deficits in white matter volume and cognitive functioning 
compared to non-heavy users (Ho, Wassink, Ziebell, & 
Andreasen, 2011). It follows that these CNR1 gene variants 
might predispose people to engage in heavy cannabis use and 
likely worsen already aberrant cognitive functioning. 
These findings have led some researchers to consider the 
“endocannabinoid hypothesis of schizophrenia” (Muller-Vahl & 
Emrich, 2008), which implicates this system in the interaction 
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between adolescent exposure to cannabis and an enhanced 
vulnerability to psychosis. However, contradictory reports 
have found no significant differences in the CB
1
 receptors of 
cannabis users and non-users — and that cannabis may not 
have an effect on cannabinoid receptor density in those with 
schizophrenia (Deng, Han, & Huang, 2007; Koethe et al., 2007). 
While disturbances in the endocannabinoid system could 
represent one potential risk factor for co-morbid cannabis use 
among individuals with schizophrenia, the conflicting evidence 
highlights the need for further research. 
Dopamine
Dopamine pathways of the mesolimbic systems in 
the brain normally mediate rewarding and reinforcing 
processes, and these pathways are altered by drugs  
of abuse such as cannabis (THC) (Blum et al., 2012).
Genetic studies could provide further insight into the 
potential common vulnerability connecting cannabis use and 
schizophrenia. Given their role in both schizophrenia (Mackay 
et al., 1982) and addiction (Di Chiara & Imperato, 1988), 
genetic variants that influence dopamine have been implicated 
in the pathophysiology of this co-morbidity. Of specific interest 
is the gene for catechol-O-methyltransferase (COMT), an 
enzyme responsible for the metabolism of synaptic dopamine 
(i.e., lowering the availability of dopamine in the brain). The 
COMT gene is coded for by two alleles: the Met and Val alleles. 
(An allele is one of two or more alternative forms of a gene 
that arise by mutation and are found at the same position on a 
specific chromosome.) As illustrated in Figure 2, the combination 
of these alleles can influence an individual’s mental health:
• Individuals who have two Met alleles show a 
substantial decrease in COMT enzymatic activity, 
leading to increased dopamine levels; 
• Individuals who have two Val alleles show 
enhanced COMT activity, leading to decreased 
dopamine levels; and 
• Individuals who have one of each allele show 
intermediate COMT activity and dopamine levels.
VTA
Val/Val
Figure 2. How the Val allele’s control of the enzymatic breakdown 
of synaptic dopamine might be implicated in the pathogenesis of 
schizophrenia
Source for image of brain: Guzman, 2015; adapted with permission from Dr. F. Guzman
Source for graph: Caspi et al., 2005; adapted with permission from Elsevier
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Several studies have uncovered an increased risk of developing 
schizophrenia or psychosis in individuals who have two Val 
alleles and are exposed to cannabis at an early age (Caspi et 
al., 2005; Henquet et al., 2006). However, other studies have 
been unable to replicate this finding (Zammit et al., 2007), 
suggesting there are likely several genes working together and 
not simply one genetic variant contributing to these disorders. 
COMT and the endocannabinoid system represent just two 
examples of the neurobiological underpinnings of cannabis use 
and schizophrenia; there are many additional lines of research 
exploring this co-morbidity (Rabin, Goodman, George, & 
Barr, 2014). 
2.3.3 Potential mechanisms by which 
cannabis increases risk for schizophrenia
If cannabis use does lead to schizophrenia, it would follow 
that the incidence of schizophrenia would increase in parallel 
to the increasing rate of cannabis consumption. While several 
longitudinal studies have found that cannabis use has increased 
dramatically in recent decades, there is no clear evidence that 
psychosis rates in the general population have also increased 
(Degenhardt et al., 2003; Hickman, Vickerman, Macleod, 
Kirkbride, & Jones, 2007). 
More recent neurobiological studies suggest there are 
distinct features that enhance risk, with researchers looking 
specifically at the shared neural pathways influencing the onset 
and maintenance of cannabis use among individuals with 
schizophrenia. Disturbances in the endocannabinoid system, 
aberrant neurophysiological functioning and genetic variations 
are just some of the areas being examined. It has been 
suggested that these factors precede the onset of concurrent 
cannabis use in individuals with schizophrenia and are influenced 
by both schizophrenia and cannabis use. From this diverse and 
somewhat conflicting body of evidence, what appears to be 
consistent is that among individuals with a predisposition for 
schizophrenia, cannabis consumption exacerbates symptoms 
and worsens the overall course of the illness. 
2.4 Cannabis’ link to mood and 
anxiety disorders
Compared to psychosis, much less attention has been given 
to the relationship between cannabis use and mood and 
anxiety disorders. However, given the increasing rates of 
suicide among adolescents (Skinner & McFaull, 2012) and 
evidence suggesting that both drug abuse and depression 
contribute to suicidal risk (Beautrais, 2000), further research 
on this co-morbidity is necessary. In addition, while the current 
research often combines mood and anxiety disorders given 
their overlapping characteristics and frequent co-occurrence, 
future research should look at these disorders separately as the 
risks associated with each and their underlying connections to 
cannabis use might not be the same. 
2.4.1 Depression
There is a growing body of evidence suggesting that problematic 
cannabis use and mood disorders often co-occur. 
Epidemiological evidence
Several longitudinal studies have revealed an increased risk of 
depression in cannabis users compared to those who have 
never tried cannabis, and that the level of risk increases with 
earlier initiation and more frequent use (Brook, Brook, Zhang, 
Cohen, & Whiteman, 2002; Ferguson, Horwood, & Swain-
Campbell, 2002; Patton et al., 2002; Rey, Sawyer, Raphael, 
Patton, & Lynskey, 2002). Cannabis use has also been shown 
to lead to an increased risk of suicidal thoughts and attempts 
(Pedersen, 2008), especially among young females (Wilcox, 
Conner, & Caine, 2004). 
At the same time, several cohort studies have found the 
association between cannabis use and depression is 
diminished when confounding variables like concomitant drug 
use, education level, marital status and other demographic 
characteristics are taken into consideration (Green & Ritter, 
2000; Rowe, Fleming, Barry, Manwell, & Kropp, 1995). 
Additionally, a number of studies were unable to find that 
adolescent onset depression predicted later cannabis use or 
dependence (Hofstra, Van Der Ende, & Verhulst, 2002; Kandel 
& Chen, 2000; Patton et al., 2002). 
While explanations of the association between these two 
disorders are inconsistent, epidemiological evidence suggests 
the direction of risk stems from cannabis use to depression and 
not the reverse.
Neurobiological evidence
Less is known about the neurobiological underpinnings of 
cannabis use and depression, with much of the evidence 
coming from pre-clinical research. However, researchers have 
begun to investigate this relationship using neuroimaging and 
post-mortem analysis. 
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In line with evidence on the cannabis–psychosis link, the 
endocannabinoid system could also contribute to co-morbid 
cannabis use and depression. It has been suggested that 
decreased endocannabinoid activity might contribute to the 
anhedonia, anxiety, decreased pain tolerance, chronic pain and 
decreased serotonergic activity often seen in individuals with 
depression (Ashton & Moore, 2011). Supporting this notion is 
the fact that rimonabant, an antagonist drug that binds to the 
CB
1
 receptor and blocks it from producing its normal response, 
has been shown to induce symptoms of depression and 
anxiety (Moreira & Crippa, 2009). Finally, post-mortem studies 
in individuals with major depression have revealed a decrease 
in CB
1
 receptor density, indicating aberrant endocannabinoid 
signalling (Koethe et al., 2007). 
Agonist and antagonist drugs
For drugs that are site-specific, actions initiated can 
be agonist, antagonist or a combination of both. 
Agonists initiate activity in the cell; antagonists act in 
the opposite way, blocking cellular activity.
While this research is preliminary, findings do suggest 
disruptions in the endocannabinoid system may underlie a 
greater vulnerability to depression and concurrent cannabis use. 
Moving forward, this field would benefit from multidisciplinary 
methodologies that incorporate clinical trials, neuroimaging, 
brain stimulation and genetics.
2.4.2 Bipolar disorder
Due to its overlapping features with depression and 
schizophrenia, research into the effects of adolescent cannabis 
use on the onset and clinical course of bipolar disorder has 
revealed similar findings to these other disorders. However, less 
is known about its co-occurrence with cannabis use, especially 
among adolescents. 
Epidemiological evidence
A few epidemiological studies beginning in adolescence and 
traversing the lifespan of participants have demonstrated that 
concurrent cannabis use and bipolar disorder is associated 
with a greater length of affective episodes and number of manic 
episodes, more rapid cycling, an increase in overall disability 
and more severe prognosis (Agrawal, Nurnberger, & Lynskey, 
2011; Baethge et al., 2005; Lev-Ran, Le Foll, McKenzie, 
George, & Rehm, 2013; Strakowski et al., 2007). Furthermore, 
Lagerberg and colleagues (2014) found a significant 
dose–response relationship between cannabis use and 
age of onset of bipolar symptoms, even after controlling for 
confounding factors such as gender, bipolar subtype, and 
family history of substance use and psychiatric illness. Similar 
to the research on schizophrenia, the association between 
cannabis use and the earlier onset of bipolar disorder suggests 
a potential role of cannabis use in the initial progression of this 
disorder in vulnerable individuals. 
Neurobiological evidence
There is limited research examining the potential underlying 
neurobiological mechanisms that connect cannabis use 
to bipolar disorder. One neuroimaging study by Bitter and 
colleagues (2014) found that adolescents with concurrent 
bipolar disorder who used cannabis did not show the same 
pattern of over-activation in brain regions associated with 
emotional processing seen consistently in those with bipolar 
disorder alone. This unexpected finding has led researchers 
to suggest that individuals with concurrent bipolar disorder 
and cannabis use may actually represent a unique subset of 
patients with bipolar disorder — and highlights the need for 
further research.
2.4.3 Anxiety disorders
Like mood disorders, research has shown that frequent 
cannabis users report higher levels of anxiety than infrequent 
users. However, the relationship between concurrent anxiety 
disorders and cannabis use has proven to be more complex 
than first assumed. 
Epidemiological evidence
Several studies have found that adolescent cannabis 
dependence is associated with increased rates of psychological 
distress and anxiety (Dorard, Berthoz, Phan, Corcos, & 
Bungener, 2008), as well as an increased risk of panic attacks 
and panic disorders (Zvolensky et al., 2009). Furthermore, the 
severity of anxiety symptoms has been shown to correlate 
with greater levels of cannabis consumption (Clough et al., 
2006). In a cohort study that followed 3,229 young adults from 
birth to age 21, researchers found those who used cannabis 
before they turned 15 and continued to use until age 21 were 
more likely to report symptoms of anxiety disorders, even after 
controlling for confounding factors (Hayatbakhsh et al., 2007). 
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Researchers have also considered the possibility that anxiety 
might lead to increased cannabis use. Specifically, social anxiety 
and post-traumatic stress disorder (PTSD) pose unique risks for 
the onset of problematic cannabis use among adolescents and 
young adults:
• In a longitudinal cohort study conducted over 14 
years, Buckner and colleagues (2008) found that 
those who met criteria for a social anxiety disorder 
upon study entry were 6.5 times more likely to 
demonstrate cannabis dependence, but not abuse, 
at follow-up. This relationship remained significant 
after controlling for potential confounding variables 
such as gender, depression and other anxiety 
disorders. 
• While few studies have systematically studied the 
relationship between PTSD and cannabis use, 
the increasing prevalence of this co-morbidity has 
given rise to increased research interest. One 
study examined this co-morbidity longitudinally in 
the adolescent offspring of adult males with and 
without a lifetime history of substance use disorders 
(Cornelius et al., 2010). Of these participants, 
31 were diagnosed with PTSD and 161 were 
diagnosed with cannabis use disorder. Results 
revealed that PTSD contributed to the development 
of cannabis use disorder beyond the familial risk of 
substance use disorders.
It has been suggested that individuals with social anxiety and 
PTSD use cannabis primarily to reduce anxiety. Thus, cannabis 
dependence stems from the belief that this substance aids 
in coping with the negative emotional states associated with 
anxiety disorders. Greer and colleagues (2014), for instance, 
found that individuals seeking treatment for PTSD reduced their 
anxiety scores (as measured on the Clinician-Administered 
PTSD Scale) by up to 75% when using medical cannabis. This 
finding suggests a more complex relationship between cannabis 
and anxiety, such that anxiety might either be enhanced or 
reduced following cannabis consumption. As there are likely a 
number of factors, both biological and environmental, that give 
rise to this bidirectional relationship, further research is needed. 
Clinical evidence
Cannabis has been used for its anxiety-reducing properties for 
centuries, but only recently have researchers investigated its 
therapeutic properties using laboratory-based methodologies. 
While most research has targeted THC, cannabidiol has been 
shown to possess psychological effects that are opposite 
to those of THC (Zuardi, 2008). This awareness has led 
researchers to start investigating the role of the endocannabinoid 
system and cannabidiol in the treatment of anxiety disorders. 
For example, studies have shown that individuals with social 
anxiety disorders who were given cannabidiol showed reduced 
symptoms of anxiety, cognitive impairment and negative self-
assessment during a simulated public speaking test compared 
to a control group given a placebo (Bergamaschi et al., 2011). 
Additionally, clinical research suggests that acute administration 
of low-dose CB
1
 receptor agonists produces anxiety-inhibiting 
effects. The administration of dronabinol, for instance, has been 
shown to significantly reduce symptoms of trichotillomania, 
an impulse-control disorder associated with repetitive and 
compulsive hair-pulling (Grant, Odlaug, Chamberlain, & 
Kim, 2011).
Neurobiological evidence
Although epidemiological and clinical evidence suggests a 
relationship between cannabis use and anxiety, the direction 
and causal nature of this co-morbidity remains unclear. 
Employing more diverse methodologies with a focus on potential 
neurobiological vulnerabilities underlying these disorders may 
provide a novel perspective. However, there is currently limited 
research on this topic in humans. 
Studies have implicated the aberrant functioning of the 
endocannabinoid system in an individual’s susceptibility to the 
anxiety-inducing properties of cannabis. For example, it has 
been reported that cannabis use increases anxiety through 
dysregulation of anandamide, an endogenous cannabinoid, 
especially among individuals vulnerable to developing anxiety 
(Witkin, Tzavara, & Nomikos, 2005). Similar to research 
conducted on the potential genetic determinants underlying 
the co-morbidity of cannabis use and schizophrenia, 
researchers have identified variations in the CNR1 gene 
as a plausible candidate for the development of an anxiety 
disorder. One study investigated gene–gene interactions 
between the CNR1 gene and regions of the serotonin 
transporter gene (SLC6A4), finding that aberrant serotonergic 
and endocannabinoid system functioning may increase a 
person’s vulnerability to anxiety (Lazary et al., 2009). While 
this finding proposes a promising neurobiological link between 
the endocannabinoid system and anxiety, further research is 
needed to better understand the relationship. 
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Clinical Vignette
Melinda
Melinda, a 24-year-old female, recently 
dropped out of college and is close to being 
kicked out of her parent’s house. She was 
diagnosed with schizophrenia at age 21, 
five years after first trying cannabis. In the 
beginning, she smoked up only on weekends 
with her friends, but this quickly progressed to 
daily use and she now smokes weed several 
times throughout the day. 
Although Melinda has now experienced a 
psychotic episode and been hospitalized 
after a period of heavy cannabis use, she 
still believes cannabis does not negatively 
affect her life. She has tried to quit several 
times but says her friends and older brother, 
who also smoke, make it too hard to abstain. 
After being placed on academic probation for 
showing up to class high and falling behind 
on her work, Melinda decided to drop out 
of college. In response, her parents have 
threatened to kick her out of the house if 
she does not quit cannabis. Now, Melinda is 
beginning to feel hopeless and depressed — 
and wonders if there is any way out.
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2.4.4 Potential mechanisms by which 
cannabis increases risk for mood and 
anxiety disorders
While it is clear that cannabis use commonly occurs in individuals 
who report symptoms of depression and anxiety, it is less clear 
as to why these disorders commonly co-occur. It was once 
believed that the presence of these disorders put adolescents 
at risk for cannabis use later in life as a means to self-medicate 
and alleviate symptoms associated with medication side 
effects and their disorder (Musty & Kaback, 1995; Wittchen 
et al., 2007). However, longitudinal research has found that 
self-medication cannot adequately account for the pattern of 
cannabis use among youth with depression, anxiety or bipolar 
disorder (Degenhardt et al., 2003; Strakowski, McElroy, Keck, 
& West, 1996). 
Recent research has turned its focus on the common underlying 
causal factors or “third variables” that might predispose 
individuals to both substance use and mental illness. 
Unfortunately, the factors that govern the behavioural outcomes 
of cannabis use in individuals with mood and anxiety disorders 
are still largely unknown, yet they are thought to include both 
biological and environmental considerations (Lynskey et al., 
2004). Evidence supporting this hypothesis indicates that 
environmental factors such as social disadvantage and family 
dysfunction are more common among individuals who meet 
criteria for problematic substance use, as well as depressive 
disorder (Warner, Mufson & Weissman, 1995). 
In terms of the neurobiological links between cannabis use and 
mood and anxiety disorders, the influence of cannabis on the 
hypothalamic–pituitary–adrenal (HPA) axis represents a potential 
mechanism underlying this co-morbidity. As a key component of 
the neuroendocrine system, the HPA axis modulates reactions 
to stress, including the emotional response. Dysregulation of 
this system has been implicated in mood and anxiety disorders. 
Interestingly, the HPA axis is regulated by the endocannabinoid 
system; it therefore follows that cannabis use activates the 
neuroendocrine stress response via the HPA axis (Steiner & 
Wotjak, 2008).
2.5 Cannabis’ link to eating 
disorders
Eating disorders are the leading cause of morbidity and mortality 
among adolescents, with a lifetime prevalence of 0.9% for 
anorexia nervosa and 1.5% for bulimia nervosa among women 
(Hudson, Hiripi, Pope, & Kessler, 2007). The association 
between substance use disorders and eating disorders has 
been well studied, with a lifetime prevalence ranging from 25% 
to 50% depending on the disorder (Mann et al., 2014). Few 
studies, however, have focused on the effects of cannabis 
specifically on the course of eating disorders.
2.5.1 Epidemiological evidence
Research has consistently demonstrated that adolescents 
with anorexia nervosa use tobacco, alcohol and cannabis 
less frequently than grade- and sex-matched comparison 
populations (Stock, Goldberg, Corbett, & Katzman, 2002). In 
contrast, those with bulimia nervosa use these substances at 
rates similar to or greater than the general population (Ross 
& Ivis, 1999). Given that cannabis use increases appetite, it 
follows that cannabis is one of the most commonly abused illicit 
drugs among binge eaters. In their examination of the reasons 
why adolescents with eating disorders choose to use different 
drugs, Stock and colleagues (2002) found that bulimic females 
were most likely to use cannabis to relax or release anger. 
Anorexic females, on the other hand, were likely not to use 
cannabis because they considered it too bad for their health or 
against their personal beliefs.
2.5.2 Potential mechanisms by which 
cannabis increases risk for eating disorders
Like mood and anxiety disorders, the direction and causal nature 
of the relationship between eating disorders and cannabis 
use is not well understood. Researchers have suggested that 
impulsive behaviours might link these two disorders. Specifically, 
those who exhibit bulimic symptoms and abuse substances 
also demonstrate increased rates of attempted suicide, theft 
and risky sexual behaviours (Wiederman & Pryor, 1996). 
An important biological link between cannabis use and eating 
disorders lies within the endocannabinoid system, which plays a 
key role in the regulation of food intake and energy metabolism. 
In fact, rimonabant, a CB
1
 antagonist, was once considered for 
the management of obesity and has been shown to decrease 
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body weight and alleviate symptoms of metabolic syndrome 
(Horcajadas, 2007). It is likely that the interaction between 
environmental and biological factors leads to the use of 
cannabis among adolescents with eating disorders. However, 
further research is necessary. 
2.6 Cannabis’ link to childhood 
behavioural disorders
With the initiation of cannabis use occurring at younger ages 
than before, researchers have now begun to investigate its 
effects on a wide range of childhood disorders. However, 
there is little research investigating the effects of cannabis 
use specifically on childhood behavioural disorders such as 
attention deficit hyperactivity disorder (ADHD), conduct disorder 
(CD) and oppositional defiant disorder (ODD). While this field of 
research is complicated by the prevalence of co-morbid mental 
illness within childhood disorders (Szatmari, Offord, & Boyle, 
1989), among all childhood behavioural disorders, high rates 
of substance use are apparent starting in early adolescence.
2.6.1 Epidemiological evidence
August and colleagues (2006) sought to evaluate adolescent 
drug use in a large sample of children who have ADHD with 
and without externalizing behaviours (primarily ODD). They 
found that the ADHD-externalizing group showed a significantly 
higher frequency of substance use (especially cannabis use) 
compared to the healthy controls and the ADHD-only groups, 
which suggests the relationship between ADHD and cannabis 
use might be driven by externalizing behaviours. This finding 
is consistent with previous research examining the relationship 
between cannabis use and CD (Heron et al., 2013). However, 
conflicting research has found that even after controlling for 
conduct problems, ADHD predicted later substance use 
problems with hyperactivity and impulsivity rather than inattention 
driving this relationship (Elkin, McGue, & Iacono, 2007). 
Externalizing and internalizing behaviours
Externalizing behaviours are characterized by high 
levels of impulsive risk taking and aggression, while 
internalizing behaviours are characterized by either 
anxiety or depression. Both types of behaviours 
represent the two most common developmental 
pathways to substance abuse disorders.
Finally, several studies looking at the interaction between ADHD 
and CD on substance use disorders found that individuals who 
presented with the most severe symptomatology were at the 
highest risk of substance use, especially cannabis use (Flory, 
Milich, Lynam, Leukefeld, & Clayton, 2003; Molina, Smith, & 
Pelham, 1999). 
2.6.2 Potential mechanisms by which 
cannabis increases risk for childhood 
behavioural disorders
As shown in Figure 3, unlike schizophrenia and mood 
disorders, childhood behavioural disorders are similar to 
anxiety in that they manifest before the onset of cannabis use 
(Applegate et al., 1997; Bellivier et al., 2003; DeLisi et al., 
1994; Keeton, Kolos, & Walkup 2009; Monshouwer, Smit, 
De Graaf, Van Os, & Volleherg 2005; Stice, Marti, & Rohde 
2013). Therefore, it is likely that these behavioural childhood 
disorders influence cannabis use and not the other way around 
(Crowley, Macdonald, Whitmore & Mikulich, 1998). 
So what factors associated with childhood behavioural 
disorders might lead to the onset of cannabis use? One of the 
most evident factors appears to be impulsivity, which is a key 
component shared between ADHD, CD and substance use 
problems (American Psychiatric Association, 2013; Moeller & 
Dougherty, 2002). Furthermore, aberrant executive functioning 
and developmental delays associated with poor decision 
Figure 3. Average age of onset of symptoms or diagnosis of several mental illnesses compared to the average age of onset of cannabis use
Age 7
ADHD Anxiety* Bipolar and Depression
Cannabis
Age 10 Age 15 Age 18 Age 25
LEGEND: Anxiety: Average age of adult onset is 31 | Schizophrenia: Average age of onset for females is 25
Eating disorders: Average age of onset ranges from 16 to 20
Schizophrenia*
Eating Disorders*
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making represent another core feature of ADHD that likely plays 
a role in the onset of substance use (Tamm et al., 2013). Thus, it 
is possible that the negative impact of ADHD on neurocognitive 
function might make these individuals more vulnerable to 
cannabis use, giving rise to a distinctive co-morbidity profile. 
2.7 Conclusions and implications
Fergusson and Horwood (1997) suggested three potential 
relationships between substance use disorders and 
mental illness: 
• A shared vulnerability;
• Prior cannabis use predicting the onset of a mental 
illness; or 
• Mental illness leading to later cannabis use. 
While the current evidence clearly outlines an analogous, 
detrimental course for both mental illness and substance 
abuse, cannabis use has been shown to have differential 
relationships on each type of psychiatric disorder. Thus there 
is no undisputable support for any one of these hypotheses. 
What then does the data suggest? Researchers have 
proposed a common underlying neurobiological vulnerability 
to both cannabis use and schizophrenia (Rabin et al., 2014). 
For individuals who are genetically vulnerable to schizophrenia, 
cannabis use can lead to an earlier onset of symptoms and 
worsening prognosis (Veen et al., 2004). In contrast, the 
evidence suggests that childhood behavioural disorders likely 
precede and might lead to the use of cannabis (Crowley et al., 
1998). Additionally, it remains unclear whether the association 
between cannabis use and mood and anxiety disorders is due 
to an increased rate of depression and anxiety among cannabis 
users, or an increased rate of cannabis consumption among 
those with depression or anxiety. Similarly, the direction and 
causal nature of the relationship between eating disorders and 
cannabis use is not well understood. 
These differential effects could be partly due to the average age 
of onset of each psychiatric disorder compared to the onset 
of cannabis use. Ultimately, what can be drawn from these 
findings is that while the link between cannabis use and mental 
illness varies across diagnoses — and regardless of whether 
cannabis use predicts mental illness or vice versa — cannabis 
use during adolescence has clear negative consequences. 
As cannabis is the most commonly abused illicit drug worldwide, 
including among treatment-seeking individuals, many patients 
and clinicians are unaware of or downplay the potential harmful 
effects of this drug (McGee, Williams, Poulton, & Moffitt, 2000). 
Moreover, there is a deficit of research on effective treatment 
options specifically for individuals with mental illness and 
co-morbid cannabis dependence. 
Given the commonality of neurobiological and environmental 
factors underlying mental illness and substance use, the 
simplest approach to improving mental health outcomes would 
be to reduce cannabis use in these individuals. As the age 
of first cannabis use is progressively decreasing, targeting 
health education and other preventative measures toward 
adolescents would be especially beneficial. Finally, addressing 
the misperception that cannabis use is safe, instead of focusing 
on the longer-term detrimental consequences for mental health 
in young people, could prove to be more successful in modifying 
cannabis use (McGee et al., 2000). Early interventions to 
reduce the harms of cannabis use in people at risk for mental 
illness may also mitigate the progression to more complex 
co-morbid presentations such as polysubstance use.
Continued research into the effects of cannabis use on 
mental illness will be needed to generate evidence-based 
treatment approaches and address public health implications. 
Moving forward, it will be especially important to address the 
methodological discrepancies that have led to conflicting 
published findings. For example, the groups of study participants 
discussed in this chapter included both community-based and 
clinical samples, poly-drug users and individuals with varying 
levels of cannabis dependence and mental illness severity. 
Because these methodological limitations are inherent to 
epidemiological studies, a multidisciplinary approach that 
includes neurobiological research into the mechanisms 
linking cannabis use to mental illnesses (including genetic, 
pharmacological, brain stimulation and neuroimaging studies) 
will be needed to bridge knowledge gaps and catalyze future 
exploration of intervention strategies. Funding is needed to bring 
together researchers from numerous fields for more intense 
investigation and to accelerate progress in understanding and 
treating co-morbid cannabis use disorders and mental illness.
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Is Cannabis 
Addictive?
3
Chapter at a Glance
• The general public perceives cannabis to be less addictive than other 
drugs of abuse. In reality, it has a significant addictive potential — in the 
same range as alcohol.
• Approximately 5 to 9% of those who use cannabis will develop 
dependence, and this rate increases to about 17% for those who start 
using during adolescence. 
• The risk of developing cannabis dependence is related to multiple 
biological and environmental factors such as genetics and age of initiation 
of use. 
• Individuals who stop using cannabis can experience symptoms of 
withdrawal. 
• Better knowledge of the factors that facilitate the transition from cannabis 
use to dependence could help reduce the risk of addiction and have 
clinical implications for cannabis-related treatment and intervention. 
By Bernard Le Foll, MD, PhD, 
Professor, Departments of Psychiatry, Pharmacology, Family and Community Medicine and Institute of Medical Sciences, 
University of Toronto, and Head, Translational Addiction Research Laboratory, and Alcohol Research and Treatment Clinic, 
Centre for Addiction and Mental Health
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3.1 Introduction
As mentioned in this report’s introductory chapter, there is a 
growing perception among youth that cannabis is relatively 
harmless. This perception was countered in Chapters 1 and 2, 
which outlined the many ways in which cannabis in fact has a 
profound negative impact on brain development, behaviour and 
mental health. 
But is cannabis an addictive substance? More specifically, does 
delta-9-tetrahydrocannabinol (THC), the main psychoactive 
component of cannabis that acts on the cannabinoid receptors 
in the brain, produce the same addictive properties as other 
drugs of abuse?
Cannabis is the world’s most widely used illicit drug (United 
Nations Office on Drugs and Crime, 2012), with approximately 
11% of Canadians aged 15 and older using cannabis at least 
once in the past year (Statistics Canada, 2015). Cannabis use 
is generally more prevalent among youth in Canada, with 22.4% 
of teens aged 15–19 and 26.2% of young adults aged 20–24 
reporting past-year use in the 2013 Canadian Tobacco, Alcohol 
and Drugs Survey (CTADS). 
Looking particularly at “heavy” or “regular” cannabis use, which 
is defined as daily or near-daily use (Hall & Pacula, 2010), the 
2013 CTADS found that approximately 23% of Canadian youth 
and 30% of young adults who used cannabis in the past three 
months reported using it daily or almost daily (Statistics Canada, 
2015). Evidence from around the world has shown this kind 
of regular use can lead to cannabis dependence, which can 
lead, in turn, to serious physical, psychological and social 
problems. In the Netherlands, for example, a study of high-risk 
young adults reporting heavy use found that nearly 40% 
developed cannabis dependence (van der Pol et al., 2013). 
Closer to home, findings from the 2012 Canadian Community 
Health Survey revealed that more than 5% of young Canadians 
between the ages of 15 and 24 met the criteria for cannabis 
abuse or dependence (Pearson, Janz, & Ali, 2013).
3.2  What is addiction?
Before exploring the frequency of addictive states associated 
with cannabis use, it is useful to explain what we mean by an 
“addictive substance,” as the estimate of prevalence depends 
on how addiction is defined and measured. 
3.2.1 Classifications of addiction
The two main classifications of addiction currently used in the 
medical field are the International Statistical Classification of 
Diseases and Related Health Problems (10th revision; ICD-10) 
and the Diagnostic and Statistical Manual of Mental Disorder 
(5th edition; DSM-5).
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Developed by the World Health Organization (2010), the 
ICD-10 lists addictive disorders under its “mental and 
behavioural disorders due to psychoactive substance use” 
category. It also distinguishes between “harmful use” and 
“dependence syndrome” as follows: 
• Harmful use is defined as a pattern of 
psychoactive substance use that causes physical 
or mental damage. 
• Dependence syndrome is defined as a cluster 
of behavioural, cognitive and physiological 
phenomena that develop after repeated use and 
typically include a strong desire to take the drug, 
difficulties in controlling its use, persisting in its 
use despite harmful consequences, a higher 
priority given to drug use than to other activities 
and obligations, increased tolerance and, in some 
cases, a physical withdrawal state.
The American Psychiatric Association (2013), which developed 
the DSM classification, now uses the term “substance 
use disorder” and has identified four broad categories of 
symptoms: impaired control, social impairment, risky use and 
pharmacological criteria (including tolerance and withdrawal). 
The previous version of the DSM (DSM-IV-TR; American 
Psychiatric Association, 2000) listed addictive disorders under 
separate “abuse” and “dependence” categories:
• Abuse was defined as repeated instances of use 
under hazardous conditions; repeated, clinically 
meaningful impairment in social, occupational or 
educational functioning; or legal problems related to 
substance use. 
• Dependence was defined as increased tolerance, 
compulsive use, impaired control and continued use 
despite the physical and psychological problems 
caused or exacerbated by substance use.
The DSM-5, however, unified these two classifications within a 
single “substance use disorder” continuum. As a result, studies 
that have artificially separated the two into different categories 
might ultimately underestimate the risk of addiction related to 
cannabis by focusing primarily on dependence when abuse 
might be more common (Hasin & Grant, 2004; Saha, Harford, 
Goldstein, Kerridge, & Hasin, 2012). 
It is important to note that tolerance and withdrawal, both of 
which are perceived as classical manifestations of dependence, 
are not necessarily present in individuals who have developed 
a substance use disorder. Rather, they are manifestations of 
physical dependence. Tolerance reflects a markedly diminished 
effect with continued use of the same amount of cannabis, 
which can lead users to increase the dose and consume 
greater amounts of the drug. Similarly, cannabis withdrawal, 
which is slower to develop after cessation of exposure than 
tobacco withdrawal, can lead to the re-initiation of use to offset 
the unpleasant symptoms associated with discontinued use.
Diagnostic criteria for cannabis use disorder
The DSM-5 defines “cannabis use disorder” as 
“a problematic pattern of use leading to clinically 
significant impairment or distress.” The DSM-5 
diagnostic criteria for the disorder include:
• Using more cannabis than intended and 
trying unsuccessfully to control use;
• Spending a significant amount of time 
obtaining and using cannabis or recovering 
from its effects;
• Experiencing a strong desire or urge to use 
cannabis;
• Failing to fulfill major obligations at work, 
home or school because of cannabis use;
• Giving up or reducing important social, 
occupational or recreational activities 
because of cannabis use;
• Continuing use despite recurring social, 
physical or psychological problems caused 
by cannabis;
• Using cannabis in physically hazardous 
situations;
• Increasing tolerance to cannabis’ effects; and
• Developing withdrawal symptoms.
(American Psychiatric Association, 2013)
3.2.2 Factors affecting the study of addiction
Research into the addictive properties of cannabis is made 
challenging due to the many different ways the drug can be 
consumed, including being smoked, eaten or inhaled using 
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vaporizers. In addition, multiple strains of cannabis are being 
produced and used, with the concentration of THC in these 
rising steadily over the past 30 years (see Figure 4; Volkow, 
Baler, Compton, & Weiss, 2014). In the United States, the 
average potency of cannabis seized by law enforcement 
officials has climbed from 3.5% in 1985 to 13.2% in 2012 
(Office of National Drug Control Policy, 2013). 
In most epidemiological studies, the concentration of THC 
in cannabis is not known or assessed (Hall, 2015). This gap 
means that as the potency of cannabis continues to increase, 
some historical findings might no longer be relevant to predicting 
the effects of cannabis on contemporary users, including the 
risk for addiction.
Various factors can contribute to the prevalence of substance 
use and substance use disorders, including a substance’s legal 
status and public perception regarding its effects on health and 
development. This variety of factors makes it important to study 
the addictive properties of substances in models that are not 
sensitive to those factors, such as preclinical models in the 
laboratory. Doing so makes it possible to attribute any addictive 
factors directly to the substance rather than to the context in 
which it is consumed.
3.3 Neurobiological and 
preclinical studies on the 
addictive potential of cannabis
When exploring the addictive potential of cannabis, the key is to 
determine if THC presents the typical features associated with 
other drugs of abuse. The subjective effects of drugs can be 
studied using various procedures, with animal models available 
to study the cardinal features of drug dependence (Le Foll & 
Goldberg, 2005). For example, withdrawal can be studied 
by exposing animals chronically to a substance of choice 
and subsequently removing this substance or administering 
an antagonist (i.e., a substance that prevents the drugs from 
having an effect) to precipitate withdrawal. Several reviews have 
covered the impact of cannabinoid drugs on these models 
(Justinova, Goldberg, Heishman, & Tanda, 2005; Oleson & 
Cheer, 2012; Panlilio, Justinova, & Goldberg, 2010). 
In the drug discrimination paradigm, one behavioural response, 
such as pressing a lever, gets associated with the effects 
induced by a cannabinoid drug while a different behavioural 
response gets associated with the effects induced by a placebo. 
Findings from this procedure have established that animals can 
be trained to discriminate THC (Jarbe & Henriksson, 1974; 
Kubena & Barry, 1972) and that the subjective effects induced 
by THC are primarily mediated by the brain’s CB
1
 receptors 
(Jarbe, Gifford, & Makriyannis, 2010).
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Enforcement Administration, 1995–2012
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3.3.1 Intravenous drug self-administration 
paradigm
The “gold standard” paradigm in the field of addiction is the 
intravenous drug self-administration paradigm. In this procedure, 
an animal can choose to directly self-administer a drug such as 
THC by pressing a lever. There is good concordance between 
animals choosing to self-administer drugs and the addictive 
potential of those drugs in humans (Panlilio & Goldberg, 2007). 
An important finding obtained using this paradigm was the 
demonstration of THC’s ability to induce self-administration 
behaviour in squirrel monkeys (Tanda, Munzar, & Goldberg, 
2000). Although the first demonstration was performed in 
psychostimulant-trained primates, subsequent work showed 
self-administration behaviour could also be obtained in drug-
naïve primates (Justinova, Tanda, Redhi, & Goldberg, 2003). 
In addition, after the animals were trained, it was possible 
to extinguish their drug-seeking behaviour by removing 
access to the drug and the stimuli present during the initial 
training. Subsequent reintroduction of a small dose of THC 
or presentation of drug-associated cues reinstated the drug-
seeking behaviour, demonstrating a classical model of relapse 
(Justinova et al., 2013). 
In parallel, neurobiological studies have shown that THC 
can stimulate the activity of dopamine neurons and elevate 
dopamine levels in the brain’s reward circuit, the nucleus 
accumbens (Chen et al., 1990; Diana, Melis, & Gessa, 1998). 
Dopamine increases in the nucleus accumbens are triggered 
by all drugs of abuse and thought to be a critical component 
of their addictive nature. Studies performed in animals have 
shown that THC can produce reward through stimulation of the 
ventral tegmental and nucleus accumbens (Zangen, Solinas, 
Ikemoto, Goldberg, & Wise, 2006).
Of note, some researchers have been successful at obtaining 
self-administrating behaviour in rodents using a synthetic 
CB
1
/CB
2
 agonist called WIN55,212-2 (Fadda et al., 2006; 
Lecca, Cacciapaglia, Valentini, & Di Chiara, 2006). However, a 
reliable model of intravenous THC self-administration in rodents 
has not yet been demonstrated. This gap might be due to the 
fact that THC is only a partial agonist of CB
1
 and CB
2
 receptors, 
which would explain its weaker reinforcing effects relative to 
WIN55,212-2 (Pertwee, 2008).
3.4 Clinical studies on the 
addictive potential of cannabis
One of the main features of all drugs of abuse is their ability 
to elevate dopamine in the reward circuit of the brain. The 
latest neuroimaging techniques have now made it possible 
to measure this elevation of dopamine in the human brain. 
Recent studies suggest the administration of THC might elevate 
dopamine in a similar fashion but with less potency than typical 
drugs of abuse such as psychostimulants (Volkow, Wang, 
Fowler, Tomasi, & Telang, 2011). While elevated dopamine 
levels typically cause users of cannabis to rate the experience 
as pleasant, a factor that may contribute to recreational use 
(Green, Kavanagh, & Young, 2003; Miller et al., 1977), cannabis 
use can also produce opposite effects such as dysphoria and 
anxiety (Johns, 2001).
3.4.1 Symptoms of cannabis dependence
Some researchers have explored the types of symptoms 
described by individuals who develop dependence to 
cannabis. Among a representative population of young adults 
(mean age 20.7 years) in an Australian longitudinal cohort 
study, 7% met the DSM-IV criteria for cannabis dependence 
(Coffey et al., 2002). Within this group of individuals who were 
cannabis-dependent:
• 91% experienced persistent desire for cannabis; 
• 84% reported unintentional use of cannabis; 
• 74% experienced symptoms of withdrawal; 
• 74% reported spending excessive time obtaining 
and using cannabis; 
• 63% reported continued use of cannabis despite 
experiencing health problems; 
• 21% experienced tolerance; and 
• 18% experienced negative social consequences as 
a result of their use. 
Interestingly, the combination of withdrawal, persistent desire 
and unintentional use was reported by 57% of those individuals 
who were dependent on cannabis. 
Research has also shown that the severity of symptoms 
associated with cannabis dependence increases among the 
treatment-seeking population. A recent clinical trial conducted 
by Mason and colleagues (2012), which involved treatment-
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seeking outpatients between the ages of 18 and 65 years, 
found that those diagnosed with cannabis dependence 
reported the following symptoms: 
• 98% reported the desire to quit using cannabis; 
• 98% experienced withdrawal; 
• 94% experienced tolerance; 
• 92% reported increased use of cannabis; 
• 84% reported continued use of cannabis despite 
experiencing health problems; 
• 72% said that cannabis interfered in life tasks; and 
• 62% reported spending excessive time obtaining 
and using cannabis. 
3.4.2 Symptoms of cannabis withdrawal
It has been established that a withdrawal syndrome develops 
upon the cessation of exposure to cannabis (Budney & Hughes, 
2006). The primary symptoms of withdrawal are behavioural and 
emotional, including irritability, sleeping difficulties, dysphoria, 
craving and anxiety; there are also symptoms associated with 
changes in appetite and weight loss (Budney, Hughes, Moore, 
& Vandrey, 2004). 
Although withdrawal symptoms might contribute to the 
continuation of drug use to alleviate the discomfort associated 
with withdrawal, the relationship between withdrawal and 
drug-seeking behaviour remains unclear. In clinical trials, THC 
has been shown to be effective in decreasing the intensity of 
withdrawal symptoms that occur following cessation of cannabis 
exposure, but ineffective at helping subjects quit cannabis use 
altogether (Budney, Vandrey, Hughes, Moore, & Bahrenburg, 
2007; Haney et al., 2004; 2008; Hart, Haney, Ward, Fischman, 
& Foltin, 2002). 
3.5 Epidemiological studies on 
the addictive potential of cannabis
While providing precise estimates of the addictive potential 
of any given drug is complicated, the results from several 
epidemiological studies in the United States have allowed for 
the determination of some addictive potentials. 
Using data collected in the early 1990s through the National 
Comorbidity Survey, Anthony and colleagues (1994) estimated 
that 4.2% of the representative sample of people aged 15–54 
qualified for a lifetime diagnosis of cannabis dependence. In 
examining the transition from cannabis use to dependence, 
an estimated 46.3% of the sample had used cannabis at 
least once; of these users, 9.1% had developed cannabis 
dependence. The lifetime risk of developing dependence was 
found to be much higher among youth aged 15–24 (15.3%) and 
among males (12% compared to 5.5% for females). Notably, 
the lifetime risk of developing cannabis dependence among 
those who had ever used cannabis was found to be lower than 
that estimated for tobacco (32%), heroin (23%), cocaine (17%), 
alcohol (15%) and stimulants (11%).
Upon analyzing data from the 1991–1992 National 
Longitudinal Alcohol Epidemiological Survey (NLAES) and the 
2001–2002 National Epidemiologic Survey on Alcohol and 
Related Conditions (NESARC), both of which are large, 
nationally representative surveys of the U.S. population aged 
18 and older, Compton and colleagues (2004) found that 
past-year cannabis abuse was more common than cannabis 
dependence. In the NLAES, the past-year prevalence of 
cannabis abuse was 0.9% and dependence was 0.3%. 
Similarly, in the NESARC, past-year cannabis abuse was 
reported by 1.1% and dependence by 0.4% of the sample. 
Whether individuals have ever been exposed to cannabis is 
an important consideration for such studies, as those who do 
not have previous experience with the drug are not at risk of 
subsequent development of addiction.
Consistent with findings reported by Anthony and colleagues 
(1994), similar estimates of cannabis dependence have been 
reported more recently by Lopez-Quintero and colleagues 
(2011) using data from the 2004–2005 NESARC. Specifically, 
they noted that 8.9% of cannabis users would become 
dependent according to DSM-IV criteria at some point in their 
life, with half of the cases of cannabis dependence being 
observed approximately five years after onset of use.
Similarly, data from the 1992 NLAES revealed that one-third 
of past-year cannabis users exhibited cannabis abuse or 
dependence. The prevalence estimates of past-year cannabis 
abuse and dependence among cannabis users were 23.1% 
and 6.3%, respectively (Grant & Pickering, 1998). Note that 
these estimates differ from those reported above by Compton 
and colleagues (2004) as this study reported prevalence 
estimates among past-year cannabis users, whereas Compton 
et al. based their estimates on the general population.
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A recent analysis of NESARC data estimated that among 
subjects with lifetime exposure to cannabis, 7% of males and 
5.3% of females would qualify for a diagnosis of cannabis 
dependence in their lifetime (Lev-Ran, Le Strat, Imtiaz, Rehm, 
& Le Foll, 2013). In addition, it was found that among those 
who had ever been exposed to cannabis, 47.4% of males 
and 32.5% of females would develop cannabis use disorder 
at some point in their life. These results clearly indicate that 
a very large percentage of cannabis users will engage in a 
risky pattern of use, with the majority abusing the substance 
at some point and only a small minority ultimately developing 
dependence. Overall, if we focus on the dependence criteria, it 
is currently estimated that around 5 to 9% of users will develop 
dependence (Lev-Ran, Le Strat, Imtiaz, Rehm, & Le Foll, 2013; 
Volkow, Baler, Compton, & Weiss, 2014).
3.6 Cannabis as a “gateway” drug
One of the risks previously associated with cannabis use was 
that it might predispose an individual to subsequent illicit drug 
use; that is, act as a “gateway drug” to other substances. Early 
studies on this hypothesis found high rates of cannabis use prior 
to the use of other illicit drugs among people who used cannabis 
in combination with other drugs (Fergusson & Horwood, 2000; 
Kandel, Yamaguchi, & Chen, 1992). Later studies suggested 
that regular or heavy cannabis use can lead to increased risk 
of using a variety of other illicit drugs (Fergusson, Boden, & 
Horwood, 2006; Secades-Villa, Garcia-Rodriguez, Jin, Wang, 
& Blanco, 2015). Multiple studies around the world also support 
the existence of developmental stages and sequences in drug 
use that were first proposed in the 1970s (Kandel, 1975).
Childhood and adolescent pathways to 
substance use disorders
While no one factor can predict later-life substance 
abuse, there are certain risk factors and behaviours 
that should trigger a closer look at how to build 
resiliency and put in place protective factors for youth.
Substance Abuse in Canada: Childhood and 
Adolescent Pathways to Substance Use Disorders 
(Leyton & Stewart, 2014) explains how childhood and 
adolescence are times when prevention efforts can 
have the most impact, particularly if they consider the 
child’s stage of development.
The issue of cannabis being a gateway drug is much more 
complex, however, as multiple confounding factors suggest a 
person’s drug use trajectory might not be linked to previous 
exposure to cannabis. Instead, subsequent drug choice might 
be due to the independent characteristics that led the individual 
to be at risk for using illicit drugs in the first place. 
Recent laboratory studies have produced some interesting 
findings. Animal studies suggest nicotine is more effective than 
THC in producing a gateway effect (Levine et al., 2011; Solinas, 
Panlilio, & Goldberg, 2004). The evidence is more mixed with 
regard to pre-exposure to THC, which has been shown to 
decrease cocaine-seeking behaviour in rats (Panlilio, Solinas, 
Matthews, & Goldberg, 2007), have no effect on the reinforcing 
efficacy of heroin (Solinas et al., 2004) and, in some cases, 
increase nicotine self-administration (Panlilio, Zanettini, Barnes, 
Solinas, & Goldberg, 2013). Taken together, these findings do 
not support a strong impact of THC acting as a gateway drug. 
(It should be noted, however, that these studies were performed 
with the chemical component THC and not cannabis itself.) 
The likelihood of initiating the use of tobacco or other licit drugs 
before using illicit drugs is much greater than the opposite 
process. One recent study found that first initiating tobacco 
was 17.6 times more likely than first initiating cannabis (Mayet, 
Legleye, Chau, & Falissard, 2011). There are also reports 
showing progression from “soft” to “hard” drugs in 75–80% 
of cases (depending on the study sample), while a hard-to-
soft progression is seen in only 20–25% of cases (George & 
Moselhy, 2005; Tarter, Vanyukov, Kirisci, Reynolds, & Clark, 
2006). Although we cannot exclude the presence of a gateway 
effect following cannabis exposure, there is evidence suggesting 
that such a phenomenon might be much more limited than the 
neurobiological impact of nicotine pre-exposure.
3.7 Factors affecting vulnerability 
to cannabis addiction
Multiple factors have been shown to modulate an individual’s 
vulnerability to addiction to cannabis. Some are biological, 
such as the person’s genetic background, while others are 
environmental. 
Verweij and colleagues (2010) conducted a meta-analysis 
of studies examining the vulnerability of twins to cannabis 
use initiation and problematic cannabis use. With respect to 
cannabis use initiation, the proportion of total variance in the 
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Clinical Vignette
Chris 
Chris is a 24-year-old male who has developed cannabis use 
disorder. In high school, Chris was bullied and had few close 
friends. His parents are divorced, with his father described as highly 
dogmatic and cold, and his mother being more accepting, as well as 
a regular cannabis smoker. He began smoking weed causally when 
he first entered university to help address his worries, cope with 
traumatic memories and regulate his negative emotions. He found it 
helped him relax after busy days and deal with his low mood, anxiety 
and interpersonal conflict. 
Chris had a falling out with his father during university, which 
worsened his mood issues. His cannabis consumption increased 
after this major depressive episode, leading to procrastination and 
decreased motivation, financial difficulties, and limited professional 
and academic progress. Still, he was fully aware of the negative 
consequences of his cannabis use and was dismayed by the fact 
that he was using it more frequently. When he tried to stop, however, 
he worried excessively and had extreme difficulties sleeping. In 
addition, he found that he was using cannabis simply to maintain 
a “neutral state” — in other words, to keep from experiencing 
withdrawal rather than to provide a positive experience. Chris has 
since been diagnosed with cannabis use disorder and is now 
receiving treatment.
His major uses for cannabis informed the focus of his treatment: 
establishing good sleep hygiene; developing behavioural and 
cognitive coping strategies for negative mood, excessive worry 
and unpleasant memories; assertiveness training for dealing with 
interpersonal conflict and refusing cannabis; and exposure to 
creative pursuits with stimulus control (e.g., scheduled creative 
activities without the availability of weed). Through treatment, Chris 
acknowledged his dependence on cannabis. Today, he is committed 
to addressing the challenges he faces on regular basis.
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study subjects accounted for by genetic factors was 48% in 
males and 40% in females. Shared environmental factors 
(something both twins were exposed to, such as time with 
parents) accounted for 25% of the variation in males and 39% 
in females, while unshared environmental factors (something 
unique to each twin, like separate social circles) accounted 
for 27% of the variation in males and 21% in females. For 
problematic cannabis use, the proportion of total variance 
accounted for by genetic factors was 51% in males and 59% 
in females, shared environmental factors accounted for 20% 
in males and 15% in females, and unshared environmental 
factors accounted for 29% in males and 26% in females. Thus, 
it can be concluded that approximately half of the vulnerability 
for both cannabis use initiation and problematic cannabis use 
is genetically driven.
It is unclear, however, how genetic factors modulate the 
vulnerability to cannabis addiction. It has been reported that 
a person’s initial response at first exposure to cannabis is a 
strong determinant of subsequent development of addiction 
(Fergusson, Horwood, Lynskey, & Madden, 2003; Le Strat 
et al., 2009). As described in Chapter 2, there are studies 
suggesting that some genetic factors (such as COMT gene 
variants) might predispose those with them to the risk of 
developing psychosis following cannabis exposure (Caspi et 
al., 2005; Di Forti et al., 2012; van Winkel, 2011). Because it 
has been proposed that the brain’s dopamine response might 
contribute to this cannabis–psychosis link, it is plausible that 
similar gene variants could influence the addictive potential of 
cannabis. For example, genes could increase the rewarding 
effects of cannabis, attenuate some of its aversive effects or 
create underlying medical issues such as mental illness that 
affect the addictive risk. However, such genes have not yet 
been identified and there could be multiple mechanisms that 
mediate such a biologically driven phenomenon.
3.7.1 Risk factors for the development of 
cannabis dependence
How individuals differ in their risk of developing cannabis 
dependence has been studied through large epidemiological 
studies performed in the general population. Using aggregated 
data from the 1991–1993 National Household Survey on Drug 
Abuse (NHSDA), Kandel and colleagues (1997) reported that 
the proportion of past-year users who are dependent according 
to DSM-IV criteria was higher for marijuana (8.2%) as compared 
to alcohol (5.2%). This study also reported that among adults, 
males were more at risk of developing cannabis dependence 
than females. For both genders combined, the highest rates 
of past-year cannabis dependence occurred between the 
ages of 18–25, with adolescent girls aged 12–17 found to be 
particularly vulnerable. The prevalence of dependence declined 
strongly with age, while ethnicity was found to have limited 
influence on the risk of dependence. 
Using data from the 2000–2001 NHSDA, Chen and colleagues 
(2005) assessed the factors associated with the development 
of dependence among a group of recent onset cannabis 
users. The factors associated with excess risk of developing 
dependence included the onset of cannabis use before late 
adolescence, low socioeconomic status and the use of other 
drugs, including tobacco and alcohol, before using cannabis. 
Similarly, when examining the adolescent precursors of young 
adult cannabis dependence in a representative sample of 
secondary students in Victoria, Australia, Coffey and colleagues 
(2003) identified several independent risk factors, including 
being male, regular cannabis use, persistent anti-social 
behaviour and persistent cigarette smoking.
Fergusson and colleagues (2003) examined the linkages 
between early subjective responses to cannabis use and the 
later development of cannabis dependence using data from 
New Zealand’s 21-year longitudinal Christchurch Health and 
Development Study (CHDS). Findings showed that positive 
responses to cannabis use prior to age 16 were associated with 
a much greater likelihood of developing cannabis dependence. 
Youth who reported experiencing five positive responses to 
cannabis were 28.5 times more likely to become dependent 
than those who did not experience any positive responses, 
an association that held even after controlling for potentially 
confounding factors such as the extent of cannabis use prior 
to age 16. Negative reactions to cannabis, meanwhile, were 
found to be unrelated to subsequent dependence. 
Using data from France’s Susceptibility Addiction Gene 
Environment (SAGE) study, Le Strat and colleagues (2009) 
found that the initial subjective positive effects of first cannabis 
exposure were associated, depending on dose, with the 
development of cannabis dependence at ages 18–21. Young 
adults who reported five positive effects from their first cannabis 
consumption were 28.7 times more likely to develop lifetime 
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cannabis dependence than those who reported no positive 
effects, with this association remaining significant even when 
controlling for individual and familial variables. Together, those 
two studies suggest that the biological factors that mediate this 
initially pleasurable response might be a strong contributor to 
addiction and dependence risk.
3.7.2 Cannabis dependence in high-risk 
users
Studies examining the predictors of cannabis dependence in 
the general population generally include a minority of heavy, 
high-risk users. These studies are generally limited to predicting 
the transition from non-dependent to dependent use, and 
subsequently fail to detect the risk factors in the high-risk 
population of cannabis users. In an attempt to define these risk 
factors, Swift and colleagues (2000) conducted a one-year 
longitudinal study of a sample of heavy, long-term cannabis 
users in Australia. They concluded that cannabis use and 
dependence are fairly stable among long-term users, finding 
that the quantity of cannabis used and the severity of the 
dependence symptoms at baseline were the primary predictors 
of those who would maintain dependence over time.
More recently, van der Pol and colleagues (2013) aimed to 
identify the predictors of the transition from non-dependent 
frequent cannabis use to DSM-IV cannabis dependence by 
following a sample of high-risk, frequent users aged 18–30 
who were not yet dependent. Their findings revealed a number 
of independent predictors of cannabis dependence, including 
living alone, using cannabis as a coping mechanism, the 
number and type of recent negative life events (e.g., major 
financial problems), and the number and type of cannabis use 
disorder symptoms (e.g., impaired control over use). 
3.8 Conclusions and implications
Despite the public perception that cannabis is not an 
addictive drug, evidence from both animal and clinical studies 
clearly indicates that cannabis use can lead to addiction. In 
fact, approximately 5 to 9% of cannabis users will develop 
dependence at some point in their life, and that number 
increases to about one in six (or 17%) among those who start 
using cannabis during adolescence. 
Epidemiological studies have revealed that certain biological 
and environmental factors are strong contributors to the risk 
of developing cannabis dependence, including gender, risk-
taking behaviours and socioeconomic status. Such factors are 
certainly less amenable to intervention than others; however, it 
will be important to use this information to help detect those who 
might be particularly vulnerable to becoming dependent. With 
the age of initiation being an especially critical factor, efforts to 
delay the onset of cannabis use will ultimately help reduce the 
risk of experiencing harms and subsequent addiction. 
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What Interventions Are Available 
for Cannabis Use Disorders?
4
Chapter at a Glance
• Treatment of adolescent cannabis use disorders is an active area of research.
• Comprehensive, school-based prevention programs have been shown to have some 
efficacy for reducing cannabis use; data on the delivery of preventative interventions in 
non-school settings are less available.
• Emerging evidence demonstrates that screening tools can be used in primary care and 
other settings to screen for substance use that warrants clinical intervention, including 
cannabis use.
• Cognitive behavioural therapy, motivational enhancement therapy, multidimensional family 
therapy and contingency management have all been shown to have some efficacy in 
reducing cannabis use.
• Medications have been evaluated targeting reduction of cannabis withdrawal symptoms, 
abstinence initiation and relapse prevention, and for the treatment of cannabis use and 
co-morbid psychiatric disorders. However, there are no approved medications for treating 
either withdrawal or dependence as of yet. 
• Alternative delivery methods, including technology-based approaches, might be useful for 
expanding cannabis treatment accessibility and acceptance among adolescents.
By Aimee McRae-Clark, PharmD, BCPP
Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina
and
Kevin Gray, MD
Associate Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina
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4.1 Introduction
The multiple detrimental effects of early-initiation cannabis use, 
as described in the preceding chapters — impaired cognitive 
functioning, poorer educational outcomes, adverse mental 
health outcomes and an increased likelihood of developing 
dependence — underscore the importance of prevention, early 
detection and treatment interventions targeting youth.
Although the development of treatments specifically for cannabis 
use has lagged behind advancements for other substances of 
abuse, an evidence base is now emerging to guide the treatment 
of adolescents with cannabis use disorders. Current research 
is looking at interventions ranging from prevention programs to 
psychosocial and pharmacological treatments. There is also a 
significant interest in using alternative delivery methods such as 
mobile- and computer-based approaches to expand cannabis 
treatment accessibility and acceptance among teenagers. 
Given the relative dearth of prevention and treatment 
interventions focusing on adolescent cannabis use disorder, 
this review will also incorporate and interpret evidence provided 
by research focused on adolescent substance use disorders, 
not necessarily specific to cannabis, and adult cannabis 
use disorder.
4.2 Prevention programs
If effective, interventions designed to prevent, delay or 
reduce cannabis use in youth can have a significant impact 
on individual outcomes and public health. School-based 
prevention programs have been widely implemented to target 
adolescent cannabis and other drug use. A recent meta-
analysis of school-based prevention programs’ effectiveness 
at reducing cannabis use (Porath-Waller, Beasley, & Beirness, 
2010) found the most effective programs incorporated elements 
from multiple prevention models, had a longer duration, were 
facilitated by non-teachers and targeted high school students 
rather than middle school students. Overall, the reviewers found 
school-based programs had a 27.9% success rate at reducing 
adolescent cannabis use. A systematic review by Lemstra 
and colleagues (2010) evaluating long-term (i.e., one year or 
longer) school-based cannabis prevention programs found 
a mean reduction of seven days of cannabis use per month 
among adolescents participating in programs that combined 
drug education with the development of drug-refusal, self-
management and social skills. 
Data on the delivery of prevention interventions in non-school 
settings are less available. A Cochrane review conducted 
by Gates and colleagues (2006) was unable to draw firm 
conclusions on the benefits of non-school-based interventions 
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due to a dearth of studies available and the methodological 
differences between the studies. From the limited data, it 
has been suggested that motivational and family-based 
interventions might reduce self-reported cannabis use (Walton 
et al., 2014). In addition, a recent primary care trial comparing 
brief interventions delivered by therapist with those delivered 
by computer showed that computer-delivered intervention can 
prevent and reduce subsequent cannabis use in cannabis-
naïve adolescents (Walton et al., 2014). 
Prevention approaches studied to date have tended to focus 
on those with universal or inclusive reach rather than those 
targeting specific high-risk populations. In general, school and 
primary care settings are considered to be the optimal locations 
for the delivery of broad prevention strategies. Further work is 
needed to test targeted prevention strategies for high-risk youth. 
4.3 Screening, brief intervention 
and referral to treatment
Screening for substance misuse should be part of routine 
healthcare practice for all adolescent patients. A number of self-
report and clinician-administered screening tools have been 
evaluated for use with adolescents, most commonly in primary 
care settings (Mitchell, Gryczynski, O’Grady, & Schwartz, 2013). 
Some protocols have included brief intervention strategies and 
referral to more intensive treatments when indicated. Together 
these approaches are commonly referred to as screening, brief 
intervention and referral to treatment (SBIRT).
4.3.1 Screening tools 
The CAGE questionnaire, which is often used as a screener for 
problematic substance use in adults, is not very effective when 
used with adolescents. Instead, tools such as the CRAFFT 
questionnaire and the Brief Screener for Tobacco, Alcohol and 
other Drugs (BSTAD) have been shown to be better suited to 
youth (Kelly, Gryczynski, Mitchell, O’Grady, & Schwartz, 2014; 
Knight, Sherritt, Harris, Gates, & Chang, 2002).  
CAGE Questionnaire
Named after key word in four questions:
• Have you felt the need to cut down on your 
drinking or drug use?
• Have people annoyed you by criticizing your 
drinking or drug use?
• Have you ever felt bad or guilty about your 
drinking or drug use?
• Have you ever needed an eye opener the 
first thing in the morning to steady your 
nerves or get rid of a hangover?
CRAFFT assesses a number of potential indicators of 
substance-related risks and impairments by asking patients the 
following questions:
• C: Have you ever ridden in a car driven by 
someone, including yourself, who was “high” or had 
been using alcohol or drugs?
• R: Do you ever use alcohol or drugs to relax, feel 
better about yourself, or fit in?
• A: Do you ever use alcohol or drugs while you are 
by yourself, alone?
• F: Do you ever forget things you did while using 
alcohol or drugs?
• F: Do your family or friends ever tell you that you 
should cut down on your drinking or drug use?
• T: Have you ever gotten into trouble while you 
were using alcohol or drugs?
The advantages of CRAFFT include its ease of use as a 
mnemonic and its assessment of high-risk, substance-
related factors. It leaves out tobacco use, however, and lacks 
an assessment of substance use quantity. BSTAD, on the 
other hand, does include tobacco use as well as a detailed 
assessment of the frequency of use of each substance, but 
does not include some aspects of substance-related risk. As 
well, it assesses both patient and peer or friend substance use, 
with additional questions regarding the quantity of substances 
used in the past year.
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One possible method for combining the attributes of these 
screening tools is a staged screening process, beginning with 
brief questions about the use of any substances in the past 
year, followed by a more detailed assessment of the quantity 
and associated risks of each substance identified. This staged 
approach was found to be effective in a recent trial among 
adolescents presenting for routine outpatient care (Levy et al., 
2014). A single screening question on past-year frequency of 
use for eight categories of commonly used substances was 
followed by a substance-associated risk assessment derived 
partly from the CRAFFT questionnaire. Delivered electronically, 
this approach was deemed valid in assessing clinically relevant 
risk categories of adolescent substance use.
4.3.2 Brief interventions
With recent advances in screening methods, significant 
attention has been given to the development of brief 
interventions that can address problematic substance use 
revealed during the screening process. The goal of this type of 
treatment is to provide practical, low-burden interventions with 
an understanding that the patient may not be highly motivated 
or invested in behaviour change (i.e., “non-treatment seeking” 
or “pre-contemplative”). 
Project CHAT
Project CHAT is a brief (15–20 minute) motivational 
interviewing intervention focused on assessing a 
patient’s motivation to change, enhancing motivation 
for change and making plans for change.
Adolescent Cannabis Check-Up
The Adolescent Cannabis Check-Up is a two-session 
intervention consisting of an initial assessment interview 
and follow-up structured feedback and skills session 
provided in a motivational interviewing style. 
High-risk adolescents assessed in a primary care setting 
who received a brief motivational intervention called Project 
CHAT demonstrated improvements in a number of cannabis-
related measures when compared to a control group receiving 
usual care (D’Amico, Miles, Stern, & Meredith, 2008). Recent 
Australian and Dutch controlled trials have also supported 
a brief two-session motivational enhancement intervention 
known as the Adolescent Cannabis Check-Up (ACCU) for non-
treatment-seeking adolescent heavy cannabis users (de Gee, 
Verdurmen, Bransen, de Jonge, & Schippers, 2014; Martin 
& Copeland, 2008). Mixed outcomes, though, were derived 
from two controlled trials of a single-session motivational 
enhancement intervention (McCambridge & Strang, 2004; 
McCambridge, Slym, & Strang, 2008). Finally, among 
adolescents presenting to pediatric emergency services who 
screened positive for recent cannabis use, those receiving a 
series of brief interventions demonstrated superior substance-
related outcomes when compared to those who did not receive 
the interventions (Bernstein et al., 2009). 
4.3.3 Referral to treatment
Referral to treatment is often indicated in cases with significant 
cannabis use frequency and associated impairments. An array 
of interventions might be necessary based on the severity and 
risks involved. As such, healthcare providers should be aware 
of their own limitations in capacity and expertise, as well as the 
appropriate threshold at which referral to treatment is preferred 
over brief intervention.
4.4 Behavioural and 
psychotherapeutic interventions
Treatment is warranted when an adolescent develops a pattern of 
problematic cannabis use (e.g., when it interferes with academic, 
occupational, family or social roles). The intensity and modality of 
the treatment will depend on the frequency and quantity of use, 
as well as the severity of role impairments.
Psychotherapeutic approaches have been the most extensively 
studied for the treatment of cannabis use disorders in 
adolescents. The majority of evidence involves the use of the 
following treatment strategies:
• Cognitive behavioural therapy (CBT): A form of 
psychotherapy based on the premise that cognition 
can influence emotions and behaviours. CBT 
interventions help individuals identify and correct 
inaccurate or negative thinking so they can respond 
to challenging situations more effectively. 
• Motivational enhancement therapy (MET): 
A client-centred but directive therapeutic style 
intended to increase an individual’s commitment to 
change and reduce resistance to treatment. Key 
components of MET include expressing empathy, 
developing discrepancies, avoiding argumentation 
and supporting self-efficacy.
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• Multidimensional family therapy (MDFT): A 
multisystem approach targeting the adolescent’s 
intrapersonal and interpersonal functioning, the 
parent’s intrapersonal and interpersonal functioning, 
parent–adolescent interactional functioning, 
and family members’ interactions with sources 
of influence outside the family (e.g., schools,        
justice system).
• Contingency management (CM): A behavioural 
treatment that provides rewards or reinforcers 
upon demonstration of a desired behaviour (e.g., 
vouchers provided contingent upon confirmation of 
a “clean” urine drug screen).
4.4.1 Cannabis Youth Treatment Study
The largest psychotherapy trial to date is the Cannabis Youth 
Treatment Study (Dennis et al., 2004), which included 600 
adolescent cannabis users randomized to five treatment 
interventions: 
• Five sessions that included two MET sessions and 
three CBT sessions;
• Twelve sessions that included two MET sessions 
and 10 CBT sessions;
• The family support network approach, a multi-
component treatment that includes parent 
education groups, therapeutic home visits and 
case management in addition to 12 sessions of 
MET and CBT;
• The adolescent community reinforcement 
approach, which consists of 10 individual sessions 
and four sessions with caregivers to educate them 
on how to support the adolescent’s abstinence; or 
• Twelve to 15 MDFT sessions. 
The treatments ranged in duration from six to 14 weeks, with 
the outcomes repeatedly assessed over a one-year follow-up 
period. No one treatment approach was found to be superior 
in terms of days of abstinence or dependence problems, with 
all interventions demonstrating significant improvements in 
abstinence and the percentage of adolescents in recovery. 
Overall, the percentage of no cannabis use in the past month 
increased from 4% at baseline to 34% at end of treatment. 
Similarly, days of use were reduced by 36% from baseline to 
end of treatment.
4.4.2 Teen Marijuana Check-Up
Brief MET interventions have been further evaluated in 
adolescents with cannabis use disorders. For example, the 
Teen Marijuana Check-Up (TMCU) is a brief MET intervention 
intended to elicit voluntary self-assessment of cannabis use 
(Swan et al., 2008). An initial clinical trial assessed outcomes 
in adolescents randomized to either the TMCU intervention 
or an assessment control condition. Significantly reduced 
cannabis use was observed in both groups at a three-month 
follow-up; however, no between-group differences were 
observed (Walker et al., 2006). In a recent follow-up trial with 
310 adolescent cannabis users, the TMCU was compared to 
one group who received drug education and another whose 
treatment was delayed (Walker et al., 2011). Both treatment 
groups demonstrated a greater reduction in use and negative 
consequences than those in the delayed treatment control. 
The TMCU group had greater reduction in use but not negative 
consequences compared to the educational feedback 
control group. 
4.4.3 Multidimensional family therapy
To evaluate the potential of outpatient, family-based approaches 
in treating cannabis use disorders, Liddle and colleagues 
(2008) compared MDFT to a CBT intervention in drug-using 
adolescents with predominant cannabis use. Both the MDFT 
and CBT treatments resulted in significant decreases in 
cannabis use, with some indication that MDFT produced more 
sustained treatment effects. Another recent randomized trial 
conducted in the Netherlands also compared MDFT to CBT 
in adolescent cannabis users. Similar to the Cannabis Youth 
Treatment Study, the researchers found that while both groups 
demonstrated a reduction in use, neither treatment method was 
superior (Hendriks, van der Schee, & Blanken, 2011). 
4.4.4 Contingency management
In the treatment of substance use disorders, CM works by 
providing a potent reinforcer contingent on participants meeting 
specified success criteria; for example, abstinence from drug 
use as measured by a “clean” urine drug screen (Higgins et al., 
1991). The key features of CM include frequent opportunities to 
earn access to reinforcement (i.e., multiple urine drug screens); 
immediate access to opportunities to earn reinforcements 
(e.g., money, vouchers) following the occurrence of the target 
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behaviour; access to reinforcers of “perceived” appreciable 
value (even if their actual value is not high); constant or escalating 
schedule of reinforcement (i.e., successive occurrences of the 
target behaviour yields more opportunities for reinforcement); 
and resetting of the reinforcement schedule for failing to meet a 
minimum response criterion.
Carroll and colleagues (2006) compared the use of MET/CBT 
with CM, MET/CBT without CM, individual drug counselling 
with CM and individual drug counselling without CM in 
cannabis-dependent young adults referred by the criminal 
justice system. A significant effect of CM on treatment retention 
and cannabis-free urine specimens was observed, with the 
combination of MET/CBT and CM shown to be more effective 
than the other three interventions. In a subsequent study by 
Stanger and colleagues (2009), 69 adolescent cannabis 
abusers were randomized to receive either individualized MET/
CBT plus CM or individualized MET/CBT without CM. While the 
group receiving CM had greater mean weeks of continuous 
abstinence when compared to the control group, there were 
no substantive differences between the two treatment groups. 
Taken together, these findings suggest that psychotherapeutic 
approaches have some efficacy in reducing cannabis use. 
However, the effects are often modest and might not be 
sustained over the long-term. Contingency management is one 
strategy that may augment treatment response. 
4.5 Pharmacological 
interventions
Optimizing patient outcomes will ultimately require the 
development of new treatment approaches for cannabis use 
disorders. One potential avenue worth exploring is the role 
of pharmacological interventions, either targeting withdrawal 
symptoms in early cannabis abstinence or as complements 
to psychosocial treatments in abstinence initiation or relapse 
prevention (Hart, 2005; Vandrey & Haney, 2009). Medications 
might also play a role in the treatment of individuals with co-
morbid cannabis dependence and other psychiatric disorders. 
4.5.1 Treatment of cannabis withdrawal
As discussed in Chapter 3, a valid and reliable cannabis 
withdrawal syndrome has been documented in both controlled 
laboratory and clinical evaluations (Budney & Hughes, 2006), 
with the common symptoms associated with withdrawal, 
including irritability, anxiety, restlessness, appetite changes and 
sleep disturbances. A number of studies have been conducted 
evaluating the potential use of medications to treat cannabis 
withdrawal on the presumption that withdrawal symptoms could 
contribute to difficulty achieving or maintaining abstinence. 
Classes of medication that have been studied include 
antidepressants (Haney et al., 2001; Haney, Hart, Ward, & 
Foltin, 2003; Penetar, Looby, Ryan, Maywalt, & Lukas, 2012), 
cannabinoid agonists (Budney, Vandrey, Hughes, Moore, & 
Bahrenburg, 2007; Haney et al., 2004; 2008), mood stabilizers 
(Haney et al., 2004; Johnston et al., 2014), antipsychotics 
(Cooper et al., 2013), sedative hypnotics (Vandrey, Smith, 
McCann, Budney, & Curran, 2011) and adrenergic agonists 
(Haney et al., 2008). 
From these studies, it was found that the majority of medications 
either did not improve or, in some cases, worsened cannabis 
withdrawal symptoms. However, promising findings have been 
reported with the cannabinoid agonist dronabinol (Budney et 
al., 2007; Haney et al., 2004; 2008), the sedative hypnotic 
zolpidem (Vandrey et al., 2011), and the combination of 
dronabinol and the adrenergic agonist lofexidine (Haney et al., 
2008). It should be noted, however, that these positive findings 
have not yet been translated into improved clinical outcomes. 
Further, although participants in these trials were largely young 
adults, adolescents were not the target population. 
4.5.2 Treatment of cannabis use disorders
As with other dependencies, pharmacotherapy clinical trials for 
cannabis use disorders generally incorporate other treatment 
modalities such as CBT, MET and CM. The inclusion of 
a behavioural platform has several advantages, including 
alleviating ethical concerns of providing a placebo or non-proven 
pharmacotherapy intervention, as all patients receive some form 
of psychosocial counselling (Carroll, Kosten, & Rounsaville, 
2004). Medications evaluated for cannabis disorder treatment 
have included antidepressants (Carpenter, McDowell, Brooks, 
Cheng, & Levin, 2009; Weinstein et al., 2014), mood stabilizers 
(Levin et al., 2004) and agonist therapy (Levin et al., 2011), 
as well as agents targeting other specific neurotransmitters 
thought to be involved in cannabis addiction (Gray et al., 2012; 
Mason et al., 2012; McRae-Clark et al., 2009). 
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Clinical Vignette
Sam
Sam began smoking cannabis at age 13 after being introduced to it by older friends. He liked the feeling it 
gave him and how it helped him socially, so he gradually increased his use. At age 16, Sam was suspended 
from school after being caught with cannabis. His mother convinced the administrators not to contact the 
police, assuring them she would have Sam medically evaluated by their family pediatrician.
The pediatrician interviewed Sam and his mother separately. During her interview, Sam’s mother said she was 
disappointed in Sam, but remarked that cannabis “isn’t a big deal these days.” She emphasized that she and 
Sam have a very open relationship, and she would know if there were any significant problems. She asked if 
the doctor could sign a form for the school to confirm that Sam was seen and treated.
During his interview, Sam appeared irritated and was slow to engage, but eventually began to describe his 
cannabis use and note that “pretty much everybody smokes weed, especially the kids I want to hang out 
with.” The pediatrician recommended that Sam receive counselling for his substance use.
Sam and his mother visited the pediatrician again the following semester, this time to request an evaluation 
for ADHD due to concerns about Sam’s declining grades and inability to focus during class. Sam admitted 
that he never followed through with the counselling and continued to smoke cannabis, usually in the morning 
before arriving at school. He also mentioned that he was smoking alone more often, as opposed to only in 
social settings. Sam admits that his grades have slipped, but insists he is “getting by.” He reports feeling that 
school “isn’t really my thing anyway.” 
Drawing on the principles of motivational enhancement therapy, the pediatrician talked to Sam about 
balancing the risks and benefits of cannabis use. Although he was initially reluctant, Sam agreed to work 
on reducing his cannabis use. Together, Sam, his mother and the pediatrician developed a treatment plan 
that included monitoring, engagement in structured social activities and family-delivered rewards for desired 
behaviours (e.g., access to the family car with a clean urine test). Sam returned for weekly visits, where the 
pediatrician provided intervention based on the principles of cognitive behavioural therapy (e.g., drug-refusal 
skills). As a result, Sam gradually reduced and eventually stopped using cannabis completely. The pediatrician 
now assists Sam with the skills needed to prevent relapse.
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Similar to the investigations into medications for cannabis 
withdrawal treatment, the majority of these trials did not target 
adolescent cannabis users and have not yielded positive 
findings. While there is speculation about potential treatment 
roles for novel agonist compounds (including nabilone, an 
oral formulation of tetrahydrocannabinol; and nabiximols, an 
oromucosal mouth formulation of tetrahydrocannabinol and 
cannabidiol), no clinical trials of these medications have been 
conducted for cannabis use disorder in any age group.
To date, the most promising medication for the treatment of 
cannabis use disorders is N-acetylcysteine (NAC), a prodrug 
(inactive substance that is converted to a drug within the body 
by the action of enzymes or other chemicals) of the naturally 
occurring amino acid cysteine. NAC administration has been 
shown to increase the release of glutamate via stimulation of 
the cystine-glutamate exchanger, which becomes dysregulated 
after chronic drug use. By normalizing this exchange process, 
NAC has been shown to reduce the reinstatement of drug-
seeking behaviour in animal models across multiple substances. 
An open-label trial of NAC in cannabis users aged 18–21 
demonstrated reductions in self-reported cannabis use and 
cannabis craving (Gray, Watson, Carpenter, & Larowe, 2010). 
A follow-up, placebo-controlled study showed that NAC, when 
paired with brief counselling and CM to promote abstinence, 
doubled the odds of cannabis-dependent adolescents 
providing clean urine cannabinoid tests during treatment (Gray 
et al., 2012).
4.5.3 Treatment of co-morbid cannabis use 
and psychiatric disorders
As reviewed in Chapter 2, there are established links between 
cannabis use and the poor prognosis of mental illness. However, 
improved substance abuse outcomes have been reported in 
adults receiving pharmacological treatment of co-occurring 
psychiatric disorders (Brady, Sonne, Anton, & Ballenger, 1995; 
Kranzler et al., 1994; Nunes et al., 1998). Looking specifically 
at cannabis use, data from the U.S. National Comorbidity 
Survey found that 90% of cannabis-dependent individuals had 
a lifetime psychiatric disorder. Given that only 55% of individuals 
who were non-dependent experienced some form of mental 
illness, these findings indicate that psychiatric co-morbidity 
commonly occurs among individuals using cannabis (Agosti, 
Nunes, & Levin, 2002). Unfortunately, a limited number of 
studies have evaluated the potential of the pharmacological 
treatment of cannabis use disorders in adolescents with other 
psychiatric diagnoses. 
While one study showed that the antidepressant fluoxetine 
significantly reduces cannabis use in adults who are depressed 
and dependent on alcohol (Cornelius et al., 1999), more recent 
trials in adolescents and young adults with co-morbid major 
depression and cannabis use disorders did not find a significant 
effect of fluoxetine on cannabis-related outcomes (Cornelius et 
al., 2010; Findling et al., 2009; Riggs et al., 2007). This lack of 
effect might have been attributable to the strong psychosocial 
platforms used. 
A placebo-controlled, randomized trial that combined CBT 
with the administration of atomoxetine for attention deficit 
hyperactivity disorder (ADHD) in adolescents with substance 
use disorders also did not find any group differences in ADHD 
or substance use outcomes (Thurstone, Riggs, Salomonsen-
Sautel, & Mikulich-Gilbertson, 2010). A similarly designed but 
larger trial of osmotic release methylphenidate also did not yield 
between-group differences in primary ADHD or substance 
use outcomes, though the osmotic release methylphenidate 
group had more clean urine drug tests and improved parent-
reported ADHD symptoms compared to the placebo group 
(Riggs et al., 2011). Trials of pemoline (Riggs, Hall, Mikulich-
Gilbertson, Lohman, & Kayser, 2004) and the methylphenidate 
spherical drug-absorption system (Szobot et al., 2008) found 
that active medication produced superior ADHD outcomes than 
the placebo but no between-group differences in substance 
use outcomes.
4.6 Emerging approaches to 
treatment
While promising advances have been made in the treatment 
evidence base, a number of novel approaches are also being 
explored for further development. One such approach is the 
incorporation of mobile communications technology, which 
offers potential benefits in both accessibility and acceptability 
while also potentially providing “in-the-moment” interventions in 
high-risk situations for cannabis use (Shrier, Rhoads, Fredette, 
& Burke, 2013). Internet and computer-based interventions 
have also shown some promise (Tait, Spijkerman, & Riper, 
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2013) — and translating these kinds of interventions to mobile 
communications devices could yield further improvements in 
real-world outcomes. 
Another direction being looked at is the combination of 
multiple potentially synergistic treatment modalities (e.g., 
pharmacotherapy combined with psychosocial treatment) to 
enhance and optimize treatment outcomes (Carroll et al., 2004; 
2012). However, little work has been done in this regard with 
adolescent cannabis users and the findings to date in adults 
have been mixed.
4.7 Conclusions and implications
Cannabis use disorders are prevalent in adolescents and 
clinicians should use evidence-based interventions in their 
treatment. To date, the strongest evidence supports the use 
of psychosocial interventions such as cognitive behavioural, 
motivational enhancement and contingency management 
therapies. Data on the benefits of pharmacological treatments 
are less available. Prevention efforts to prevent, delay or 
reduce cannabis use among adolescents are also critical. 
Future research will explore alternative delivery methods 
for interventions, such as mobile- and computer-based 
approaches, which might be useful for expanding cannabis 
treatment accessibility and acceptance among adolescents. 
While work is needed to further develop and refine prevention 
and treatment approaches, a number of currently available 
effective interventions may be used to reduce the considerable 
clinical and public health burden of cannabis-associated 
adverse outcomes in youth. Clinicians are strongly urged 
to use evidence-based approaches to address adolescent 
cannabis use.
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Cannabis and Youth — A Summary 
of Key Findings and Major 
Questions, and a Call to Action
5
Chapter at a Glance
• The high rate of cannabis use by Canadian youth cannot be explained by biological differences between 
them and the youth of other countries. It is essential to study how their high level of use is influenced by 
the prevalent values, attitudes and expectations of Canadian society as a whole about cannabis and 
other drugs.
• In Canada, as in most western societies, the 15- to 24-year-old segment of the population has much 
higher use of cannabis than those aged 25 and over. At the same time, youth have relatively high levels 
of alcohol use, but much lower use of tobacco. There is a need to study motivational factors that are 
specific for cannabis and for youth, and the effect of individual differences in those factors.
• Canadian youth lack knowledge and have misconceptions about the effects of cannabis that contribute 
to favourable attitudes towards its use.
• School-based preventive education programs vary in content and efficacy. The best programs not only 
provide sound factual knowledge, but also attempt to change attitudes and expectations about cannabis 
use and its consequences. There is room for improvement of results for even the best programs.
• Peer group influences on youth views and behaviour about cannabis might be more potent than family 
and school influences.
• Adolescents are more sensitive than adults to the adverse effects of regular heavy use of cannabis, 
including cognitive impairment, dependence, poor psychosocial development, impaired school and work 
performance, drug-related psychiatric illness, and generally poorer treatment outcomes.
• There is a need for research on improved pharmacological and psychosocial treatment methods, and 
follow-up studies of their long-term efficacy.
By Harold Kalant, MD, PhD
Professor Emeritus, Department of Pharmacology and Toxicology, University of Toronto, and Research Director 
Emeritus, Biobehavioural Research, Centre for Addiction and Mental Health
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5.1 Introduction
This report deals with the effects of cannabis on the health, 
psychological and social functioning, and maturation of young 
users. It does not deal with medical uses of cannabis or 
with debates about the legal status of non-medical use. The 
many, varied reasons for producing a report on cannabis and 
Canadian youth have been set out in the preceding chapters. 
The main reasons can be summarized:
• The 15–25 year age group has the highest rate 
of commencing use of cannabis in the Canadian 
population, and Canadian youth have the highest 
percentage of users in the developed world;
• Youth have the highest vulnerability to more serious 
adverse effects of cannabis use;
• Among heavy regular users, youth have generally 
poorer treatment outcomes than adults;
• Among those starting regular use at the youngest 
ages, some of the adverse effects may be 
irreversible;
• These effects can seriously limit the educational, 
occupational and social development of the 
affected individuals; and
• Youth have widespread misinformation and 
misperceptions about cannabis use that contribute 
to their motives for use and their vulnerability to 
adverse effects.
Given our present knowledge of these problems, it is important 
to reduce the harm to youth by decreasing the numbers of 
users and delaying the start of use to a later age. The report 
therefore emphasizes the need to develop and implement 
effective programs of preventive education, and to improve our 
understanding of why youth use cannabis, their patterns of use 
and the efficacy of different therapeutic interventions. These 
needs suggest a range of research questions that it is possible 
and desirable to explore. However, given the limited resources 
available for research on the spectrum of health problems, it is 
necessary to focus efforts on solving a more limited range of 
the most serious problems in order to reduce cannabis-related 
harms. The following discussion attempts to identify the most 
pressing research questions. It may stimulate others to draw up 
their own priority lists, and that in turn may stimulate a valuable 
range of other research activities and practical interventions.
In addition, this chapter proposes a number of measures that 
can be taken now — on the basis of existing knowledge — to 
mitigate the risks posed to youth by cannabis, and to inform 
policy and practice so as to eliminate some of the harms resulting 
from society’s past attitudes and responses to cannabis.
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5.2 Increased understanding of 
cannabis use among Canadian 
youth
That Canadian youth have the highest prevalence of cannabis 
use among the 28 countries compared in the UNICEF report 
(2013) indicates that the reasons for use are not restricted to 
youth per se. There is no evidence that Canadian youth differ 
biologically from youth in other countries in ways that would 
predispose them to greater use of cannabis. Past year use 
by 15-year-olds in Canada was 28%, compared to less than 
10% in Germany, Finland, Norway and Sweden. Somewhat 
surprisingly, a survey of youth in a working-class district of 
Santiago, Chile, found considerably lower rates of cannabis 
use than among Canadian youth (Delva et al,. 2014), despite 
the higher prevalence of low socioeconomic status, family 
problems and other factors generally considered to be risk 
factors for use (von Sydow, Lieb, Pfister, Höfler, & Wittchen, 
2002; Lemstra et al., 2008, 2009). In the Chilean sample, at 
age 14 only 3.7% had used once or twice in the past year, and 
0.4% had used 40 times or more; at age 16 the corresponding 
figures were 8.1% and 1.9%. 
These figures suggest strongly that the values, traditions and 
social attitudes of a given population, including views about 
alcohol and other substances, affect the behaviour of youth 
in that population just as they do for older age groups. To 
understand the high use of cannabis by Canadian youth, it is 
important to compare the prevalent values, attitudes 
and expectations of Canadian society with those of 
a range of other countries in relation to drug use in 
general and cannabis in particular. Such information could 
be important in indicating where efforts should be directed to 
decrease use by Canadian youth.
Nevertheless, within most western societies with a relatively 
high standard of living, cannabis use is more common among 
adolescents and young adults than among older age groups 
(Table 2). It is necessary to identify what factors give rise to 
this difference. The Introduction to this report examines this 
question in detail, but some of the motives discussed there 
are not specific either to youth or to cannabis. For example, 
use for coping with emotional and other problems, conformity 
with the actual or perceived norms of one’s peers, and relief 
of boredom have also been recognized as motivating factors 
for the use of alcohol, tobacco and other drugs by adults as 
well as youth (e.g., Enman, Zhang, & Unterwald, 2014; Rothe, 
2005; Schry & White, 2013; Yeh, Chen, & Sim, 1995). We 
need to look for reasons that are more selective for 
youth and for cannabis, as well as determine how 
those reasons evolve during the course of growing 
involvement of young people with cannabis. There is 
a need for longitudinal studies of changing patterns 
of attitudes, expectations, motivations and values, as 
young adolescents become regular users.
Table 2. Recent data on past-year cannabis use by Canadians in 
different age groups
(Health Canada, 2013, Statistics Canada, 2015)
As pointed out in the Introduction, adolescence is a time of 
increasing independence from family, development of closer 
social links with peers, and exploration of new social identities. 
It is also a time of questioning and challenging the authority of 
elders and other authority figures, of high enthusiasm combined 
with limited experience and knowledge, and of relative freedom 
from the responsibilities of adulthood. This combination of 
characteristics was clearly demonstrated in the 1960s and ’70s 
in the adoption of cannabis as the drug of youth, as opposed 
to alcohol, the drug of the older generations, and the deliberate 
defiance of police and other authorities by openly smoking 
cannabis in large groups in public places. 
The distinction between the drug preferences of youth and 
adults is no longer as sharp as in the 1970s, and combined 
use of both cannabis and alcohol is reflected in the growing 
frequency of motor vehicle accidents involving young drivers 
under the influence of both substances (Beasley, Beirness, 
& Porath-Waller, 2011; Terry-McElrath, O’Malley, & Johnston, 
2014). However, the distinction is still evident in some ways 
in the large decrease of tobacco smoking by youth, who 
nevertheless find no inconsistency in smoking cannabis. A 
second important area of research is more detailed 
analysis of motivations for cannabis use that are 
specific to youth. The findings of such research could be 
CADUMS 2012 CTADS 2013
Age group % users Age group % users Age at start
15–24 20 15–19 22 15.1
25+ 8 20–24 26 16.6
25+ 8 18.3
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helpful in designing preventive programs aimed at decreasing 
the recruitment of young people to cannabis use. Preventive 
measures should be directed toward the specific causal factors 
operating in youth.
A closely related research challenge arises from the fact that 
individual users differ from one another as to which motivational 
factors predominate in their initiation of use. It would be 
useful to see if there is a correlation between different 
principal causal factors and different outcomes; that is, 
to determine whether different causes predict early cessation 
of use, continuation of occasional light and harmless use, or 
heavy, prolonged use leading to major adverse effects. If such 
a correlation is found, it would have important prognostic 
significance that could lead to selective direction of therapeutic 
intervention to those who require it most.
In addition to these longer-term research projects, the early 
detection of potentially harmful use of cannabis could 
be improved by working with Canadian associations of 
healthcare professionals to encourage physicians to 
administer screening and early detection questionnaires 
to all adolescents and young adults (ages 15–25 years) 
who come for non-emergency treatment or routine 
examination.
The medical uses of marijuana and the regulatory systems 
created for managing such use are not within the scope of the 
present report. However, one aspect of those systems that is 
germane to the subject of cannabis and youth is the role of 
“medical marijuana” as a source of the material used by youth for 
non-medical purposes. The illicit market is generally assumed 
to be the source of the cannabis for Canadian youth. However, 
studies in the United States have shown a significant amount of 
diversion of marijuana from state medical marijuana programs 
to non-medical use by adolescents (Thurstone, Lieberman, 
& Schmiege, 2011). There is no reliable information about 
such diversion in Canada, but there have been instances of 
preparations made by licensed producers under the Marihuana 
for Medical Purposes Regulations (MMPR) that were packaged 
and promoted in ways that would appeal to youth. Three 
practical steps should be taken immediately to prevent 
or reduce diversion from this source:
1. Enforce the regulations that forbid packaging 
marijuana for medical purposes in any way other 
than the plain wrappers intended by the MMPR.
2. Inform physicians that marijuana should not be 
prescribed for children or adolescents, other 
than with the possible exception of low-delta-9-
tetrahydrocannabinol (THC), high-cannabidiol (CBD) 
preparations that are currently being investigated 
for treatment of certain forms of childhood epilepsy, 
and possibly for treatment of inflammatory illnesses.
3. Alter the MMPR by setting maximum permissible 
THC concentrations and minimum CBD:THC ratios 
that are in accord with the best available knowledge 
concerning therapeutic efficacy.
5.3 Comprehensive preventive 
education efforts
Much research has been devoted to evaluating preventive 
education programs differing in objectives, complexity, duration 
and educational methodology. It has been claimed that 
preventive education programs have a benefit-cost ratio of 18:1, 
meaning that an expenditure of $1 in delivering the program 
produces a savings of $18 in health and social costs of drug 
use (Kim, Coletti, Crutchfield, Williams, & Hepler, 1995; Miller & 
Hendrie, 2008). However, cost-benefit analyses suffer from the 
inherent theoretical weakness of having to assign a monetary 
value to every cost and every benefit, even when these are 
of a subjective nature not normally conceived and expressed 
in monetary terms. In addition, most of these analyses have 
grouped all drug use together, so that the large reduction in 
tobacco smoking would tend to outweigh the contribution of 
cannabis use to the cost-benefit assessment. It is therefore 
more meaningful to assess the ability of programs to delay or 
reduce the onset of use of each drug separately.
The two major approaches in preventive programs have been 
(1) to increase accurate factual knowledge about cannabis and 
its effects among adolescents in particular, and (2) to change 
their beliefs and expectations about cannabis, and their attitudes 
toward its use. These approaches are discussed by both 
Henderson (Introduction) and McRae-Clark and Gray (Chapter 
4). Both aspects are of practical importance. The Monitoring 
the Future project in the United States (Keyes et al., 2011) has 
found that marijuana use by high school students is inversely 
related to attitudes (approval vs. disapproval) towards use 
and to beliefs about its effects (harmfulness vs. harmlessness 
and pleasure). Such attitudes are determined strongly by birth 
cohort effects rather than by individual attitudes. The authors 
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interpret this finding as evidence that adolescents are more 
strongly influenced by their peers’ views than by those of family 
or other influence groups.
Porath-Waller and colleagues (2013) have documented a series 
of erroneous beliefs held by Canadian adolescents about the 
actions and effects of cannabis, and have noted that youth with 
poor communication with their families are more likely to use 
cannabis. The latter point appears to agree with the suggestion 
by Keyes et al. It is therefore important to learn how to 
change the beliefs and attitudes of significant numbers 
of adolescents, who can then influence their peers in 
a self-propelling change of drug use among the whole 
same-age cohort.
A large proportion of programs designed for this purpose have 
been school-based. Porath-Waller and colleagues (2010) 
conducted a meta-analysis of high-quality studies to determine 
which features of school programs are associated with superior 
outcomes in their ability to prevent or deter initiation of cannabis 
use. The findings are reviewed in detail in Chapter 4, and only 
two points will be commented on here. The first is that school 
programs with elements drawn from multiple models, and 
longer and more intensive programs, had a greater success 
than single-model and shorter programs, in terms of lower 
numbers of students who had initiated cannabis use by the 
time of the follow-up. The most effective programs were 28% 
more effective than control conditions of the ordinary curriculum 
with no cannabis program. 
This result appears similar to the reported results of a computer-
based brief intervention (CBI) administered to 12- to 18-year-old 
American youth who had not yet begun to use cannabis. The 
intervention was given during visits to urban primary medical 
care clinics, and the results were followed up at three, six and 
12 months (Walton et al., 2014). At the one-year recall, 16.8% 
of those who received the CBI reported any use of cannabis 
during the year, compared to 20.9% of those who received the 
same intervention from treatment personnel (TBI), and 24.2% 
of the control group (no intervention). The CBI reduced the 
initiation of use by about 30% relative to the controls, while the 
TBI reduced it by 13%. 
A somewhat similar study by Harris and colleagues (2012) used 
a computer-based screening program followed by brief advice 
from a therapist. The study compared the changes in alcohol 
use and cannabis use in groups of American and Czech 
adolescents (mean age about 15 years, range 12–18) with and 
without this program. At the one-year follow-up, in the American 
sample alcohol was used by 29.3% of the test group vs. 37.5% 
in the controls, which represents a 22% reduction of users in 
the test group relative to the control group. In the Czech group 
the corresponding reduction in cannabis use was 41% (17% of 
users in the test group vs. 28.5% in the control group).
If these results are generalizable, it appears that quite different 
prevention approaches — the long, intensive, multi-component 
school program on the one hand, and the CBI on the other — 
produce comparable results. Two possible explanations come 
to mind. One is that the same individuals would benefit from 
either type of program because they are either undecided or 
disinclined to use cannabis, and any type of prevention program 
gives them enough support and encouragement to enable them 
to refrain from using cannabis. The other possible explanation is 
that different groups of adolescents, of roughly equal numbers, 
benefit from the different types of program. Another useful 
research objective, therefore, is to study responders and 
non-responders to each type of program to determine 
what characteristics in the user predict success with 
a given type of preventive education program. If there 
are different responsive groups for the different programs, 
the total preventive result could be considerably improved by 
differentially directing adolescents to the appropriate programs. 
On the other hand, if the same students benefit from either type 
of program, it might be sufficient to replace the long school 
program with computer-based screening and brief intervention 
carried out in schools rather than in primary care medical 
centres. The CBI program probably represents a considerable 
saving of personnel time and resources relative to the long, 
intensive, multi-component programs. Either exclusive use of 
the CBI in the one case or correctly assigning students to their 
individually appropriate type in the other case would mean a 
more efficient and economical use of resources, as well as an 
improved total result.
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The second point arising from the Porath-Waller et al. review 
(2010) is that better results in school-based programs were 
obtained when outsiders rather than teachers directed the 
sessions. This finding is troublesome because it appears to 
suggest that such programs impose demands on the teachers 
that they are potentially not qualified to meet. The review 
suggests various possible explanations, but the question 
has evidently not been explored systematically. Qualitative 
research involving students and teachers would be a 
useful way to begin identifying the potential factors 
underlying this relationship. 
In addition to the proposed longer-term research, two 
immediate measures based on present knowledge 
could improve the efficacy of school-based preventive 
education programs:
1. A conference of health and education experts 
from federal and provincial government agencies 
could be convened to standardize school-based 
education programs by selecting two of the best 
programs—a long multi-component program and 
a brief computer-based program—assign schools 
to one or the other in all parts of the country, and 
provide standard training sessions for those who 
are to deliver the programs. In addition to improving 
the programs as now taught, this measure would 
make it possible to begin gathering data to evaluate 
studies included in the research agenda set out 
above. 
2. Set up a register of experts from agencies outside 
the school system who would administer the 
standardized programs in the designated schools 
to take advantage of the greater credence afforded 
them by students.
5.4 More research and better 
data on adverse effects to inform 
policy, practice and programs
Most knowledge of adverse effects of cannabis was gathered 
in earlier years when even the most potent preparations of 
cannabis had THC contents of less than 10%, whereas contents 
of 15–25% or more are now encountered, and extracts and oils 
with contents of 50% and more are increasingly being used. 
Since adverse effects are largely dose-related, it is important 
to re-examine frequencies, patterns and severity of 
adverse effects, such as those discussed below, at 
present levels of cannabis potency.
5.4.1 Driving accidents
Henderson (Introduction) points out that adverse acute effects 
of cannabis in youth are not numerically a major concern with the 
exception of impaired driving skills and resulting increase in the 
numbers of cannabis-impaired young drivers involved in motor 
vehicle accidents, injuries and fatalities. This topic is already 
the subject of a considerable amount of research effort (e.g., 
Beasley et al., 2011; Boak, Hamilton, Adlaf, & Mann, 2013; 
Terry-McElrath et al., 2014), which will undoubtedly continue 
as further data accumulate after the legalization of cannabis in 
various states and countries (e.g., Salomonsen-Sautel, Min, 
Sakai, Thurstone, & Hopfer, 2014). The evidence is reviewed in 
detail by Smith in Chapter 1. 
However, one of the reasons for the increase in frequency of 
adolescents and young adults driving under the influence of 
cannabis is the knowledge that there is at present no roadside 
test for identifying the presence of cannabis in the driver that 
is comparable to the breath tests for alcohol. Two practical 
steps towards correcting this situation could be taken 
immediately:
1. Convene a meeting of federal and provincial 
government experts in highway safety to explore 
starting a large-scale program to evaluate roadside 
oral fluid collection from impaired, erratic and 
speeding drivers suspected of being under the 
influence of cannabis and rapid, laboratory-
based quantitative analysis of the samples for 
cannabinoids. 
2. Make the commencement of this program widely 
known to youth by announcing it in all schools. 
Depending on the quality and usefulness of the 
results of the evaluation phase, this collection and 
analysis could be incorporated into the highway 
traffic code.
5.4.2 Long-lasting cognitive impairment
The special vulnerability of adolescents to adverse effects of 
chronic cannabis use on cognitive functions has been reported 
by many investigators (Jager & Ramsey, 2008), together with 
its resulting impairment of educational achievement (Horwood 
et al., 2010; Homel, Thompson, & Leadbeater, 2014; Silins 
et al., 2014) and career options. Attention to this vulnerability 
has been greatly heightened by the report of long-lasting and 
possibly permanent reductions of cognitive functioning, as 
reflected in reduction of IQ (Meier et al., 2012). Adolescents 
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who began using cannabis at an early age and continued using 
it regularly experienced an impairment of brain maturation. The 
impairment especially affected maturation of neuronal pathways 
serving “executive functions” such as learning, memory, 
problem solving, assessment of alternative courses of action 
and impulse control. 
The data analysed by Meier et al. came from a study of a 
birth cohort of over 1,000 children born in a one-year period 
in Dunedin, New Zealand, whose physical and mental health, 
education and psychosocial development were followed 
through regular recall interviews and examinations from birth 
to age 38. The finding of long-lasting cognitive impairment 
is potentially one of the most important considerations with 
respect to legalizing non-medical use of cannabis. It has been 
challenged on scientific grounds by proponents of legalization, 
and given great credence by opponents of legalization. It is 
important to be able to reach a secure conclusion as to its 
validity, so the Meier et al. paper, considered in detail in 
Chapter 1, deserves additional attention here. 
Mokrysz and colleagues (2014) in an abstract in conference 
proceedings reported that in an English birth cohort study of 
2,612 participants tested at ages 8 and 15 years, those who 
had started using cannabis in the interval and had used it at 
least 100 times had a decline of 3.71 IQ units relative to the 
non-users. However, when the results were controlled for 
the effects of sex, socioeconomic status, maternal factors, 
mental health and other drug use, the cannabis effect was 
attenuated, although the authors do not say whether it was 
no longer significant. There are problems with this study that 
the abstract does not explain or deal with. An alcohol effect 
remained significant despite these controls, but only in the 
moderate users and not in the heaviest users. No information 
is given about the age at which cannabis use began or the 
duration of use preceding the retests at 15 years of age, so it 
is not possible to tell whether this study is comparable to the 
Dunedin study.
A criticism of the Meier et al. paper by Rogeborg (2013) is 
based on the assumption that cannabis use is more common 
among children of low socioeconomic status (SES) families and 
the argument that low SES per se is capable of explaining the 
findings of Meier et al. The reasoning is that low SES children 
sort themselves into groups with other low SES children, which 
reduces their cognitive development by impairing educational 
history and intellectual stimulus. Rogeborg entered the Dunedin 
data on SES into a simulation model with hypothetical values for 
the influence of SES and education on the IQ, and concluded 
that they are capable of reproducing the differences shown in 
the Meier paper without invoking any causal role for cannabis. 
However, Moffitt and colleagues (2013) showed that cannabis 
use in the Dunedin study was not confined to children of low 
SES families, but was distributed across all SES levels. They 
then reanalysed the data from only those children of middle 
class SES, so as to minimize any influence of SES variation, 
and still found the same results as in their original analysis. They 
therefore reject the Rogeborg interpretation. 
Finally, two earlier longitudinal studies that did not find long-
lasting cognitive loss in cannabis users are not really relevant 
because they did not examine the same questions under the 
same conditions as the Dunedin study. Lyketsos, Garrett, Liang 
and Anthony (1999) carried out a study of a general population 
sample in East Baltimore that began in 1981 and re-examined the 
subjects in 1982 and 1993–1996. The primary purpose of the 
study was to examine age-related decline in cognitive function 
as measured by the Mini Mental State Examination (MMSE), 
but they also gathered data on the effects of a number of other 
factors, including alcohol and cannabis use. Subjects were 
divided by age into five groups: 18–30, 31–40, 41–50, 51–60 
and 61–65 years. Only the 61–65 year olds showed a clinically 
significant decline in MMSE score between 1982 and 1993–
1996. Subdivision of the age groups by levels of cannabis use 
showed no significant differences in decline between never, light 
and heavy users. However, this study is also not comparable to 
the Dunedin study for the following reasons:
1. More than half of the 3,401 original subjects were 
lost to the final follow-up, and there was no way of 
knowing whether the lost group differed from the 
follow-up group with respect to cannabis use; 
2. No drug tests were done to confirm the self-reports 
concerning cannabis use; 
3. The MMSE is not a sensitive test, and might have 
underestimated the cognitive declines; and 
4. The youngest age group was significantly older than 
the most vulnerable subjects in the Dunedin study. 
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In addition, no data were collected on the age of starting 
cannabis use, and its duration and heaviness of exposure.
The other study, by Fried, Watkinson, James and Gray (2002), 
compared the IQ scores at ages 9–12 years, before the start of 
cannabis use, and again at ages 17–20 years, in four groups 
of subjects related to level of cannabis use: 37 non-users, 9 
light current users, 15 heavy current users, and 9 former users 
abstinent for at least three months. The heavy current users 
showed a significantly lower IQ than they had shown at age 
9–12, whereas the other three groups showed gains in IQ 
score. The fact that the former users showed a gain led to the 
conclusion that acute toxicity due to current heavy use impairs 
cognitive function, but does not cause any lasting effects. The 
authors urged caution in interpreting their findings because of 
the small numbers of subjects. Additional reasons for caution 
are that no data were given concerning the age at which use 
of cannabis started, and the “non-user” group was defined in a 
way that included light occasional users who had not used any 
cannabis during the previous two weeks.
In summary, the criticisms of the Meier et al. paper do not 
appear to be valid, yet it is true that it is a single study that has 
not been replicated. Because of the important role of effects 
on adolescent users in the debate about cannabis legalization, 
it is important that an independent replication of the 
Dunedin study be undertaken in a Canadian or North 
American context. Such a complex and large-scale 
longitudinal study cannot be undertaken lightly or inexpensively. 
It will require a long-term commitment of funding, and might 
have to be undertaken concurrently in more than one centre to 
achieve the necessary cohort size and number of researchers. 
Its importance for policy purposes is sufficiently great to warrant 
a major effort to make it possible.
5.4.3 Mental health
As reviewed by Goodman and George in Chapter 2, the relation 
between cannabis use and various mental health problems is 
complex and poorly understood. The precipitation of clinical 
symptoms of schizophrenia by cannabis in those with a genetic 
predisposition has been clearly demonstrated, but there has 
been little research on whether psychosis precipitated by 
cannabis use has a different clinical symptom pattern and 
course from psychosis originating without cannabis use. 
Schizophrenic patients also have a recognized tendency to 
increase their use not only of cannabis, but also of alcohol, 
tobacco and possibly other psychoactive substances (Drake 
& Brunette, 1998; Rabin, Goodman, George, & Barr, 2014), 
perhaps as a form of intuitive self-medication for relief of their 
symptoms. This increase adds to the difficulty of distinguishing 
between cannabis use as a cause, a consequence or a co-
occurrence with psychosis. It has also given rise to claims by 
advocates of cannabis use that it is therapeutically useful in 
treatment of mental disorders, one of the misconceptions about 
cannabis found by Porath-Waller et al. (2013) in their study of 
Canadian youth. It is important, both for purposes of 
preventive education and for improved treatment of 
patients with co-morbidity, to continue both clinical 
and basic neurobiological studies of the temporal and 
mechanistic links between cannabis use and mental 
disturbances.
The links between cannabis use and depression are less 
clear than those with psychosis. Earlier evidence reviewed 
by Degenhardt, Hall and Lynskey (2003) and more recent 
evidence reviewed by Goodman and George make clear 
that the link between cannabis and depression is complex, 
and there are numerous reasons why it is difficult to interpret. 
No association has been found between occasional light 
use of cannabis and depression, but many cross-sectional 
epidemiological studies have shown that heavy cannabis use 
and depression are frequently found together. It is still uncertain, 
however, to what extent cannabis use causes depression, 
depression causes cannabis use, or other factors cause both 
depression and cannabis use. Major methodological problems 
in the study of cannabis use and depression include lack of 
attention to the relation between level of cannabis use and 
severity of depression, failure to use standard diagnostic criteria 
to distinguish between temporary lowering of mood and full 
clinical depression, and lack of precision about the temporal 
relations between the drug use and the onset of depression.
Despite the mood elevation experienced by recreational users 
of small amounts of cannabis, the medical use of cannabis 
has often produced dysphoria leading to refusal to continue 
treatment. However, depression does not appear to be an 
acute overdose effect, comparable to the acute toxic psychosis 
produced by high-dose cannabis. A number of longitudinal 
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studies analyzed by Silins and colleagues (2014) have shown 
that early regular use of cannabis during adolescence is 
associated with greater risk of depression in early adulthood, 
whereas early experience of depression is not a predictor of 
later problematic use of cannabis. Though a number of possible 
confounders were ruled out by Silins et al., it is impossible to 
prove whether pharmacological the actions of cannabis initiate 
neuronal mechanisms leading directly to depression, or the 
effects of heavy cannabis use lead to social, educational and 
economic disturbances that are the proximal causes of the 
depression.
There is a need for more rigorously planned longitudinal 
studies of the link between cannabis and depression, 
as well as functional neurobiological imaging studies 
to explain the nature and mechanism of the link 
between heavy cannabis use and clinical depression 
and depressive phenomena.
A third important link of cannabis use and mental health is with 
anxiety disorders, including post-traumatic stress disorder. 
As reviewed by Goodman and George, cannabis has a long 
history of use as a sedative-anxiolytic agent, yet cannabis use 
by adolescents is often followed by anxiety. Contemporary 
research is consistent with both these observations. The 
endocannabinoid anandamide, which acts on the same CB
1
 
receptors in the brain as the plant cannabinoid THC, has an 
anti-anxiety effect (Gunduz-Cinar, Hill, McEwen, & Holmes, 
2013). Yet the synthetic cannabinoid “Spice,” which acts 
strongly at the same receptors, commonly produces anxiety 
(Spaderna, Addy, & D’Souza, 2013). The increasing use by 
youth of high-potency cannabis preparations with high THC 
and low CBD content has been followed by greater frequency 
of anxiety disorder (Copeland, Rooke, & Swift, 2013). The plant 
cannabinoid CBD, which partially blocks the action of THC 
at the CB
1
 receptor, is currently being explored as an anti-
anxiety agent, as well as for its possible anti-depression and 
anti-psychotic actions (Campos, Moreira, Gomes, Del Bel, & 
Guimaräes, 2012). 
One possible explanation for these apparently contradictory 
findings is the fact that dose–effect curves for the cannabinoids 
are commonly biphasic. That is, increasing dose produces 
increasing effect in the lower dose range, but after a peak effect 
is reached, further increase in dose causes a decrease and 
then a reversal of effect (Kalant, 2014). However, just as with 
psychosis and depression, the link between cannabis 
and anxiety is complex. There is a need for both basic 
neurobiological and clinical studies to define the 
nature of the link, the direction of causality and the 
possible therapeutic use of CBD or other cannabinoid 
derivatives in the treatment of anxiety disorder.
5.4.4 Addiction
The evidence reviewed by Le Foll (Chapter 3) leaves no doubt 
that heavy users of cannabis have a significant probability 
of becoming addicted to it, as defined in the DSM-IV 
(dependence) or the DSM-5 (cannabis use disorder, severe). 
Despite the change in terminology over the years, the term 
“addiction” continues in general use, and is usually equated 
with dependence or severe substance use disorder. There 
appears to be a greater vulnerability to addiction in young 
users than in adults. It has been estimated that among regular 
(daily or near-daily) users of cannabis, adults have an 8–10% 
risk of becoming addicted, while adolescents have a 16% risk 
(Anthony, 2006). 
One of the continuing problems in assessing the significance of 
these figures, however, is that the concept of addiction differs 
markedly, depending on the disciplines of those who use 
the term. Passive exposure to drugs can produce tolerance 
and physical dependence without resulting in drug-seeking 
behaviour and addiction, whereas self-administration of the 
same drugs carries a real risk of addiction. The essential features 
of addiction are related to drug-seeking, self-administration, 
difficulty controlling the amount and frequency of use, and 
inability or difficulty in achieving and maintaining cessation of 
use when adverse effects of use make it desirable or necessary 
to do so. 
Recent neurobiological research has emphasized the concept 
of addiction as a brain disorder caused by chronic exposure to 
a drug. It has focused on the neural mechanisms underlying 
tolerance, withdrawal reactions, the “reward system” in the brain 
and adaptive changes in the connections between nerve cells. 
It has identified specific tracts and nuclei in which functional 
alterations have been found in dependent subjects, both 
human and non-human. Research in the behavioural and social 
sciences has focused more on behavioural, environmental 
and economic factors that affect accessibility of the drug, 
encourage or discourage its use, and promote linkage of drug 
use to specific situational cues and internal sensory stimuli. 
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Most of the animal models used for studying the mechanisms of 
addiction have been criticized by behavioural scientists on the 
grounds that they study reinforcement and neuro-adaptation, 
but do not actually study addiction (Winger, Woods, Galuska, & 
Wade-Galuska, 2005). 
Further research on addictions must bridge the 
gap between these two approaches and study how 
environmental and behavioural factors activate and 
modify the neural mechanisms that mediate the 
development of addiction (Kalant, 2010, 2015). Animal 
models continue to be used for preliminary testing of potential 
therapeutic agents for treatment of addictions. If they are to be 
useful for this purpose, they should be as close as possible to 
addiction in humans, not to individual features that are not essential 
to addiction, such as tolerance and physical dependence.
Knowledge of the extent of harm produced by cannabis use by 
Canadian youth and application of this knowledge to prevention 
efforts could be improved by immediate application of practical 
measures to the gathering of accurate data:
• Data should be routinely gathered on the diagnoses 
and outcomes of hospital admissions attributed 
to cannabis, as is now done for alcohol-related 
admissions. Since the number of cannabis-linked 
admissions each year is small, this should not be 
an onerous task. It would give physicians a better 
idea of the range and severity of health hazards 
attributable to cannabis.
• To help assess the harm produced specifically by 
cannabis, annual statistical data on drug offences 
in Canada should be divided into separate groups 
for cannabis, opioids, psychostimulants, sedative-
anxiolytic agents and other major categories of 
drugs used by youth.
5.5 More effective prevention, 
early identification and treatment
As pointed out by McRae-Clark and Gray (Chapter 4), the 
treatment of established cannabis use problems in adolescents, 
just as in adults, relies mainly on psychotherapeutic methods 
rather than on pharmacotherapy. They note in their chapter 
that cognitive behavioural therapy, motivational enhancement 
therapy, multidimensional family therapy and contingency 
management have each been shown to have some efficacy 
in reducing cannabis use. Two further points arising from this 
summary provide additional suggestions for research: attitudinal 
change and longer-term follow-up.
5.5.1 Attitudinal change toward cannabis use
The importance of attitude in prevention of cannabis use was 
clearly demonstrated by Terry-McElrath et al. (2014). Attitude 
should be equally important in attempting to treat established 
cannabis abuse and dependence. One of the problems 
encountered in earlier years was that a high proportion of cases 
were referred for treatment by courts, police, school authorities 
or parents, rather than by the users’ own recognition that they 
needed treatment (Reilly, Scantleton, & Didcott, 2002). In such 
cases, there is little opportunity to assess whether the referred 
adolescents believe they need treatment, or whether the 
experience has changed their attitude about cannabis use from 
favourable to unfavourable. 
Copeland and Maxwell (2007) examined the records of 27,198 
adult Texans treated for a cannabis use problem in a publicly 
funded treatment program during six years ending in 2005. About 
69% were referrals from the criminal justice system (“coerced”), 
while the remainder were referred by self, family, social service 
agencies or local medical and drug problem services (“non-
coerced”). The coerced referrals were generally simpler cases, 
involved smaller amounts of drug use, were less distressed, 
had a shorter and simpler treatment period, and were more 
likely to have completed it than the non-coerced referrals. At the 
90-day follow-up, the coerced subjects were less likely to have 
used cannabis during the preceding month, but this was by 
self-report only, without chemical verification. However, reviews 
of experience with police referral programs in Australia and the 
United States (Harvey, Shakeshaft, Hetherington, Sannibale, 
& Mattick, 2007; Tresidder & Homel, n.d.) have found that 
the great majority of such programs are poorly designed and 
evaluated, and there has been little attempt to assess outcome 
with respect to cannabis use at longer-term follow-ups. 
Canadian youth are to a small but increasing extent referred 
for treatment or counselling when detained by police for 
simple possession of small amounts of cannabis. A valuable 
line of research would be to compare those referred 
by the justice system with those referred by self or 
non-justice agencies with respect to their attitudes, 
expectations, cannabis-related problems, extent of 
use and long-term outcomes at repeated follow-ups 
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for a total period of not less than two or three years. 
The findings could provide information on which to base future 
screening and referral systems, and develop more effective 
treatment methods.
5.5.2 Pharmacotherapy and long-term 
follow-up
Both Goodman and George (Chapter 2) and McRae-Clark 
and Gray (Chapter 4) refer to the need to develop effective 
pharmacotherapeutic agents to be used in combination with 
psychosocial therapies in the treatment of cannabis use 
problems in youth. This approach is widely used in the treatment 
of other drug use problems in adults, and has a logical, well-
supported basis. Though their effect is usually modest, 
pharmacotherapies that relieve immediate symptoms of drug 
or withdrawal effects, and that in some cases also diminish 
the rewarding effects of the drugs in question, can result in 
better adherence to the treatment program, longer retention in 
treatment and more opportunity for the psychosocial measures 
to take effect. This pattern has been demonstrated, for 
example, with naltrexone and acamprosate in the treatment of 
alcoholism (Anton et al., 2006; Yahn, Watterson, & Olive, 2013). 
The well-designed, placebo-controlled trial of N-acetylcysteine 
combined with contingency management and counselling in 
the treatment of cannabis-dependent youth (mean age 18.9 
years, range 15–21) represents a promising similar approach 
(Gray et al., 2012). 
The problem with all such approaches to date is that the effect of 
the therapeutic agent gradually diminishes with time, so that the 
difference between the treated and the control groups in their 
abstinence from the problem drug gradually disappears. That is 
also evident in the study by Gray and colleagues (2012): at the 
follow-up visit four weeks after the end of treatment, the treated 
group and the placebo group no longer differed significantly in 
the percentage of urine testing negative for cannabinoids. This 
is not surprising because the nervous system has an ability to 
re-adapt to changing inputs of all kinds. The duration of effect 
of proposed pharmacotherapeutic agents must be measured 
to enable decisions about their utility in combined treatment 
programs. There is a need for continued research on 
potential new therapeutic agents to enhance the overall 
efficacy of combined treatment programs, but long-
term follow-up on their duration of effect is necessary 
to permit assessment of their utility in practice.
5.6 Adverse effects of the legal 
prohibition of cannabis
The arguments for and against legalization of non-medical use 
of cannabis are not within the scope of the present report. 
Nevertheless, consideration of the adverse effects of cannabis 
use on youth would not be complete without recognition of 
the possibility of adverse effects of criminal records imposed 
on those convicted of possession. Numerous researchers 
have called for legalization of non-medical use of cannabis 
as a remedy for the adverse of effects of incarceration and 
criminal records on young people convicted of possession of 
small amounts of cannabis for personal use or for small-scale 
trafficking to friends and associates (e.g., Haden & Emerson, 
2014; Rehm & Fischer, 2015). Others have presented 
evidence that this problem might not be as extensive as is 
believed (Pauls, Plecas, Cohen, & Haarhoff, 2012). At present, 
however, there is insufficient evidence about the outcomes 
of cannabis-related detentions by police in parts of Canada 
other than British Columbia. It is important to analyze the 
outcomes of police detentions for cannabis possession 
in Canadian provinces and territories, so as to permit 
policy decisions based on knowledge of the effects of 
the current legal prohibition of non-medical use.
There is still little research on the effects of cannabis legalization 
in a number of American states and other countries on the 
numbers of young cannabis users, their levels of use and the 
consequences of their use. There is no knowledge of the long-
term effects of legalization. For purposes of policy planning, 
it is important to gather information on the levels and 
consequences of cannabis use by young people after 
legalization in those jurisdictions where it has been 
adopted (Canadian Centre on Substance Abuse, 2014).
5.7 Conclusions
While progress continues to be made in recognizing and 
understanding cannabis problems in youth, their causes and 
mechanisms, their long-term effects, and their prevention 
and treatment, there are still many questions. Prevention and 
treatment of cannabis problems in adolescents and young 
adults are not yet at the level of efficacy that our society 
would wish. This overview has identified research topics that 
would help to improve outcomes, and has suggested interim 
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steps based on existing knowledge that can be taken now 
to improve policy, prevent cannabis-linked harms, reduce the 
numbers of at-risk users, and improve the treatment of harmful 
consequences of their use. 
This chapter makes the following recommendations for research:
• Identify the attitudes and values of Canadian adults 
about cannabis that have contributed to the high 
level of use by Canadian youth;
• Analyze the motives specific to youth for cannabis 
use, including the evolution of the individual’s 
motives in the course of transition from exploratory 
to regular use;
• Study the predictive value of different motives as 
indicators of the outcome of use;
• Identify the individual differences of personality, 
motivation and temperament between responders 
and non-responders to different types of preventive 
education programs;
• Undertake comparative study of methods for 
changing beliefs and expectations in school-based 
programs of preventive education, and therapeutic 
programs for heavy users;
• Explore reasons for lesser efficacy of teachers than 
of outside experts in school programs;
• Study changing patterns of adverse effects with 
increasing potency of “street” cannabis; 
• Conduct a longitudinal cohort study to replicate the 
Dunedin study under Canadian conditions;
• To guide the development of new therapeutic 
approaches, conduct a clinical and neurobiological 
study of the links between cannabis use and 
psychosis, depression and anxiety;
• Conduct functional imaging studies of the 
interaction between environmental factors and 
neurobiological mechanisms in the development of 
cannabis addiction in youth;
• Develop pharmacological agents, analogous to 
those used in alcohol and opioid addictions, to 
prolong retention of cannabis-dependent youth in 
treatment; and
• Compare long-term outcomes of self-referred 
and health- or police-referred youth in treatment 
programs.
In addition to these longer-term research projects, the chapter 
proposes a number of practical measures to improve the 
gathering of data, and early detection and prevention programs:
• In cooperation with healthcare professional 
societies, encourage physicians to use brief 
screening procedures for cannabis and other drug 
use by young patients;
• Recruit a pool of experts to take part in school-
based preventive education programs;
• Separate data recording for different drug types in 
police incident reports;
• Record diagnoses for cannabis-linked hospital 
admissions and emergency service visits, and begin 
national collection of the data, as is done for alcohol;
• Begin systematically collecting data on sources of 
cannabis used by youth and tracking the diversion 
of medical marijuana to young non-medical users;
• Begin monitoring effects on cannabis use, 
addiction, vehicular accidents and other adverse 
consequences in youth of legalization in selected 
American states; and
• Convene meetings of federal and provincial 
agencies to discuss and implement programs 
for routine roadside collection of oral fluid from 
suspected impaired drivers for laboratory analysis 
of cannabinoid levels, and publicize this program in 
schools, colleges and universities. 
It is urgent that the evidence reviewed in this report and the 
need for further research, as well as for the immediate measures 
that are already possible, be taken seriously into account by 
governments and research agencies now, when important 
policy issues are being contemplated.
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CURRENTLY ACCEPTED FACTS
• Canadian youth, 15–25 years of age, have a higher proportion of users of cannabis than their counterparts in 
any other advanced country. They also constitute a majority of Canadian users of all ages.
• Young users’ motives for use of cannabis differ from those of older users, but are not sufficiently well 
explored and understood.
• Young users have many incorrect ideas and beliefs concerning the actions, effects and long-term 
consequences of cannabis use, especially of regular use.
• Youth cannabis use is inversely related to the extent of their favourable attitudes and expectations about the 
effects of cannabis, which are more strongly influenced by the views of their peers than by those of their 
parents or teachers.
• Though most occasional users do not suffer serious problems, even occasional use can cause acute 
problems such as motor vehicle accidents, injuries and fatalities. Youth are at greater risk from these 
problems than adult users.
• Combined use of cannabis and alcohol carries greater risk of these consequences than use of either         
one alone.
• Adolescents who begin use before the age of 15 years are at considerably increased risk of adverse effects 
on physical and mental health, psychosocial adjustment, school and work performance, other drug use, and 
career opportunities.
• The earlier that adolescents begin use and the longer their use continues, the more serious are structural 
and functional brain changes that impair maturation of executive functions such as working memory, learning, 
problem solving, judgment, planning and control of impulsivity.
• Early commencement and persistence of use by adolescents predict increased risk of addiction, psychosis, 
depression and anxiety disorders.
• Preventive education programs delivered in schools or healthcare facilities are highly variable in content and 
execution, but the best ones can delay the commencement of use by 20–40% compared to the outcome in 
groups not exposed to such programs.
• Treatment of established hazardous use or addiction is primarily based on psychosocial interventions and 
there are not yet pharmacotherapeutic aids of proven efficacy.
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AREAS OF UNCERTAINTY
• It is unclear what are the determinants of the long-term changes in attitudes and beliefs of youth concerning the 
safety and desirability of using cannabis.
• Most preventive education and treatment programs have insufficiently long follow-up to permit adequate 
assessment of their long-term efficacy.
• The adverse effects of early, continued use by adolescents on the maturation of brain structures and mental 
functions have not yet been studied in well-designed longitudinal studies to permit conclusions as to whether 
the changes are reversible.
• Changes in control policies in different parts of the world have not yet been observed for long enough to assess 
how the effects on youth are affected by different patterns of cannabis availability or by different social norms.
ON THE HORIZON
• New pharmacotherapeutic tools, aimed at facilitating the retention of patients in combined treatment programs, 
are now beginning to be tested clinically.
• Recent data from Canadian and American sources indicate that youth are again beginning to recognize the 
potential dangers of cannabis, and are starting to decrease use. This data offers an opportunity to learn more 
about effective methods of prevention.
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